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Alles heeft zijn tijd
Voor alles wat gebeurt is er een uur,
een tijd voor alles wat er is onder de hemel.
Er is een tijd om te baren
en een tijd om te sterven,
een tijd om te planten
en een tijd om te rooien.
Er is een tijd om te doden
en een tijd om te helen,
een tijd om af te breken
en een tijd om op te bouwen.
Er is een tijd om te huilen
en een tijd om te lachen,
een tijd om te rouwen
en een tijd om te dansen.
Er is een tijd om te ontvlammen
en een tijd om te verkillen,
een tijd om te omhelzen
en een tijd om af te weren.
Er is een tijd om te zoeken
en een tijd om te verliezen,
een tijd om te bewaren
en een tijd om weg te gooien.
Er is een tijd om te scheuren
en een tijd om te herstellen,
een tijd om te zwijgen
en een tijd om te spreken.
Er is een tijd om lief te hebben
en een tijd om te haten.
Er is een tijd voor oorlog
en er is een tijd voor vrede.
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Chapter 1: General introduction
Introduction
The mysterious ability of blood to clot has fascinated people over millennia. In the beginning 
of the 20th century, the mechanisms became better understood. In 1922, the development of 
hemorrhagic disease in cattle caused by mouldy sweet clover was described by Schofield.[1] 
The absence or delay of blood clotting was correlated to a greatly diminished quantity of 
prothrombin. This discovery remained unnoticed until twenty years later the ‘hemorrhagic 
agent’ was identified as dicoumarol, 3,3-methylene-bis.[2, 3] It was promptly made avail-
able for clinical studies and already one year later first experiences on the effectiveness 
in deep vein thrombosis as well as its hemorrhagic complications were published.[2, 4, 5] 
From the coumarin derivates synthesized, the most potent one was warfarin, an acronym 
for the Wisconsin Alumni Research Foundation (WARF). As it was used successfully to fight 
rats, its name may also contribute to that ‘warfare’. It was patented in 1948 and is since 
then the most frequently used coumarin worldwide. In 1929, Dam observed haemorrhage 
and markedly prolonged coagulation times in chickens fed with diets from which fat was 
completely extracted.[6, 7] He concluded that the substance whose absence in the diet was 
responsible for the coagulation and bone growth pathologies should be a new fat-soluble 
vitamin which he named vitamin K (“Koagulation”). For the discovery of vitamin K and the 
purification, characterization and synthesis of the vitamin, Dam and Doisy were awarded the 
Nobel Prize in Medicine in 1943. It was known then empirically that vitamin K reversed the 
bleeding problem of mouldy sweet clover poisoning. However, it took three more decades 
until the vitamin K cycle was proposed in 1974.[8] After another three decades, in 2004, the 
complex biochemical relationship between vitamin K, its epoxide, and coumarins was en-
lightened by identifying the VKORC1 gene. [9, 10] This gene encodes the protein which is the 
target of the coumarins. Genetically mutated variants of the gene have been shown to cause 
warfarin-resistance phenotypes as well as pathogenic deficiency of all vitamin K-dependent 
coagulation factors.
Since 60 years, oral anticoagulants of the coumarin type are extensively used worldwide 
as the first choice in treatment and prevention of arterial or venous thrombosis.[11] Being 
orally administered, they have advantages over heparin, an injectable biological extract, and 
the thorough experience with longterm treatment of millions of patients makes them still 
superior to the recently available direct thrombin inhibitors. However, coumarins are difficult 
to handle in clinical practice as they have a narrow therapeutic range. This means that their 
effective dose is very close to the poisoning dose at which the risk of disabling or lethal major 
bleeding occurs, the most feared complication of coumarin treatment. Furthermore, dosage 
needs of coumarins can differ between persons tenfold and change also intra-individually 
over time. Currently, bleeding by coumarins is one of the most frequent iatrogenic causes of 
hospital admission. It might be preventable by better insight into individual drug response.
[12, 13] It is an ongoing matter of concern to find the right balance between benefits and 
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risks of coumarin treatment. The aim of this thesis is to contribute to the ongoing research to 
assess relevant risk factors for blood coagulation, to predict individual risks in anticoagula-
tion therapy and to develop strategies for improvement of medication safety.
Blood coagulation cascade
Blood coagulation depends on a cascade of reactions between various factors (figure 1)[14]. 
It starts after direct contact of the tissue factor with blood, which leads to formation of the TF-
factor VIIa-complex. This activates factor X, that stimulates production of thrombin and finally 
the change of fibrinogen to fibrin. The fibrin network surrounds the clot of thrombocytes and 
forms the thrombus, together with erythrocytes and leucocytes. Obstruction of a blood ves-
sel by a thrombus can result into thrombosis or embolism. Arterial thrombosis and embolism 
can lead to myocardial infarction or stroke. Venous obstructions encourage development of 
deep venous thrombosis or pulmonary embolisms. As venous thrombi consist primarily of 
fibrin and erythrocytes they can be treated effectively with anticoagulants. Arterial thrombi 
are composed mostly of thrombocytes and their treatment requires combinations of antico-
agulants, thrombotic aggregation inhibitors and thrombolytic drugs.[15]
Coumarin treatment and pharmacodynamics
The effectiveness of coumarins has been established by well-designed clinical trials for the 
primary and secondary prevention of venous thromboembolism, for the prevention of sys-
temic embolism in patients with prosthetic heart valves or arterial fibrillation, for the primary 
prevention of acute myocardial infarction in high-risk men, and for the prevention of stroke, 
recurrent infarction, or death in patients with acute myocardial infarction.[15] Therapy with 
other drugs used for prevention or treatment of thromboembolic diseases such as heparins, 
thrombolytic and platelet inhibiting drugs such as aspirin, and glycoprotein IIb/IIIa antago-
nists and thrombin inhibitors such as dabigatran, are beyond the scope of this thesis and will 
not be discussed further.
Coumarins are antagonists of vitamin K, a fat-soluble vitamin that is essential for the forma-
tion of the hepatic coagulation factors II (prothrombin), VII, IX, and X, as well as protein C, 
S and Z, and Matrix Gla protein (MGP).[6, 16] These clotting factors and proteins are glyco-
proteins with glutamic acid residues (Glu), which are transformed by γ-carboxylation into 
γ-carboxyglutamic (Gla) residues.[17] Calcium binding of the Gla residues of the coagulation 
factors leads to the conformational changes that are needed for their effects in the coagula-
tion cascade.[18]
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Figure 1 Blood coagulation[58]
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The carboxylation of the coagulation factors requires reduced vitamin K as a cofactor, 
which is oxidized to vitamin K epoxide in the process. Due to limited availability of vitamin 
K in tissues, the epoxide must be rapidly reduced again to vitamin K in what is known as the 
vitamin K cycle (figure 2).[6, 16] The enzyme for this reduction is called ‘vitamin K epoxide 
reductase complex’ (VKOR). Coumarins block this enzyme and prevent the regeneration of 
reduced vitamin K. This prevents the activation of coagulation factors II, VII, IX and X and thus 
stops the coagulation cascade. As this mechanism only effects the new development of these 
coagulation factors and does not have any effect on already carboxylated ones, the effect of 
coumarins is delayed until 72 to 96 hours after starting treatment. Therefore, the initiation of 
anticoagulant therapy is normally accompanied by heparins.
Figure 2 The vitamin K cycle
In hepatic tissue it is not clear if VKOR itself catalyzes the conversion of vitamin K to reduced vitamin K or if 
this is accomplished by a separate enzyme such as the DT diaphorase and possibly other enzymes. [16]
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Coumarin chemistry and pharmacokinetics
The most commonly used coumarins are acenocoumarol, phenprocoumon and warfarin. 
In North America, the UK and in Scandinavia, warfarin is most frequently used, whereas 
acenocoumarol and phenprocoumon are the most commonly used coumarins in the other 
European countries. In the Netherlands, acenocoumarol is used most (1,100,000 prescrip-
tions in 283,600 users in 2007) while phenprocoumon is used to a lesser extent (197,000 
prescriptions in 72,000 users in 2007).[19] The choice is made by the referring physician and 
is often based on his or her experience with one of the two drugs.[17]
Chemically, the vitamin K antagonists belong to the group of 4-hydroxycoumarins that 
share a similar chemical structure (figure 3).[20] Each drug has a single, chiral centre that 
gives rise to two different enantiomeric forms, of which the S-form is approximately 2- to 
5-fold more potent than its R-counterpart. In pharmacotherapy, the racemic 50:50 mixture 
of both enantiomers is administered orally. After rapid and almost complete absorption from 
the upper gastrointestinal tract, all coumarins are highly protein bound with low volumes of 
distribution.[20] They are metabolized in the liver by cytochrome P450 enzymes to mostly 
inactive metabolites, which are excreted in urine and feces.[21, 22] In principal, the more ac-
tive (S-) enantiomers are mainly metabolized by cytochrome P450 CYP2C9.[20, 23] However, 
due to their differences in structure, there are differences between the pharmacokinetics of 
the three coumarin drugs. Phenprocoumon is metabolized for 60% and 40% is eliminated 
unchanged. Thus phenprocoumon is less dependent on biotransformation than warfarin 
and acenocoumarol. (S-)acenocoumarol undergoes extensive first pass metabolism and has 
a very low bioavailability in most patients. Therefore acenocoumarol effectiveness mainly de-
pends on the less effective (R-)form. (R-) acenocoumarol is transformed for 50% by CYP2C9, 
for 30% by CYP1A2 and for 20% by CYP2C19.[20] Consequently the elimination half-lives of 
the coumarin anticoagulants vary widely and thereby the duration of effect. Table 1 gives an 
overview of the pharmacokinetics of the three coumarins.
Figure 3 Chemical structure of coumarins
Figure 3 Chemical structure of coumarins 
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Monitoring of coumarin anticoagulant therapy
In order to achieve optimal treatment effects with coumarins, underanticoagulation with an 
exponentially increasing risk of thrombosis as well as overanticoagulation with its increased 
risk of bleeding have to be avoided.[24] This is difficult because of the narrow therapeutic 
range and large inter- and intrapersonal differences in dosage requirement over time. Conve-
niently, coumarin effectiveness can be directly monitored by the Prothrombin (PT) test, which 
is indicative for a reduction of the carboxylated clotting factors II, VII, and X.[25] Because the 
PT test requires thromboplastins which vary in their responsiveness to vitamin K dependent 
coagulation factors, PT values are not a suitable standard measure for anticoagulation.[17] 
For a standardized expression of the degree of anticoagulation, the International Normalized 
Ratio (INR) system has been adopted in which INR is assessed as follows:
INR=(patient PT/ mean normal PT)ISI
Table 1: terminal elimination half-lives, main hydroxylation products, and main metabolizing CYP 
isoenzymes of the (S)- and (R)-enantiomers of warfarin, acenocoumarol, and phenprocoumona [17]
Enantiomer Elimination half-live
(hours)
Hydroxylation product Metabolizing
CYP-isoenzymes
Ref
(S)-warfarin 24-33 4’-OH
6-OH
7-OH
2C8, 2C19
2C9
2C9
[55]
(R)-warfarin 35-58 4’-OH
6-OH
7-OH
8-OH
10-OH
2C8, 2C19
1A2, 2C19
1A2, 2C8
1A2, 2C19
3A4
[55]
(S)-acenocoumarol 1.8b 6-OH
7-OH
8-OH
2C9
2C9
2C9
[22]
(R)-acenocoumarol 6.6 6-OH
7-OH
8-OH
2C9
2C9, 1A2, 2C19
2C9, 2C19
[22]
(S)-phenprocoumon 110-130 4’-OH
6-OH
7-OH
2C8, 2C9, 3A4
2C9, 3A4
2C9, 3A4
[56]
(R)-phenprocoumon 110-125 4’-OH
6-OH
7-OH
3A4
2C9, 3A4
2C9, 3A4
[56]
Ref= reference, studies of the hydroxylation routes and contributing metabolizing enzymes in vitro; 
bold print = major metabolic pathway for the enantiomer or major metabolizing enzyme within a 
hydroxylation route
a Table is based on the comparative review of Ufer[56] and modified and supplemented by 
Schalekamp[17] according to the indicated references.
b Elimination half-life for the CYP2C9*1/*1 genotype. In carriers of at least one *3 allele, elimination half-
life is increased to 9 hours in vivo.[57]
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In this formula ISI is the International Sensitivity Index, a factor correcting for the responsive-
ness of the used thromboplastin and for the available instrument.[25] Use of the INR permits 
physicians to obtain the appropriate level of anticoagulation independent of laboratory 
reagents and to follow published recommendations for intensity of anticoagulation.[26] The 
optimal target range of coumarin anticoagulant therapy, as recommended by the Federation 
of Dutch Thrombosis Centers, lies between an INR of 2.5 and 3.5, or between 3.0 and 4.0 [24, 
27], depending on the indication for treatment. The necessary duration of treatment ranges 
from four weeks to lifelong.
In the Netherlands, there is a dense network of 61 regional anticoagulation clinics, moni-
toring about 300,000 patients.[17] There is evidence that management of anticoagulation by 
specialized clinics improved the quality of anticoagulation while saving costs by preventing 
major bleeding and thromboembolic events compared to usual medical care.[28] Although 
each anticoagulation clinic operates independently, many use one of several available com-
puterized systems to assist with dosing schemes for coumarins.[26] These systems evaluate 
INR results and in about one-half of cases, they produce a dosage recommendation that can 
be followed by the physician[24]. In the other half of cases, consisting mainly of patients who 
are unstable or have had complications or for whom the prescription of concomitant drugs 
has changed, the physician adjusts the dosage according to a standard operating procedure 
without a recommendation from the system. Table 2 shows the common range of mainte-
nance dosage per coumarin. INR measurements and consequent adjustments of the dosing 
usually occur at intervals of 1 to 6 weeks, dependent on INR target range, the stability of the 
anticoagulant level and patient’s co-medication.
Genetic factors affecting coumarin effectiveness
Coumarin maintenance dosage is influenced by age, gender, co-morbidity, vitamin K intake, 
and co-medication[25], but the highest amount of interpersonal dosage differences can be 
explained by genetic variation. In 1992, the cytochrome P450 isoform CYP2C9 was identified 
as the main metabolizing enzyme of the warfarin (S)- enantiomeric form.[29] The human 
gene coding for the CYP2C9 protein has been mapped on chromosome 10q24.2 and is 
greater than 55 kb in length.[30, 31] A total of 13 polymorphisms of the CP2C9 gene have 
been identified of which two are used most to explain the enzyme activity (figure 4). The two 
most commonest CYP2C9*2 and CYP2C9*3, occur at a frequency of 6-13% and 1-9% respec-
Table 2 Mean maintenance dosages of coumarins in Caucasians [20]
Coumarin Maintenance dose (mg/day)
Warfarin 1.5 - 12
Acenocoumarol 1.0 – 9.0
Phenprocoumon 0.7 – 9.0
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tively.[32] Variation in the CYP2C9 gene explained 12% of warfarin dosage variation[33] and 
6% of acenocoumarol dosage variation.[34] In relation to its lower dependency on CYP2C9 
biotransformation, studies on the influence of CYP2C9 on phenprocoumon dosage gave 
inconsistent results.[35, 36]
In 2004, the gene vitamin K epoxide reductase complex subunit 1 (VKORC1) was identified, 
which encodes for the crucial enzyme of the vitamin K cycle and which product is a direct 
target of coumarins.[9, 10] This gene is located on chromosome 16p11.2 and is approximately 
Figure 4 Gene structure of Cytochrome P450 isoform 2C9 (CYP2C9)
Figure 4 Gene structure of Cytochrome P450 isoform 2C9 (CYP2C9) 
 
a Allelic frequency in Caucasians.[32] a ll lic frequency in C ucasians [32]
Figure 5 Gene structure of Vitamin K epoxide reductase complex subunit 1 (VKORC1)
Figure 5 Gene structure of Vitamin K epoxide reductase complex subunit 1 (VKORC1) 
 
a Allelic frequency in Caucasians.[47]a Allelic frequency in Caucasians [47]
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4 kb long (figure 5). Quite soon it was apparent that nearly all of the genetic variability of 
the VKORC1 gene in Europeans is reflected by six single nucleotide polymorphisms (SNPs) 
which formed three main haplotypes and were in complete linkage disequilibrium.[37] Con-
sequently one of these SNPs should be informative enough to explain differences in VKORC1 
functionality.[38] In the Rotterdam Study, we genotyped rs9934438, the SNP that D’Andrea et 
al had identified as a marker for low dose warfarin requirement.[39] An important part of this 
thesis consists of studies regarding the contribution of this gene in addition to the already 
known influences of CYP2C9 in the Rotterdam Study.
The Rotterdam Study
The Rotterdam Study (RS) is a large prospective population based cohort study of Caucasian 
subjects of 45 years and older, living in Ommoord, a suburb of Rotterdam, the Netherlands. 
The study was designed to investigate the incidence and determinants of neurological, car-
diovascular, locomotor and ophthalmologic diseases.[40-42] Until now, three cohorts have 
been formed. The first (RS-I) cohort consisted of 7,983 subjects (response rate 78%) at base-
line in 1990, the RS-II cohort consisted of 3,011 participants (response rate 67%) and was en-
rolled one decade later, and the recent RS-III cohort comprised 3,932 subjects (response rate 
65%). All cohorts had baseline examinations with completed standardized questionnaires, 
sampling of blood and isolation of DNA and examinations such as ECG, echocardiography 
and laboratory assessments which were routinely repeated within the cohorts during up to 
five follow-up rounds.
All cohort members of the Rotterdam Study, treated with coumarins, are monitored by 
a regional anticoagulation clinic, the Star Medical Diagnostic Center. From this clinic, since 
1984, all data on dosing, laboratory and clinical data, including data on bleeding complica-
tions are fully computerized. The patients own treating physician decides about the type of 
anticoagulant. Prothrombin times are monitored every 1-6 weeks, depending on the target 
level, stability of the INR and co-medication. Coumarin doses are adjusted on the basis of 
computerized dose calculations. More than 99% of RS I-III participants fill their drug prescrip-
tions at seven regional pharmacies, which are fully computerised. Complete data on drug use 
from these pharmacies were available as of January1st, 1991. The pharmacy data include the 
Anatomical Therapeutical Chemical (ATC)-code[43], the filling date, the total amount of drug 
units per prescription, the prescribed daily number of units, and product name of the drugs.
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Candidate genes, genome-wide association studies and CHARGE
The first genetic studies used a candidate gene approach to demonstrate an association be-
tween genetic variation in a candidate gene and the risk of a certain phenotype. For instance, 
the polymorphisms in the CYP2C9 gene and their effects on INR outcomes during coumarin 
treatment were largely discovered with a candidate gene approach following earlier clinical-
Figure 6 Taqman assay of VKORC1 1173C>T (rs9934438)
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pharmacological kinetic studies.[44, 45] For a more detailed description of candidate gene 
analyses, the reader is referred to the study of Wadelius et al.[46] For VKORC1 it soon became 
apparent that one SNP could reflect the activity of the enzyme.[37-39] One of them is VKORC1 
1173C>T, rs9934438. To study the effects of genetic variation in the VKORC1 gene, this SNP 
was determined in the RS on the basis of earlier literature.[39, 47] By means of a Taqman assay 
colour alleles could be distinguished into genotypes being homozygous for the most fre-
quent allele, defined as the wild type genotype, being heterozygous and being homozygous 
for the variant allele (figure 6).
A limitation of candidate gene studies is that they only focus on associations with specific 
and a priori defined genes and often suffer from low statistical power, lack of replication and 
low precision.[48] To identify novel genetic loci, genome-wide association studies (GWAS) 
have to be performed, often without a prior hypothesis on biological mechanisms. They have 
proven to be successful in their ability to localize genetic effects in certain regions of the 
genome when they have adequate sample sizes and replication opportunities.[48]
Recently, it became technically and economically feasible to genotype in a single DNA 
sample more than 550,000 SNPs per person and to subsequently impute another 2 million 
SNPs per subject.[49] This has been done for all participants of the Rotterdam Study with 
DNA available which was the case in about 70% of the total cohort.
In the Single Nucletoide Polymorphism database (dbSNP) all genetic variation is docu-
mented, covering at the moment about 20 million SNPs.[50] The International HapMap proj-
ect documents linkage relationships between SNPs by grouping those SNPs that are strongly 
correlated with each other into linkage blocks.[51] Currently in Caucasians about 1 million 
independent linkage blocks of correlating SNPs are known. With genome-wide association 
studies, associations between these linkage blocks and the phenotypes of interest can be es-
timated. Because of the multiplicity of testing so many markers, the number of false positive 
findings by chance increases.[51] Stringent thresholds have been considered to declare an 
association ‘genome-wide significant’. The threshold agreed on for genome-wide significance 
is 5*10−8, which is the nominal p-value of the commonly used 0.05 divided by the number of 
independent linkage blocks.[52]
To confirm findings from a GWAS performed within one study population, they have to 
be replicated in another population. This is done by taking the ‘top-hits’ from the study 
population (for instance, all genetic markers above the significance threshold) and analyse 
the particular SNPs subsequently as candidate gene SNPs in the replication cohort. GWAS 
and replication studies often require 10 thousands subjects and for rare variants up to hun-
dred thousands of subjects. Of course, this is more than a single cohort study can supply. 
Therefore international cooperation was needed with regular exchange of information on 
genotyping, validation of determinants and outcomes, and solving methodological ques-
tions. In 2008, the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) 
Consortium was formed from three prospective cohort studies from the United States (the 
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Atherosclerosis Risk in Communities Study, the Cardiovascular Health Study, the Framingham 
Heart Study), and two cohorts from Europe (the Reykjavik Study and the Rotterdam Study).
[48] This consortium facilitates GWAS meta-analyses and replication among multiple large 
and well-phenotyped cohort studies with DNA for all participants. Examples of milestones 
are the identification of genetic loci associated with a variety of conditions such as type 2 
diabetes[53] and coronary heart disease[54]. At the moment, many meta-analyses on differ-
ent disease outcomes are ongoing.
Aim and outline of this thesis
This thesis is a continuation of the research in an earlier thesis from our department in 2004 
which demonstrated important variation in response to acenocoumarol and phenprocou-
mon in participants from the Rotterdam Study with different CYP2C9 genotypes.[26] In 
this thesis, the role of the VKORC1 gene was studied in addition. With the discovery of the 
VKORC1 gene in 2004 and SNPs that could explain the activity of the corresponding enzyme, 
it became possible to study the association between variant alleles responsible for reduced 
activity of this enzyme and outcomes such as anticoagulation and aortic calcification. Results 
from a study on the association between VKORC1 variant alleles and aortic calcification are 
described in chapter 2.1. The additional influence of VKORC1 variant alleles on acenocoumarol 
and phenprocoumon treatment with INR increase, bleeding and the need of dosage reduc-
tion as phenotypes are described in chapter 3 together with the results from GWAS in search 
for additional genetic factors with influence on coagulation therapy. Recent case reports on 
coumarin-drug interactions with PPIs and SSRIs and the lack of large cohort studies gave 
reason to study drug-drug interactions of acenocoumarol with proton pump inhibitors and 
selective serotonin reuptake inhibitors. The results are shown in chapter 4.1 and 4.2, and the 
role of the known genetic effect modifiers is part of it. Finally, in chapter 5 the main findings 
of these thesis are discussed and placed in a broader perspective.
23
Chapter 1: General introduction
References
 [1] Scholfield F. A brief account of diseae in cattle simulating hemorrhagic septicaemia due to feeding 
sweet clover. Can Vet Rec 1922; 3: 74.
 [2] Allen E, Barker N, Waugh J. A preparation from spoiled sweet clover (3,3’-methylene-bis-(4-hy-
droxycoumarin))which prolongs coagulation and prothrombin time of the blood: A clinical study. 
JAMA 1942; 120: 1009.
 [3] Overman R, Stahmann M, Sullivan W. Studies on the haemorrhagic sweet clover disease: IV. The 
isolaton and crystallization of the haemorrhagic agent. J Biol Chem 1941; 141: 941.
 [4] Busch W, Stewart J. Clincial experience with dicoumarin. 3,3’-methylene-bis-(4-hydroxycoumarin). 
JAMA 1942; 120(10256).
 [5] Lehmann J. Hypoprothrombinaemia produced by methylene-bis-(hydroxycoumarin): It’s use in 
thrombosis. Lancet 1942; 1: 318.
 [6] Oldenburg J, Marinova M, Mueller-Reible C, Watzka M. The vitamin K cycle. Vitamins and Hormones 
2008; 78: 35-62.
 [7] Dam H. Cholesterinstoffwechsel in Huehnereiern und Huehnchen. Biochem Zeitung 1929; 214: 
475-92.
 [8] Matschiner J, Willingham A. Influence of sex hormones on vitamin deficiency and epoxidation of 
vitamin K in the rat. J Nutr 1974; 104: 660-5.
 [9] Li T, Chang C-Y, Jin D-Y, Lin P-J, Khvorova A, Stafford DW. Identification of the gene for vitamin K 
epoxide reductase. Nature 2004; 427(6974): 541-4.
 [10] Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, et al. Mutations in VKORC1 
cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004 Feb 5; 
427(6974): 537-41.
 [11] Hirsh J, O’Donnell M, Eikelboom JW. Beyond Unfractionated Heparin and Warfarin: Current and 
Future Advances. Circulation 2007 July 31, 2007; 116(5): 552-60.
 [12] van der Hooft C, Dieleman J, Siemes C, Aarnoudse A, Verhamme K, Stricker B. Adverse drug 
reaction-related hopsitalisations: a population-based cohort study. Pharmacoepidemiology and 
Drug Safety 2998; 17(4): 365-71.
 [13] Leenderste A, Egberts A, Stoker L, P. Bvd. Frequency of and risk factors for preventable medication-
related hospital admissions in the Netherlands. Arch Intern Med 2008; 168: 1890-6.
 [14] Loewenberg E, Dielis A, Meijers J, Ten Cate H, Levi M. Voortschrijdend inzicht in de werking van de 
bloedstolling in vivo. Ned Tijdschr Geneeskd 2009; 153(1/2): 30-7.
 [15] Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of 
the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic 
Therapy. Chest 2004; 126(3 Suppl): 204S-33S.
 [16] Stafford DW. The vitamin K cycle. J Thromb Haemost 2005 Aug; 3(8): 1873-8.
 [17] Schalekamp T. Thesis: effects of CYP2C9 and VKORC1 polymorphisms and drug interactions on 
coumarin anticoagulation control. ISBN: 978-90-393-4502-3 2007.
 [18] Oldenburg J, Bevans CG, Muller CR, Watzka M. Vitamin K epoxide reductase complex subunit 1 
(VKORC1): the key protein of the vitamin K cycle. Antioxid Redox Signal 2006 Mar-Apr; 8(3-4): 347-
53.
 [19] Dutch Foundation of Farmaceutical Statistics; SFK. Personal information 2008.
 [20] Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and 
acenocoumarol. Clin Pharmacokinet 2005; 44(1227-12246).
24
 [21] He M, Korzekwa K, Jones J, Rettie A, Trager W. Structural forms of phenprocoumon and warfarin 
that are metabolized at the active site of CYP2C9. Archives of Biochemistry and Biophysics 1999; 
372(1): 16-28.
 [22] Thijssen H, Filinois J, Beaune P. Cytochrome P450 2C9 is the principal catalyst of racemic acenocou-
marol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000; 28: 1284-90.
 [23] Beinema M, Jacobus R, Brouwers J, Schalekamp T, Wilffert B. Pharmacogenetic differences between 
warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 2008; 100: 1052-7.
 [24] Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briet E. Optimal 
oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995 July 6, 
1995; 333(1): 11-7.
 [25] Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, et al. Pharmacology and manage-
ment of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical 
Practice Guidelines (8th Edition). Chest 2008; 133((6 Suppl): 160S-198S).
 [26] Visser L. Thesis: Genetic and environmental factors affecting the coumarin anticoagulant level. 
ISBN: 90-8559-003-5 2004.
 [27] Hylek E, Skates S, Sheehan M, Singer D. An analysis of the lowest effective intensity of prophylactic 
antioagulation for patients with nonrheumatic anticoagulation for patients with nonrheumatic 
artrial fibrillation. N Engl J Med 1996; 335: 540-6.
 [28] Sullivan P, Arant T, Ellis S, Ulrich H. The cost effectiveness of anticoagulation management services 
for patients with artrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 2006; 
24: 1021-33.
 [29] Rettie A, Korzekwa K, Kunze K, Lawrence R, Eddy A, Aoyama T, et al. Hydroxylation of warfarin by 
human cDNA-expressed cytochrome P-450: a role for P-450 2C9 in the etiology of (S)-warfarin-drug 
interactions. Chem Res Toxicol 1992; 5: 54-9.
 [30] Goldstein J, De Morais S. Biochemistry and molecular biology of the human CYP2C subfamily. 
Pharmacogenetics 1994; 4: 285-99.
 [31] Meehan R, Gosden J, Rout D, Hastle M, Friedberg T, Adesnik M. Human cytochrome p-450 PR-1: a 
multigene family involved in metphenytoin and steroid oxidations that maps to chromosome 10. 
Am J Hum Genet 1988; 42: 26-37.
 [32] Gage B, Eby C. Pharmacogenetics and anticoagulant therapy. J Thromb Thrombolysis 2003; 16(1-2): 
73-8.
 [33] Takeuchi R, McGinnis R, Bourgeois S, Garnes C, Eriksson N, Soranze N, et al. A genome-wide associa-
tion study confirms VKORC1, CYP2C9 and CYP4F2 as principal genetic determinants of warfarin 
dose. PLoS Genet 2009 Pulished online 2009 March 20.doi: 10.371/journal; 5(3): e1000433.
 [34] Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, et al. A genome-wide scan 
for common genetic variants with a large influence on warfarin maintenance dose. 2008; 112(4): 
1022-7.
 [35] Hummers-Pradier E, Hess S, Aham I, Papke T, Pieske B, Kochen M. Determination of bleeding risk 
using genetic markers in patients taking phenprocoumon Eur J Clin Pharmacol 2003; 59: 213-9.
 [36] Visser LE, van Vliet M, van Schaik RHN, Kasbergen AAH, de Smet PA, Vulto AG, et al. The risk of 
overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on aceno-
coumarol or phenprocoumon. Pharmacogenetics 2004; 14: 27-33.
 [37] Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, et al. VKORC1 haplotypes and 
their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb 
Haemost 2005 Oct; 94(4): 773-9.
25
Chapter 1: General introduction
 [38] Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes 
on transcriptional regulation and warfarin dose. N Engl J Med 2005 Jun 2; 352(22): 2285-93.
 [39] D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism 
in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant ef-
fect of warfarin. Blood 2005 Jan 15; 105(2): 645-9.
 [40] Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability 
in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991 Jul; 7(4): 403-22.
 [41] Hofman A, Breteler M, van Duijn C, Krestin G, Pols H, Stricker B, et al. The Rotterdam Study: objec-
tives and design update. Eur J Epidemiol 2007 2007; 22: 819-29.
 [42] Hofman A, Breteler M, Van Duijn C, Janssen H, Krestin G, Kuipers E, et al. The Rotterdam Study: 2010 
objectives and design update. Eur J Epidemiol 2009; 24: 553-72.
 [43] World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for 
ATC Classification and DDD Assignment. Oslo 2004.
 [44] Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 
CYP2C9 with warfarin dose requirement and risk of bleeding complications. The Lancet 1999; 
353(9154): 717-9.
 [45] Visser L, van Schaik R, van Vliet M, Trienekens P, de Smet P, Vulto A, et al. The risk of bleeding com-
plications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or 
phenprocoumon. Thromb Haemost 2004; 92(61-66).
 [46] Wadelius M, Chen L, Eriksson N, Bumpstead S, Ghori J, Wadelius C, et al. Association of warfarin 
dose with genes involved in its action and metabolism. Hum Genet 2007; 121: 23-34.
 [47] Schalekamp T, Brasse B, Roijers J, Youssef C, van Geest - Daalderop G, De Vries-Goldschemding 
H, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction 
between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006; 80(13-22).
 [48] Psaty B, O’Donnell C, Gudnason V, Lunetta K, Folsom AR, J., Et al. Cohorts for heart and aging 
research in genomic epidemiology (CHARGE) consortium. 2 2009(73-80).
 [49] Li Y, Abecasis G. Rapid haplotype reconstruction and missing genotype inference. Am J Hum Genet 
2006; S79: 2290.
 [50] NN. Single Nucletoide Polymorphism database (dbSNP) http: //wwwncbinlmnihgov/projects/SNP/
snp_tableListcgi?type=method visited on 5th of december 2010.
 [51] The International HapMap Consortium. A hapoltype map or the human genome. Nature 2005; 
437(7063): 1299-320.
 [52] Pe’er I, Altshuler D, Daly M. Estimation of the multiple testing burden for genomewide association 
studies of nearly all common variants. Gen Epidemiol 2008; 32: 381-5.
 [53] Zettini E, Saxena R, Boight B, Consortium Ftdal-sraM-aD. Meta-analysis of genome-wide associa-
tion data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat 
Genet 2008; 40: 638-45.
 [54] Newton_Cheh C, Rice K, Bakker de P, Yin X, Estrada K, Bis J, et al. Common variants at ten loci influ-
ence myocardial repolarisation: the QTGEN consortium. Nature Genetics 2009; 41(6): 677-87.
 [55] Kaminsky L, Wang Z. Human p450 metabolism of warfarin. Pharmacol Therap 1997; 73-67-74.
 [56] Ufer M, Svensson J, Krausz K, Gelboin H, Rane A, Tybring G. Identification of cytochromes P450 
2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 
20004; 60: 173-82.
 [57] Thijssen H, Ritzen B. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 geno-
type. Clin Pharmacol Ther 2003; 74: 61-8.
 [58] NTVG. Blood coagulation. Nederlands Tijdschrift voor Geneeskunde 2009; 153: 1-2.

Chapter 2
Vitamin K Epoxide Reductase Complex 
Subunit 1 (VKORC1) polymorphism and 
aortic calcification: the Rotterdam Study
28
Abstract
Besides effects on hemostasis, vitamin K-dependent proteins play a role in bone mineraliza-
tion and arterial calcification. We investigated the association between the VKORC1 1173C>T 
polymorphism and calcification of the aortic far wall in a large population-based cohort. Aor-
tic calcification was diagnosed by radiographic detection of calcified deposits in the abdomi-
nal aorta. In all cohort members for whom DNA was available, the C1173T SNP of VKORC1 
(rs9934438) was determined. With multivariable logistic regression analysis the association 
between this polymorphism and the risk of aortic calcification was calculated, adjusted for 
potential confounders. The T allele frequency of the VKORC1 1173C>T polymorphism was 
38.8%. 1185 (37.2%) persons were homozygous CC, 1529 (48,0%) were heterozygous CT 
and 473 (14.8%) were homozygous TT. Persons with at least one T-allele had a statistically 
significant 19% (95% CI 2 to 40%) risk increase of calcification of the aortic far wall compared 
to CC homozygous persons, adjusted for age and gender. The T-allele of the VKORC1 1173C>T 
polymorphism was associated with a significantly higher risk of aortic calcification in Whites.
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Introduction
Vitamin K epoxide reductase (VKOR) mediates recycling of vitamin K 2,3 epoxide to vitamin 
K hydroquinone, an essential cosubstrate for modification of multiple glutamic acid residues 
to γ-carboxyglutamate in vitamin K-dependent proteins such as the coagulation factors 
II, VII, IX, and X, protein C, S, and Z, Matrix Gla protein (MGP), and osteocalcin.[1] Recently, 
numerous single nucleotide polymorphisms (SNPs) were identified on chromosome 16 in the 
gene encoding the vitamin K epoxide reductase complex subunit 1 (VKORC1),[2, 3] of which 
several reflect 3 main natural haplotypes of VKORC1.[4-6] Five SNPs (rs 9934438, rs 9923231, 
rs8050894, rs 2359612, and rs 7294) were found to be in strong linkage disequilibrium (D’>0.9 
and r2 ≥0.9), indicating that any of these could reflect VKORC1 haplotypes.[5, 7] One of these 
SNPs, rs9934438 or VKORC1 1173C>T, is as informative about coumarin sensitivity as 5 
VKORC1 haplotypes which predicted warfarin dose requirement and together accounted for 
96% to 99% of the total haplotypes in European-American White populations.[5] The VKORC1 
1173C>T SNP is likely to be one of the putative functional SNPs of the VKORC1 gene.[8]
The T-allele of this SNP modifies the effectiveness of coumarins, which reduce the activity 
of the VKORC1 enzyme.[4-6, 9-16] In carriers of the T-allele, additional inhibition by coumarins 
had a higher impact on hemostasis than in those with the 1173CC genotype. Beyond hemo-
static effects, different studies suggest an influence of vitamin K-dependent proteins on bone 
mineralization and arterial calcification. The key function of MGP is to inhibit calcification 
in cartilage and arteries.[17-19] Hereto, MGP has to be activated by γ-carboxylation of its 5 
glutamic acid residues, which is mediated by vitamin K hydroquinone. During carboxylation, 
the hydroquinone becomes oxidized to vitamin K epoxide (Figure). Vitamin K hydroquinone 
is derived from dietary vitamin K intake or by recycling of the epoxide. First, the epoxide is 
reduced to vitamin K, catalyzed by the Vitamin K epoxide reductase (VKOR). Second, vitamin 
K is further reduced to the hydroquinone. This second reduction step differs between tissues.
[20] VKORC1 seems crucial for reduction of vitamin K in extra hepatic tissues, whereas in the 
liver also other enzymes such as DT diaphorase mediate further reduction of vitamin K into 
the hydrochinone.[21, 22] Inhibition of the VKORC1 with coumarins for coagulation factors 
could be antagonized by dietary vitamin K but not for MGP as extra hepatic protein. Price et 
al used the implication of this fundamental difference between tissues on the activation of 
vitamin K-dependent proteins by giving warfarin in combination with vitamin K to young 
rats. Thus mineralization of arteries could be promoted without inducing fatal bleeding 
before measurement of arterial calcification.[23] In human studies the recommended daily 
allowance for vitamin K was shown to be sufficient for maintaining functional hemostasis, 
whereas undercarboxylation of at least 1 nonhemostatic protein was observed.[18, 24] More 
recent studies showed that, despite their similar in vitro cofactor activity, the 2 forms of 
vitamin K differ concerning their ability to counteract effects of warfarin.[25, 26] High doses 
of vitamin K1 could counteract the effect of coumarins on coagulation factors in the liver but 
30
not in extrahepatic tissue. In extrahepatic tissue only vitamin K2 was able to inhibit warfarin 
induced arterial calcification.[25]This implicates different effects of VKORC1 activity and of 
vitamin K1 and K2 intake on coagulation factors as hepatic proteins and on extrahepatic 
proteins such as MGP.
A diminished functionality of the VKORC1 enzyme is therefore not likely to influence 
coagulation factors and hemostasis in persons with normal vitamin K1 intake and not using 
coumarins. A lifelong decreased activity of the VKORC1 enzyme, however, might impair MGP 
activity and by this increase the risk of vascular calcification. This could be further worsened 
by reduced intake of vitamin K2. The association between impaired carboxylation of MGP 
and intimal and medial vascular calcification in humans has been described before.[27] Cal-
cification of the aortic far wall has shown to be a good indicator of vascular calcification.[28] 
Therefore, we investigated whether carriers of the VKORC1 1173C>T allele had an increased 
risk of calcification of the aortic far wall in a large population-based cohort of Whites.
Figure 1 The vitamin K cycle
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Methods
Setting
Data were obtained from the Rotterdam Study, a prospective population-based cohort study, 
designed to study neurological, cardiovascular, locomotor, and ophthalmologic diseases. The 
rationale and design of this study have been described elsewhere.[29, 30] Participants were vis-
ited at home for a standardized questionnaire and were subsequently examined at the research 
center. At baseline, information was obtained on several characteristics, including age, gender, 
smoking, blood pressure, diabetes mellitus, body mass index (BMI), medication use, measures 
of atherosclerosis such as vascular calcification, and a verified history of myocardial infarction 
and heart failure. During the first examination of the participants from 1990 to 1993, blood was 
taken and DNA was isolated, information on weight, height, morbidity, and blood variables 
was collected, and calcified deposits in the abdominal aorta were assessed by radiography.
Genotyping
Genomic DNA was extracted from samples of peripheral venous blood according to standard 
procedures. 1 to 2 ng genomic DNA was dispensed into 384-wells plates using a Caliper Sci-
clone ALH3000 pipetting robot (Caliper LS). We chose the 1173C>T SNP at intron 1, dbSNP: 
rs9934438. Genotyping was performed using a Taqman allelic discrimination assay as previ-
ously described.[31] To confirm the accuracy of genotyping results, 315 (5%) randomly se-
lected samples were regenotyped with the same method. No inconsistencies were observed.
Outcome
In the present study, we used the measurements of calcified deposits in the aortic far wall 
taken at the baseline visits between 1990 and 1993. Aortic calcification was diagnosed by 
radiographic detection of calcified deposits in the abdominal aorta as described elsewhere. 
The interobserver agreement for absence versus presence of atherosclerotic plaques was 
0.88, and the ĸ statistic was 0.74.[32] We defined moderate and severe extent of calcification 
with an area of the posterior aortic wall involved >2.5 cm as the outcome of interest and used 
persons with absent aortic calcification as the reference group.
Radiography of the aortic far wall only measured calcified plaques and could not detect 
plaques without calcification. To check whether the VKORC1 1173C>T allele was associated 
with calcification independently from existing plaques, we performed further analyses with 
the data available on carotid plaques. With the ultrasonography used for the carotid mea-
surements, it was possible to detect plaques composed of calcified as well as of noncalcified 
components. In the Rotterdam Study from 1990 until October 1991, with ultrasonography 
calcified and noncalcified plaques were assessed separately in the carotid artery as described 
elsewhere.[33] Assessment of calcified plaques was available from 3 locations in the carotid 
artery.
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Cofactors
We adjusted for cardiovascular risk factors for atherosclerosis such as age, gender, present 
smoking, hypertension, hypercholesterolemia, and diabetes mellitus.[34] We further adjusted 
for nutritional vitamin K intake, separately for vitamin K1 and vitamin K2. The daily intake of 
these 2 forms of vitamin K was determined using a food frequency questionnaire.[35]
Statistical Analyses
Allele and genotype proportions were tested for deviations from Hardy-Weinberg equilib-
rium by a χ2 test. For the 1173C>T SNP 3 different genotypes were present: CC, CT, and TT. 
With multivariable logistic regression analysis, adjusted for age and gender, we studied the 
association between the T allele and aortic calcification with an allele-dose-effect model 
(number of T-alleles with no T-alleles as a reference), genotype-effect model (genotype CT 
and TT separately with CC as a reference), a recessive model (TT versus CT plus CC), and with 
a dominant model (TT plus CT versus CC). We compared the risk of calcification of the aortic 
far wall to no detectable form of calcification as reference group. For each analysis an odds 
ratio (OR) and a 95% confidence interval (CI) was computed. Analyses were repeated for 
severe aortic calcification (area of plaque involved ≥5 cm) compared to no detectable form of 
calcification in the aortic far wall.
In multivariable logistic regression analyses we studied the association between the T-allele 
and calcification, adjusting for gender and age. Subsequently, we tested each risk factor for 
aortic calcification whether it changed the association between the T-allele and the outcome 
by more than 10%. Missing values for total serum cholesterol, dietary vitamin K1 and vitamin 
K2 intake, BMI, and systolic blood pressure were imputed with a predictive model that in-
cluded age, gender, presence of the T-allele of the VKORC1 1173C>T polymorphism, and the 
presence of aortic calcification. We adjusted for missing values in present smoking, diabetes, 
and carotid plaques by computing 3 categories for each factor: measured present, measured 
absent, and measurement missing. We also checked for multiplicative interactions between 
the T-allele and each potential cofactor with interaction terms.
With multivariable logistic regression we analyzed the association of the T-allele with the 
presence of 4 to 6 calcified plaques in the carotid artery compared to no calcification detectable, 
adjusted for age and gender. To evaluate the independent risk estimate of calcification beside 
existing atherosclerotic deposits, we further adjusted for the total number of plaques (calcified 
or noncalcified). All statistical analyses were performed with SPSS software (version 11.0; SPSS).
Results
For 6547 of the 7983 persons in the Rotterdam Study a blood sample was available for ge-
notyping of VKORC1 1173C>T. For 153 persons (2%) genotyping failed, leaving 6394 persons 
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with a genotype assessed. During the study period, 233 of the 6394 persons had used cou-
marins before measurement of aortic calcification and were excluded. Within the remaining 
6161 patients, calcification of the aortic far wall was measured in 5123 persons during the 
first visit to the study center between 1990 and 1993. Measurements could not be evalu-
ated for 123 persons, leaving 5000 persons. For 1667 persons no aortic calcification could 
be detected. In 1813 out of 3333 persons with plaques, the area of the aorta involved in the 
detected plaques was smaller than 2.5 cm whereas in the remaining 1520 persons the area of 
plaques involved a length of at least 2.5 cm. In the analyses we categorized persons without 
any detectable aortic calcification as calcification absent and those with plaques above 2.5 
cm as calcification present. In total, our study population consisted of 3187 persons.
Characteristics of the study population are given in Table 1. Genotype proportions were 
similar to those in the whole population genotyped, and the population was in Hardy-
Weinberg equilibrium (P=0.58).
Within persons with aortic calcification the numbers of the VKORC1 CT genotype were 
higher than in persons without detectable calcification (Table 2). In the study population, the 
Table 1 Characteristics of the study population
Variable Population (N= 3187)
VKORC1 1173 C>T
Genotype (%)$
 CC
 CT
 TT
Allele frequency (%)
C-1173
T-1173
1185 (37.2)
1529 (48.0)
473 (14.8)
61.2
38.8
Calcification of aortic far wall (%)
 Absent
 Present *
3187 (100)
1667 (52.3)
1520 (47.7)
Female gender (%) 1894 (59.4)
Age [years] (SD) 67.5 (8.0)
Body mass index [kg/m2] (SD) 26.3 (3.6)
Systolic blood pressure [mm Hg] (SD) 138.8 (22.1)
Diastolic blood pressure [mm Hg] (SD) 73.9 (11.0)
Total cholesterol [mmol/l] (SD) 6.9 (1.2)
HDL-cholesterol [mmol/l] (SD) 1.4 (0.4)
Diabetes mellitus (%) 168 (5.3)
Smoking
 Current (%)
 Past (%)
730 (23.1)
1329 (41.7)
History of myocardial infarction (%) 227 (7.1)
History of stroke (%) 93 (2.9)
Vitamin K1 intake (mcg) (SD)
Vitamin K2 intake (mcg) (SD)
250 (118)
28 (16)
$ Hardy-Weinberg Equilibrium χ2 = 0.314 (p= 0.58),
* involved area with calcified deposits of the posterior aortic wall with a length of at least 2.5 cm.
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frequency of the T-1173 allele of the VKORC1 polymorphism was 38.8%. Persons with aortic 
calcification were found to have a higher T-allele frequency than persons with no detect-
able aortic calcification (39.8% versus 37.9%). From the models tested, only in the dominant 
model, persons with at least one T-allele had a statistically significant 1.19-increased risk (95% 
CI 1.02–1.40) for calcification of the aortic far wall compared to persons with the wild-type 
genotype of VKORC1 (Table 3). Systolic blood pressure, diabetes, present smoking, total 
serum cholesterol, BMI, and vitamin K1 and vitamin K2 intake did not change the point esti-
mate by more than 10%, and for these variables no effect modification was observed for the 
association of the T-allele with aortic calcification. When adjusting for all these variables, the 
estimate for the T-allele slightly increased (1.21, 95% CI 1.02–1.43). Restricting the outcome 
to aortic calcification with an area of the posterior wall involved ≥5 cm instead of 2.5 cm, the 
risk in carriers of a T-allele was increased to 1.27 (95% CI 1.02–1.58).
Table 2 Frequency of the VKORC1 1173C>T genotype within the groups of absent and present aortic 
calcification
Genotype (%) Aortic calcification Total
Absent Present*
CC 654 (39.2) 531 (34.9) 1185 (37.2%)
CT 762 (45.7) 767 (50.5) 1529 (48%)
TT 251 (15.1) 222 (14.6) 473 (14.8%)
Total 1667 (100) 1520 (100) 3187 (100%)
Allele frequency (%)
 C-1173 62.1 60.2
 T-1173 37.9 39.8
* Involved area with calcified deposits of the posterior aortic wall with a length of at least 2.5 cm
Table 3 Association between the VKORC1 1173C>T genotypes and the risk of mild, moderate and severe 
aortic calcification
Number
N=3187 (%)
Basic model&
OR (95%CI)
Adjusted model$
OR (95%CI)
Allele-dose-effect model
 Number of T-alleles with ‘no T-alleles’ as a reference
Genotype effect model
 CC
 CT
 TT
Recessive model
 CC or CT
 TT
Dominant model
 CC
 CT or TT
3187 (100)
1185 (37.2)
1529 (48.0)
473 (14.8)
2714 (85.2)
473 (14.8)
1185 (37.2)
2002 (62.8)
1.07 (0.95 – 1.19)
1 (reference)
1.25 (1.05 – 1.47)
1.04 (0.82 – 1.32)
1 (reference)
0.92 (0.74 – 1.14)
1 (reference)
1.19 (1.02 – 1.40)
1.08 (0.96 – 1.21)
1 (reference)
1.26 (1.06– 1.51)
1.05 (0.82 – 1.35)
1 (reference)
0.92 (0.74 – 1.16)
1 (reference)
1.21 (1.02 – 1.43)
& adjusted for age and gender, $ adjusted for age, gender, total serum cholesterol, systolic blood pressure, 
current smoking, diabetes mellitus, BMI and vitamin K1 and vitamin K2 intake.
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Within the study population, there were 1084 persons with measurements of carotid 
calcification, 471 had no calcification detectable in the carotid artery and 75 persons had 
4 to 6 calcified carotid plaques. In the carotid artery, the T-allele was not associated with a 
risk of 4 to 6 calcified plaques compared to no calcified plaques detectable (OR=0.68, 95% 
CI 0.44–1.07). When including the numbers of calcified plaques and noncalcified plaques 
together in analyses to evaluate the independent risk estimate of calcification given the total 
number of plaques, also no association was found for the T-allele with 4 to 6 calcified carotid 
plaques compared to no calcified plaques (OR=0.60, 95% CI 0.13–2.91).
Discussion
In our study, presence of the T-allele of the VKORC1 1173C>T was associated with a small 
but significantly increased risk of aortic calcification. To our knowledge this is the first study 
analyzing the association between the T-allele and aortic calcification. Persons with a T-allele 
have a lifelong reduced activity of VKORC1. Effects from this are expected in extrahepatic 
proteins such as MGP because γ-carboxylation here fully depends on VKORC.1 The estimated 
risk of aortic calcification for persons with the CT genotype (1 copy of the risk allele T) was 
higher than for those with the CC genotype (no risk allele). The risk of aortic calcification for 
homozygous persons with TT compared to CC individuals was not significantly increased, 
possibly because this group was much smaller with a less precise estimate and a wider 95% 
confidence interval. However, the point estimate for CT individuals was within the adjusted 
confidence interval of the TT individuals. This may be in line with a dominant effect of the 
T-allele, as already stated in another study.[7] Restricting the outcome to aortic calcification 
with an area ≥5 cm involved and its lower chance of misclassification, this was associated 
with a significant risk increase of 27% in the dominant model. So far as we know, there are 
few similar studies but with conflicting results.[7, 24]
Dietary vitamin K2 intake could have modified the association between the T-allele and 
aortic calcification. Previously, menopausal women in the Rotterdam Study with low dietary 
vitamin K intake had an increased risk of aortic calcification. In our study population, persons 
with aortic calcification had a significantly lower daily intake of vitamin K2 than persons 
without detectable aortic calcification (27.3 mcg/d versus 29.5 μg/d) However, there was 
no difference in dietary vitamin K intake in persons with or without a T-allele and further 
no interaction between a T-allele and dietary vitamin K2 intake was found. We also did not 
detect any confounding or multiplicative effect modification on this association by any of the 
known cardiovascular risk factors.
It is unlikely that our results can be explained by bias or confounding. Selection bias in this 
population-based setting is improbable, especially as the population was in Hardy-Weinberg 
equilibrium. In our study population we found a 38.9% allele frequency of the risk allele. 
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The frequency of the T-allele in Whites has been reported so far between 39.8 and 42%.[4, 
6, 10, 11] The absence of significant deviation from the HWE is also an indicator of good 
SNP genotyping quality in our population. As our data were collected prospectively and 
independently from our research hypothesis, information bias is also unlikely. We adjusted 
for known cardiovascular risk factors as potential confounders, and these furthermore did 
not substantially change our risk estimates.
It is however possible that plaques already present in vessels might promote calcification 
and thus form an independent risk factor for aortic calcification. Vascular calcification can 
occur in the intima, always in the context of atherosclerosis, and in the media (Mőnckeberg’s 
sclerosis) where it is independent of atherosclerosis and almost exclusively associated with 
vascular smooth muscle cells.[18, 27] Calcification in the media is very diffuse and was not 
detectable by radiography or ultrasonography. Radiography, which was used to measure 
the calcification in the aorta, could not detect noncalcified plaques. Sonography, however, 
could distinguish calcified plaques in the intima from plaques consisting of lipids or polysac-
charides only. Such measurements were taken in our study population in the carotid artery 
during 1990 and October 1991. In contrast to the association between the T-allele and aortic 
calcification in our study population, the T-allele was not associated with an independent 
higher risk of 4 to 6 calcified plaques in the carotid artery. Repeating the analyses for ca-
rotid plaques in the whole population doubled the number of persons with available carotid 
measurements (884 with no carotid plaques detectable and 140 persons with 4 to 6 calcified 
carotid plaques) but did not change our results. A previous study within the Rotterdam Study 
had detected graded associations for coronary calcification with aortic calcification as well as 
with calcified carotid plaques.[28] In our study we found a high predictive value of calcified 
carotid plaques on aortic calcification (OR=3.05, 95% CI 2.61–3.56). However, cooccurrence 
of calcification in both vessels was quite low (Cohen’s kappa=0.41), and this may explain why 
the association with aortic calcification was not seen in carotid arteries. Thus we could not 
verify our hypothesis that the VKORC1 1173C>T polymorphism increases the risk of calcifica-
tion independently from the number of preexisting plaques. Yet this seems plausible, as in 
the animal experiment vascular calcification occurred in newborn rats which were unlikely to 
suffer from plaques already present.[17]
Our results may be important as vascular calcification is regarded as one of the major 
complications of cardiovascular disease.[36] It is now appreciated that the development 
of the atherosclerotic lesion ultimately causes plaque erosion and leads to rupture and to 
thrombus formation as one of the final events in atherosclerosis.[18, 37] On the other hand, 
in vitro studies for the impact of calcification on plaque stability showed protective rather 
than destabilizing influence on the atheromas.[38] This was in contrast to lipid pools that 
dramatically destabilized the plaques. Whether intimal calcification stabilizes atherosclerotic 
plaques or promotes its rupture is therefore still a matter of debate.[39]
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Abstract
The objective of this study was to investigate the influence of genotypes associated with re-
duced activity of vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome 
p450 2C9 (CYP2C9) on anticoagulation with acenocoumarol during the first 6 weeks of 
treatment. in 1,525 patients from the Rotterdam Study who were started on anticoagulation 
therapy with acenocoumarol, the presence of VKORC1 1173C>T and CYP2C9*2 and *3 allele 
variants was determined. The first international normalized ratio (INR) after initial standard 
dose, risk of overanticoagulation, and mean dosage at the end of the initiation period were 
compared between genotypes. The initial standard dosage significantly increased the risk of 
severe overanticoagulation by 85% for each additional VKORC1 T-allele present. at the end 
of the initiation period, each VKORC1 T-allele present was shown to decrease the required 
acenocoumarol dosage by 5.1 mg/week, while each CYP2C9 variant allele present reduced 
the required dosage by 1.8 mg/week. our conclusion was that an initial standard dosing regi-
men with acenocoumarol increases the risk of severe overanticoagulation in patients with 
variant alleles of the VKORC1 and CYP2C9 genes.
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Introduction
Clinical management of anticoagulation with coumarins is difficult, as the target range must 
be achieved with the use of drugs that have a narrow therapeutic index but high intra- and in-
terindividual variability in pharmacokinetic and pharmacodynamic response. Several recent 
studies have identified polymorphisms in the vitamin K epoxide reductase complex subunit 
1 (VKORC1) gene that contribute most to the variability between patients in response to 
coumarins.[1-8] Other known genetic risk factors for this variability are polymorphisms of the 
cytochrome P450 isoform 2C9 (CYP2C9) gene.[9] Important non-genetic risk factors are age, 
heart failure, impairment of liver function, vitamin K intake, drug-drug interactions, smoking, 
fever and non-compliance.[10-14] Genetic variations in the VKORC1 and CYP2C9 genes have 
been shown to account for 30-50% of the variability in dosing of warfarin. In view of this, the 
Food and Drug Administration, in 2007, added to the product information for warfarin a note 
that genetic data might be relevant to prescribing decisions.[15] In 2008, an expert group 
concluded that there was insufficient evidence to recommend routine CYP2C9 and VKORC1 
testing in warfarin-naïve patients and that prospective clinical trials were needed to provide 
evidence of the benefits and risks in the setting of initial warfarin dosing.[16] A recent review 
reached the same conclusion.[17] In the meantime, warfarin-dosage algorithms were devel-
oped and validated, and they are accessible online.[12, 18, 19] Recently, a pharmacogenetic 
approach was developed to allow clinicians to initiate warfarin therapy and then to change 
to a genetically predicted dose after 2-4 days of therapy.[18-20] However, this approach does 
not prevent the risk of severe overanticoagulation consequent to an initial standard dosage 
regimen in patients who are highly sensitive to coumarins.[21]
Given that most studies were performed using warfarin, we focused our study on aceno-
coumarol, a coumarin anticoagulant which is widely used in the Netherlands[22] and is 
effective in preventing thrombotic events.[23, 24] To date, only a few studies have been per-
formed relating to the association of polymorphisms in the VKORC1 and the CYP2C9 gene to 
anticoagulation response during initiation of acenocoumarol[4, 25] and during maintenance 
dosage of this drug.[26] Carriers of variant alleles of either of these genes all showed an 
increased risk for severe overanticoagulation with standard dosages of the drug and needed 
lower maintenance dosages. These studies included between 113 and 231 Caucasian sub-
jects and showed inconsistent results with respect to the arithmetical relationships between 
the two genes regarding dosage and the risk on severe overanticoagulation. Therefore, the 
objective of our study was to investigate the influence of variant alleles of the VKORC1 and 
CYP2C9 genes, independently and in combination, on the international normalized ratio 
(INR), severe overanticoagulation, and bleeding events after an initial standard dosage regi-
men of acenocoumarol in a large population-based cohort. In addition, the effect on severe 
overanticoagulation and the incidence of bleedings during the first 6 weeks of treatment and 
dosage at the end of initiation were evaluated.
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Methods
Setting
Data were obtained from the Rotterdam Study, a prospective population-based cohort study 
designed to study neurological, cardiovascular, locomotor, and ophthalmologic diseases in a 
population of people ≥55 years of age. The rationale and design of this study have been de-
scribed elsewhere.[27, 28] Participants were visited at home for a standardized questionnaire 
and were subsequently examined at the research center. During the first examination of the 
participants from 1990 to 1993, blood was taken and DNA was isolated. Additional patient 
information gathering, physical testing, and laboratory tests were performed at the first visit 
to the study center. A regional anticoagulation clinic monitors all inhabitants of Ommoord 
for indications requiring anticoagulant therapy. The choice of anticoagulant is made by the 
physician. All patients start with a standard dosing scheme of acenocoumarol (6-4-2 mg) 
from days 1 to 3. Prothrombin times are monitored every 1–6 weeks by reference to the INR 
depending on the stability of the anticoagulant level. Doses are adjusted on the basis of the 
INR of the patient via computerized calculations of required doses. Since 1984, collection of 
all data on dosing and on laboratory and clinical findings, such as data on bleeding episodes, 
is fully computerized.
Cohort definition
The study cohort consisted of all patients in the Rotterdam Study who started with aceno-
coumarol in the study period between 30 October 1985 and 8 December 2006 in whom 
genotyping for CYP2C9 as well as VKORC1 was successful and for whom an INR assessment 
was available within 4 days after the initial standard dosage of their treatment.
Outcomes
During this initiation period of acenocoumarol treatment, we distinguished three end points 
according to time points within the initiation period: the first INR assessment after initial 
standard dosage, the titration period of acenocoumarol during the first 6 weeks, and the 
end of the initiation period of 6 weeks. For these time-related end points, we estimated INR, 
severe overanticoagulation, bleeding episodes, or dosage as outcomes. The first end point 
at the first assessment after the initial standard dosage of acenocoumarol comprised the 
first INR as well as an INR≥6.0 and bleeding events. The second end point, at any time during 
the first 6 weeks of treatment, was an INR ≥6.0, or bleeding episodes (with distinction being 
made between minor and major episodes). Minor bleeds were skin bleeds and nosebleeds 
lasting for <10 min. Major bleeds were gastrointestinal, cerebrovascular, and urinary tract 
bleeds, and those within the eye or the female genital tract. The third end point, at the end of 
the initiation period of 6 weeks, was the mean dosage.
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Genotyping
Two common SNPs in the CYP2C9 system are associated with impaired metabolism of cou-
marins.29 Genotyping for the CYP2C9*2 and CYP2C9*3 allele variants was performed using 
PCR followed by restriction enzyme digestion analysis, as previously described.[9, 29] All 
CYP2C9*2 and CYP2C9*3 heterozygote and homozygote variants detected were reanalyzed. 
Patients with neither CYP2C9*2 nor CYP2C9*3 alleles were regarded as having the wild-type 
genotype (CYP2C9*1/*1). Allelic variants of CYP2C9, CYP2C9*2 (Arg144Cys), and CYP2C9*3 
(Ile359Leu) code for enzymes with ~12 and 5% of the enzymatic activity of the wild-type 
genotype CYP2C9*1/*1 (Arg144/Ile359), respectively. For genotyping of VKORC1 variant alleles, 
we chose the 1173C>T SNP in intron 1, dbSNP: rs9934438. This SNP is likely to be one of the 
putative functional SNPs of the VKORC1 gene and is recommended for genotyping.[30, 31] 
For carrying out the genotyping, genomic DNA was extracted from samples of peripheral 
venous blood in accordance with standard procedures.49 1–2 ng genomic DNA was dis-
pensed into 384-well plates using a Caliper Sciclone ALH3000 pipetting robot (Caliper LS, 
Mountain View, CA). Genotyping was performed using a Taqman allelic discrimination assay, 
as previously described.[32] In order to confirm the accuracy of genotyping results, 315 (5%) 
randomly selected samples were re-genotyped using the same method. No inconsistencies 
were observed. Patients with the VKORC1 CC genotype were regarded as having the wild-
type genotype.
Statistical analysis
Allele proportions were tested for deviations from Hardy-Weinberg equilibrium, using 
a χ2-test. The first INR after an initial standard dosage and the weekly dosage in those on 
acenocoumarol at the end of the initiation period were compared in VKORC1 and in CYP2C9 
genotypes, using linear regression analysis adjusted for age and gender. For the weekly dos-
age at the end of initiation period, we further adjusted for target INR and usage of CYP2C9 
co-medication. The following substrates and inhibitors of the CYP2C9 enzyme were consid-
ered as CYP2C9 co-medication: amiodarone, carbamazepine, chloramphenicol, cimetidine, 
diclofenac, fluconazole, fluvastatine, losartan, miconazole, phenylbutazone, phenytoin, 
sulfadiazine, sulfamethizole, sulfamethoxazole, sulfinpyrazone, tolbutamide, trimethoprim, 
and zafirlukast.[9]
All the genetic analyses described were performed with an allele-effect or genotype-effect 
model. Given the literature and confirmed by our findings (not shown), dominant/recessive 
models were not applicable. Subanalyses were performed for the CYP2C9 alleles within the 
strata of the VKORC1 genotype. Effect modification between variant alleles of the two genes 
was studied by adding multiplicative interaction terms to our model. Furthermore, the pos-
sibility of additive interaction was studied and expressed as excess relative risk reduction due 
to interaction.[33] The risk of experiencing an INR ≥6.0 after the initial standard dosage was 
analyzed using logistic regression analysis, adjusted for age and gender. These analyses were 
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performed using SPSS software, version 15.0 (SPSS, Chicago, IL). The risk on an INR ≥6.0 and 
the risk of experiencing bleeding episodes during the first 6 weeks of treatment were calcu-
lated by means of generalized estimating equation logistic regression analysis for repeated 
measurements, using STATA software, version 10.0 (StataCorp, College Station, TX) and also 
by means of Cox proportional hazard models in SPSS software, adjusted for age and gender.
Results
Among the 7,983 patients in the Rotterdam Study, genotyping showed polymorphisms in 
VKORC1 in 6,624 individuals (80%) and of CYP2C9 polymorphisms in 6,590 individuals (83%). 
A total of 6,355 patients (79.5%) had both VKORC1 and CYP2C9 genotyped. From the total of 
2,531 individuals from the regional anticoagulation clinic who were using acenocoumarol 
during the study period, 2,310 were participants of the Rotterdam Study. Of these, 1,680 
(73%) were genotyped for VKORC1 as well as CYP2C9 polymorphisms. We excluded 88 users 
who did not start with acenocoumarol but had been switched from phenprocoumon and 
67 patients for whom no data were available on the first INR after the initial starting dosage. 
Consequently, 1,525 patients were included in our study population (Table 1). The mean age 
of these patients was ~76 years, and 58% were female. All patients were of Caucasian origin. 
The main indications for anticoagulation were short-term prophylactic treatment (very low 
target INR); short-term prophylactic treatment, deep venous thrombosis, pulmonary embo-
lism, atrial fibrillation, and cerebral ischemia (low target INR); atrial fibrillation, myocardial 
infarction, vascular surgery, stroke, transient ischemic attacks, and peripheral artery disease 
(medium target INR); and prosthetic heart valves (high target INR). The frequency of occur-
rence of the VKORC1 T-allele was 39.3%, of the CYP2C9*2 allele, 13.4%, and of the CYP2C9*3 
allele, 5.7%. The cohort was in Hardy-Weinberg equilibrium for VKORC1 1173C>T SNP (P = 
0.41) and also for the CYP2C9*2 and *3 SNPs (P = 0.47 and P = 0.20, respectively).
The first end point was mean first INR, INR ≥6.0 and bleeding events after initial standard 
dosage. Measurement of the first INR after initial standard dosage was carried out on day 4 
because this interval is considered to be sufficient to monitor the anticoagulation effects 
of acenocoumarol, whose effect starts within 18–24 h and reaches a maximum at 36–48 h 
after initiating treatment.[34] We considered an INR ≥6.0 as to be severe overanticoagulation, 
given that an INR above 6 units is associated with a greatly increased risk of bleeding.[35]
For the 1,525 patients who started on a standard dosing scheme with acenocoumarol, 
there was a statistically significant association between the mean first INR and the number of 
variant alleles for VKORC1 (trend 0.33, 95% confidence interval (CI) 0.25–0.42, P value for trend 
<0.0001) and for CYP2C9 (trend 0.13, 95% CI 0.06–0.19, P value for trend <0.0001) (Table 2). 
A direct comparison of heterozygous and homozygous VKORC1 variant allele carriers with 
the wild-type CC genotype revealed a significant increase in the mean first INR in carriers of 
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variant alleles, with 0.35 units of INR for the CT genotype (95% CI 0.22–0.48) and 0.66 units 
(95% CI 0.48–0.84) for the TT genotype, respectively. Within CYP2C9 variant alleles, the mean 
first INR, as compared to the wild-type genotype, showed significant increases: 0.20 INR units 
(95% CI 0.05–0.35) for the CYP2C9*1/*2 genotype, 0.49 INR units (95% CI 0.06–0.92) for *2/*2, 
and 0.53 INR units (95% CI 0.08–0.97) for the *2/*3 genotype. No multiplicative interaction 
between variant alleles of was found for either of the genes. As shown in Figure 1, the risk 
of a high INR increased with the type and number of variant alleles. However, within the 
strata of VKORC1 genotypes, the tendency of average INR to increase with increasing number 
of CYP2C9 variant alleles was comparable, although averages were somewhat imprecise in 
the VKORC1 TT stratum. Twenty-eight patients (2%) had a first INR ≥6.0 at the first assess-
ment after an initial standard dosage (Table 2). The risk of an INR ≥6.0 after initial standard 
starting dosage rose significantly with the increase in the number of VKORC1 T-alleles (OR 
Table 1 Characteristics of the study population
Number of patients 1,525
Age in years, average (SD) 75.8 (7.9)
Gender (%)
 Male
 Female
642 (42.1)
883 (57.9)
Number of patients within a target INR level (%)*
 Very low INR: 2.0 – 2.5
 Low INR: 2.5 – 3.5
 Medium INR: 3.0 – 4.0
 High INR: 3.5 – 4.5
58 (3.8)
881 (57.8)
583 (38.2)
3 (0.2)
Mean weekly dosage at the end of the initiation period (range) [mg] 15.9 (2 – 50)
Genotype CYP2C9, n # (%)
 CYP2C9*1/1
 CYP2C9*1/2
 CYP2C9*1/3
 CYP2C9*2/2
 CYP2C9*2/3
 CYP2C9*3/3
1,003 (65.8)
321 (21.0)
141 (9.2)
30 (2.0)
28 (1.8)
2 (0.1)
Genotype VKORC1$ (%)
 VKORC1 CC
 VKORC1 CT
 VKORC1 TT
554 (36.3)
743 (48.7)
228 (15.0)
HWE: p-value for VKORC1 T-allele = 0.410. P-value for CYP2C9*2 = 0.472, p-value for CYP2C9*3 = 0.197. In 
the study of Schalekamp et al the allelic frequency was 9.5% for the CYP2C9*2 allele and 10.4% for the 
CYP2C9*3 allele, for the VKORC1 T-allele of the same SNP it was 40.9%.[4]
CYP2C9, cyotochrome P450 isoform 2C9; HWE, Hardy Weinberg Equilibrium; INR, international normalized 
ratio; VKORC1, vitamin K epoxide reductase complex subunit 1.
* In our study population target INR levels were mainly used with the following indications: very low 
target INR for short-term prophylactic treatment. Low target INR for short-term prophylactic treatment, 
deep venous thrombosis, pulmonary embolism, artrial fibrillation and cerebral ischemia. Medium target 
INR for artrial fibrillation, myocardial infarction, coronary bypass, vascular surgery, stroke, transient 
ischemic attacks, periphery artery disease. High INR target for prosthetic heart valves.
#Allelic frequency 80.9 %, for CYP2C9*1, 13.4% for CYP2C9*2 and 5.7 % for CYP2C9*3.
$ Allelic frequency for the VKORC1 C-allele 60.7% and for the T-allele 39.3%.
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1.85, 95% CI 1.08–3.16). Patients with a VKORC1 TT genotype had a 3.54-fold increased risk 
(95% CI 1.1–11.3) of an INR ≥6.0 after initial standard dosage as compared to patients with 
the VKORC1 CC genotype. For CYP2C9 there was a slight but nonsignificant trend toward an 
Table 2 After initial standard dosage with acenocoumarol: first INR and risk of severe overanticoagulation
Genotype Number of 
patients
within 
population
First mean 
INR (SE)
Difference with wild type 
genotype(95% CI) a
Number of patients with 
an INR≥6 at the first 
assessment (% of patients 
within genotype)
OR on INR≥6 at the first 
assessment (95% CI) b
CYP2C9 1,525 Trend: 0.13 (0.06 – 0.19) 28 (2.0) Trend 1.26 (0.89 – 1.78)
*1/*1c 1,003 2.7 (0.04) - 17 (1.7) -
*1/*2 321 2.9 (0.07) 0.20 (0.05 – 0.35) 5 (1.6) 0.92 (0.34 – 2.53)
*1/*3 141 2.8 (0.10) 0.16 (-0.05 – 0.37) 3 (2.1) 1.25 (0.36 – 4.33)
*2/*2 30 3.2 (0.27) 0.49 (0.06 – 0.92) 2 (6.7) 4.08 (0.90 – 18.5)
*2/*3 28 3.2 (0.21) 0.53 (0.08 – 0.97) 1 (3.6) 2.21 (0.28 – 17.3)
*3/*3 2 3.3 (0.15) 0.52 (-1.13 – 2.16) 0 (0) 0
VKORC1d 1,525 Trend 0.33 (0.25 – 0.42) 28 (2.0) Trend 1.85 (1.08 – 3.16)
CC 554 2.5 (0.04) - 5 (0.9) -
CT 743 2.8 (0.05) 0.35 (0.22 – 0.48) 16 (2.2) 2.43 (0.88 – 6.68)
TT 228 3.1 (0.09) 0.66 (0.48 – 0.84) 7 (3.1) 3.54 (1.11 – 11.3)
Statistically significant values are in bold printing
a linear regression model, adjusted for age and gender
b logistic regression model, adjusted for age and gender
c CYP2C9 *1/*1 genotype is defined as wildtype genotype.
d VKORC1 CC genotype is defined as wildtype genotype.
Figure 1 After an initial standard dosage with acenocoumarol: first INR
Figure 1 After an initial standard dosage with acenocoumarol: first INR 
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INR ≥6.0 after initial dosage (OR 1.26, 95% CI 0.89–1.78) for each variant allele. Interactions 
of variant alleles of both genes could not be calculated, because among the subjects with a 
combination of a VKORC1 wild-type genotype and a CYP2C9 variant genotype there were no 
patients with an INR ≥6.0. We therefore repeated this analysis with the 67 patients with an 
INR ≥5.0 and compared the results with those of patients with an INR below 5.0. Again, no 
multiplicative or additive interaction was found for VKORC1 and CYP2C9 variant alleles (P = 
0.123 for multiplicative interaction and the relative excess risk reduction due to interaction 
was 0.6 (95% CI −2.2 to 3.5)). Of the five bleeding events after initial standard treatment, one 
was minor and four were major bleeds. The minor bleed, a nosebleed for <10 min, was in a 
patient with the VKORC1 CC genotype and the CYP2C9 *1/*3 genotype. Of the major bleeds, 
one gastrointestinal bleed occurred in a patient who also had the VKORC1 CC genotype and 
the CYP2C9 *1/*3 genotype. The other two gastrointestinal bleeds and one vaginal bleed 
occurred in patients with the VKORC1 CT genotype and the CYP2C9 *1/*1 genotype.
The second end point was INR ≥6.0 and bleeding events during the first 6 weeks of treatment. 
The full first 6 weeks of treatment of the initiation period on acenocoumarol were completed 
by 1,521 patients. In total, there were 126 events of an INR ≥6.0 in 111 patients, representing an 
incidence rate of two events per 1,000 days of use. Repeated measurements analysis showed 
that there was a statistically significantly increase in the risk of occurrence of an INR ≥6.0 as-
sociated with an increase in the number of variant alleles of VKORC1 (OR for trend 1.57, 95% 
CI 1.19–2.07) (Table 3) and of CYP2C9 (OR for trend 1.28, 95% CI 1.04–1.56). For each of the 
genes, the homozygous variant genotypes were associated with a significantly increased risk 
Table 3 During initiation period of six weeks: risk of bleeding and severe overanticoagulation
Geno-
type
Number of 
patients
Number 
INR mea-
surements
Patients with 
at least one 
bleeding (%)
Combined 
genotype
OR bleedings a 
(95% CI)
OR on INR≥6 b 
(95% CI)
HR of the INR≥6 c 
(95% CI)
CYP2C9 1,521 8,939 58 (3.8) Trend 0.98 (0.62 – 
1.54))
Trend 1.28 (1.04 
– 1.56)
Trend 1.36 (0.81 
– 2.29)
*1/*1 1,002 5,864 35 (3.5) *1/*1 - - -
*1/*2 320 1,896 12 (3.8) *1/*2, *1/*3 0.93 (0.39 – 2.23) 1.17 (0.76 – 1.80) 0.92 (0.34 – 2.49)
*1/*3 139 830 9 (6.5)
*2/*2 30 166
1 (3.3)
*2/*2, *2/*3, 
*3/*3 0.65 (0.09 – 4.89)
2.73 (1.28 – 5.86) 3.41 (0.79 – 14.8)
*2/*3 28 167 0 (0)
*3/*3 2 16 1 (50)
VKORC1 1,521 8,939
58 (3.8)
Trend 0.75 (0.41 
– 1.38)
Trend 1.57 (1.19 
– 2.07)
Trend 1.86 (1.04 
– 3.31)
CC 552 3,296 20 (3.6) - - -
CT 743 4,349 29 (3.9) 0.63 (0.26 – 1.51) 1.56 (0.98 – 2.48) 1.80 (0.63 – 5.11)
TT 226 1,294 9 (4.0) 0.69 (0.23 – 2.03) 2.46 (1.42 – 4,.28) 3.44 (1.09 – 10.9)
Statistically significant values are in bold printing
a GEE logistic regression model for repeated measurements, adjusted for age and gender; b logistic 
regression model, adjusted for age and gender; c COX proportional hazards model on INR≥6.0 and time to 
event, adjusted for age and gender
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of an INR ≥6.0. Also, in these analyses we did not find a significant multiplicative or additive 
interaction between the effects of the two genes. Cox proportional hazard models showed 
comparable hazard ratios, although with broader CIs, due to the fact that in these models 
only the first event was taken into account (Table 3). During the initiation period, 82 bleeding 
episodes were recorded in 58 patients, of which 40 were classified as major. The percentage 
of patients experiencing bleeding and severe overanticoagulation during the first 6 weeks of 
treatment increased with the number of variant alleles of both genes that were present (Figure 
2). However, repeated measurements analysis did not detect any significantly increased risks 
for bleeding events in patients with variant alleles of either of the genes (Table 3).
The third end point was mean dosage at the end of the 6-week treatment period. We took 
the mean dosage at the end of the first 6 weeks of treatment. The steady state of a drug 
level is usually achieved within 5–7 half-lives of drug elimination. For acenocoumarol with a 
half-life of 2 days for the S-enantiomer, this period would be sufficient even if its elimination 
is prolonged in patients with CYP2C9 variant alleles.[16, 30, 34] In the 1,521 patients who 
completed the 6-week initiation period on acenocoumarol, the dosage in mg/week had 
to be significantly titrated downward in association with an increasing number of VKORC1 
T-alleles (−5.1, 95% CI −5.5 to −4.7, P value for trend <0.0001) and of CYP2C9 variant alleles 
(−1.8, 95% CI −2.1 to −1.5, P value for trend <0.0001) (Table 4 and Figure 3). There was a 
significant multiplicative interaction between the effects of the genes on decrease of dos-
age (P = 0.02). All analyses were adjusted for age and gender. Repeating the analyses and 
adjusting additionally for target INR did not change the results. In our study population at the 
end of the initiation period, the VKORC1 variant alleles explained 28% of the variation in the 
acenocoumarol dosage, whereas 5% of the dosage variation was due to CYP2C9 genotype. A 
combined model, including age and gender, could explain 46% of the variation in acenocou-
marol dosage at the end of the initiation period.
Figure 2 Percentage of patients with an INR≥6 and bleeding events during the first six weeks of treatment
Figure 2 Percentage of patients with an INR6 and bleeding events during the first six weeks of 
treatment 
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Discussion
The results of our study showed an unambiguous association between the first INR after an 
initial standard dosage of acenocoumarol and the presence of three genetic polymorphisms 
with a repeatedly demonstrated influence on coumarin and vitamin K metabolism.[1, 2, 4, 6, 
7, 12, 25, 36-38] Initial INRs were consistently higher in patients with one or two variant alleles. 
After initial standard dosage, 2% of all the acenocoumarol-treated patients developed an INR 
that put them at a strongly increased risk of bleeding. The general assumption that patients 
can be safely treated by titration of dose on the basis of regular INR assessment may be too 
optimistic, given that the level of the first INR cannot be predicted without prior knowledge 
of the genotype status of an individual. It is also a likely explanation for the fact that, despite 
many efforts to bring down the risk, bleeding during the use of coumarin anticoagulants is 
still one of the leading causes of drug-related hospital admissions in most Western countries.
[39, 40] In many European countries, for instance, France and the Netherlands, the coumarin 
anticoagulant acenocoumarol is used instead of warfarin. Of the 100,646 patients who were 
started on acenocoumarol in the Netherlands in 2007, 2% of bleeding episodes after initial 
standard treatment would correspond to more than 2,000 patients developing an INR ≥6.0 
within 4 days after initial treatment. This might account for the substantial number of hospi-
tal admissions resulting from bleeding due to coumarins in the Netherlands.[41] Given that 
Figure 3 At the end of the initiation period: dosage of acenocoumarol [mg/week]
Figure 3 At the end of the initiation period: dosage of acenocoumarol [mg/week] 
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the combination of age, gender, and polymorphisms of CYP2C9 and VKORC1 explains nearly 
50% of acenocoumarol dosage variation, substantial improvements can be expected from a 
dosage algorithm that includes these variables. As long as the first dose of acenocoumarol is 
standard and only the second dose is titrated, the risk of overanticoagulation at the start of 
treatment will not decline. Only prior knowledge of the VKORC1- and CYP2C9-gene status of 
a patient may bring down this risk.
During the 6-week initiation period, each dosage following an INR measurement was 
titrated if not within the INR target range, resulting in a significant dosage decrease in those 
with VKORC1 and CYP2C9 variant alleles. Despite this, the risk of severe overanticoagulation 
remained higher in patients with variant alleles of either of the genes. When we adjusted for 
prior dosage in subanalyses of INR measurements, the effects of variant alleles on serious 
overanticoagulation were shown to be even stronger. This finding indicates that persons with 
variant alleles remain relatively unstable in comparison to those with the wild-type geno-
type, and that the step-by-step dosage titration is not sufficient to cope with this condition. 
Our results are in agreement with earlier studies that showed that variant alleles of VKORC1 
and CYP2C9 are associated with an increased risk of severe overanticoagulation in users of 
acenocoumarol and warfarin, respectively. These events occurred mainly in the early stages 
of treatment [4, 5, 7, 25] but persisted even after stabilization.[26] Furthermore, these studies 
showed that a prolonged time is required to achieve stability in patients with variant alleles.
[42] We did not find an increased risk of bleeding episodes in patients with variant alleles of 
either of the genes. Although this finding is in agreement with the results of earlier studies of 
the effects of VKORC1 and CYP2C9 variant alleles during initiation with acenocoumarol, it may 
also be explained by a lack of power in the study design, given that the bleeding episodes are 
less frequent than the occurrence of an INR ≥6.0.[3, 43]
The modifications brought about by CYP2C9- and VKORC1-gene status on the effects 
of coumarins are regarded as being independent of each other rather than synergistic.
[25, 30] However, no strict arithmetical relationship was found. Another study found a 
multiplicative interaction between variant alleles of the two genes with respect to the risk 
of severe overanticoagulation.[4] Our results did not confirm these findings. Instead, we 
found an independent additive effect of both genes on INR and severe overanticoagulation. 
However, we did find a multiplicative interaction between genotypes of the two genes for 
the mean dosage at the end of the initiation period. This might be because, in patients 
with the VKORC1 CC genotype, variant alleles of CYP2C9 had a higher impact on the mean 
dosage than in individuals with the variant VKORC1 genotype. Thus, different studies 
show inconsistent arithmetic relationships between the two genes for dosage and severe 
overanticoagulation. Etiologically, however, it is less likely that the effects of variant alleles 
of VKORC1 differ in the presence of variant alleles of CYP2C9, or vice versa, because the 
mechanisms of operation are very different. Linkage disequilibrium is unlikely because the 
VKORC1 gene is located on chromosome 16p11.2 and the CYP2C9 gene on chromosome 
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10q24, and their polymorphisms would therefore be expected to segregate independently 
in populations.[30]
The mean weekly dosage at the end of the initiation period might have been affected by 
the target INR. Moreover, interacting drugs could lead to changes being made in coumarin 
dosage. Although this is usually an effect modifier rather than a confounder, in the case of 
CYP2C9- metabolized drugs confounding might occur. However, adding these variables to our 
regression model did not change the results (Table 4). In subanalyses we further compared 
the number of dose adjustments needed during the first 6 weeks of the initiation period, and 
we did not detect any differences between the genotypes. We further studied whether pa-
tients had an increased risk of being below or above their target range. Here also, we did not 
detect any difference between the genotypes (data not shown). Despite the observational 
nature of our study, we think that the chance of bias and confounding is negligible. First, the 
Rotterdam Study is a prospective cohort study, and the regional anticoagulation clinic cov-
ered a complete area containing more than one million inhabitants in the Rotterdam region. 
Consequently, everyone who is treated as an outpatient with a coumarin anticoagulant will 
be registered as such, and selection bias is highly unlikely. This is confirmed by the fact that, 
in our study population, genotypes for both genes were in Hardy-Weinberg equilibrium. The 
allele frequencies of the variant alleles were comparable to results for the same SNPs in other 
Caucasian populations,[4] except that the frequency of occurrence of the CYP2C9*3 allele was 
quite high in that study, whereas other studies showed lower allele frequencies for this SNP 
Table 4 At the end of the initiation period: mean dosage of acenocoumarol
Geno-
type
Number of 
patients
Mean dosage 
at the end of 
initiation in 
mg/week
Difference with wild type 
genotype in mg/week (95% 
CI) a
Difference with wild type 
genotype in mg/week 
(95% CI)b
Difference with wild type 
genotype in mg/week 
(95% CI)c
CYP2C9d 1,521 Trend –1.80 (-2.14-[-1.46]) Trend - 1.80 (-2.14 - [-1.46]) Trend -1.80 (-2.14 - [-1.40])
*1/*1 1,002 16.9 - - -
*1/*2 320 14.8 -2.27 (-3.03 - [-1.51]) -2.26 (-3.02 - [-1.50]) -2.27 (-3.02 - [-1.51])
*1/*3 139 13.7 -3.73 (-4.80 - [-2.66]) -3.72 (-4.79 - [-2.65]) -3.71 (-4.77 - [-2.64])
*2/*2 30 11.8 -5.06 (-7.25 - [-2.87]) -5.09 (-7.27 - [-2.90]) -5.12 (-7.31 - [-2.94])
*2/*3 28 10.9 -6.43 (-8.70 - [-4.17]) -6.44 (-8.71 - [-4.18]) -6.46 (-8.73 - [-4.20])
*3/*3 2 8.5 -9.43 (-17.8 - [-1.07]) -9.32 (-17.7 - [-0.95]) -9.44 (-17.8 - [-1.09])
VKORCe 1,521 Trend –5.09 (-5.47 - [-4.71]) Trend –5.09 (-5.47 - [-4.71]) Trend 5.08 (-5.46 - [-4.70])
CC 552 20.1 - - -
CT 743 14.7 -5.08 (-5.65 - [-4.51]) -5.08 (-5.65 - [-4.51]) - 5.09 (-5.66 - [-4.52])
TT 226 9.9 -10.2 (-11.0 - [-9.38]) -10.2 (-11.0 - [-9.38]) -10.2 (-11.0 - [-9.35])
The first six weeks of treatment were taken as initiation period. Statistically significant values are in bold 
printing
a linear regression model, adjusted for age and gender. b linear regression model, adjusted for age, gender 
and target INR. c linear regression model, adjusted for age, gender, target INR and CYP2C9 co-medication. 
d CYP2C9 *1/*1 genotype is defined as wildtype genotype. e VKORC1 CC genotype is defined as wildtype 
genotype.
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also.[44] Furthermore, another CYP2C9 genotype, *1l, which is associated with the need for 
a lower warfarin dose, is not detected by the Taqman system.[45] This might cause misclas-
sification of this genotype into the group of the *1 genotypes. However, irrespective of the 
direction of misclassification, such misclassification will be random and would therefore lead 
to conservative risk estimates rather than to falsely increased ones.
Because all data on exposure and diseases are prospectively gathered without knowledge 
of future research hypotheses, information bias is improbable. Furthermore, we adjusted 
for all known confounders, including the target INR range. Also, we expected few- if any 
-confounding in the association between genotypes and the outcomes in this study. As we 
had data only from the regional anticoagulation clinic, we might have missed information 
pertaining to patients with treatment initiation in a hospital. However, the exclusion of pa-
tients with hospital admissions prior to the start of coumarin therapy recorded by the local 
anticoagulation clinic did not change our results.
Personalized dosage of coumarins by genotyping prior to coumarin therapy might help to 
prevent serious adverse effects.[46] The feasibility of prospective application of gene-based 
coumarin dosing has been shown earlier, and adverse effects were fewer in patients with 
a personalized starting dosage than in those with a standardized starting dosage.[18, 46, 
47] Additionally, it is important to investigate cost-effectiveness and the clinical utility of 
pharmacogenetic testing, keeping in mind that, although genotype-based dosage regimens 
reduce the risk of serious adverse effects, the delay in initiating therapy while awaiting geno-
typing could expose the patient to a higher risk of clotting.[30, 48] However, as initiation of 
coumarins is accompanied by therapy with low-molecular heparins, no serious harm should 
be expected in delaying treatment by a day. Initiation of a standard therapy and changing to a 
genetically adjusted dose algorithm after 2–4 days may be an alternative. The time and costs 
needed for genotyping are rapidly decreasing, while the accuracy, speed, and sophistication 
of diagnostic instruments are improving.[49, 50] If the level of the first INR can be modified by 
a genetically adjusted dose algorithm, this might contribute to safety in health care.
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Abstract
Several genome-wide association studies have been performed on warfarin. For acenocou-
marol, the most frequently used coumarin in many countries worldwide, pharmacodynamic 
influences are expected to be comparable. Pharmacokinetics however might differ. We aimed 
to confirm known or identify new genetic variants contributing to interindividual variation on 
stabilized acenocoumarol dosage by a GWAS. The index population consisted of 1451 Cauca-
sian subjects from the Rotterdam study and results were replicated in 287 subjects from the 
Rotterdam study extended cohort. Both cohorts were genotyped on the Illumina 550K Hu-
man Map SNP array. From polymorphisms tested for association with acenocoumarol dosage, 
35 single nucleotide polymorphisms (SNPs) on chromosome 16 and 18 SNPs on chromosome 
10 reached genome-wide significance. The SNP with the lowest P-value was rs10871454 on 
chromosome 16 linked to SNPs within the vitamin K epoxide reductase complex subunit 1 
(VKORC1) (P= 2.0 × 10−123). The lowest P-value on chromosome 10 was obtained by rs4086116 
within cytochrome P450 2C9 (CYP2C9) (P=3.3 × 10−24). After adjustment for these SNPs, the 
rs2108622 polymorphism within cytochrome P450 4F2 (CYP4F2) gene on chromosome 19 
reached genome-wide significance (P= 2.0 × 10−8). On chromosome 10, we further identified 
genetic variation in the cytochrome P450 2C18 (CYP2C18) gene contributing to variance 
of acenocoumarol dosage. Thus we confirmed earlier findings that acenocoumarol dosage 
mainly depends on polymorphisms in the VKORC1 and CYP2C9 genes. Besides age, gender, 
body mass index and target INR, one polymorphism within each of the VKORC1, CYP2C9, 
CYP4F2 and CYP2C18 genes could explain 48.8% of acenocoumarol dosage variation.
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Introduction
Clinical management of anticoagulation with coumarins is difficult, as a target range has to 
be achieved by drugs with a narrow therapeutic index and high intra- and interindividual 
variability in pharmacokinetic and pharmacodynamic response. In Caucasians, single nucleo-
tide polymorphisms (SNPs) in the vitamin K epoxide reductase complex subunit 1 (VKORC1) 
and cytochrome P450 2C9 (CYP2C9) genes are more strongly correlated with stabilized cou-
marin dosage than all other known patient-related factors.[1-11] Other candidate genes that 
are part of the vitamin K pathway, vitamin K dependent clotting factors or minor metabolic 
or transport pathways have been systematically screened and showed weaker associations 
with warfarin maintenance dosage.[12] Recently, a candidate gene study on warfarin dos-
ing found that CYP4F2 genetic variation explained an additional 2% of dosage variation.
[13] This result was replicated.[14] As genetic variation in the VKORC1 and CYP2C9 genes 
in combination with age, gender and body mass index (BMI) accounted for 30–50% of the 
variability in dosing of warfarin, the Food and Drug Administration in 2007 extended the 
product labelling information of warfarin mentioning that genetic data might be relevant 
to prescribing decisions.[15] Most studies focused on warfarin, the worldwide mostly used 
coumarin drug. Acenocoumarol, which is the preferred coumarin in The Netherlands [16] 
and many other countries worldwide, has been studied for associations of polymorphisms 
in the VKORC1 and the CYP2C9 genes with outcomes in acenocoumarol treatment in four 
studies for initiation period [2, 17-19] and in three studies for maintenance dosage [1, 20, 
21]. Both VKORC1 and CYP2C9 polymorphisms were not only independently correlated with 
acenocoumarol maintenance dose, but also with first international normalized ratio (INR) 
after initial standardized dosage, time to stabilized dose, time within the target therapeu-
tic range and to bleeding events. It is expected that more reliable personalized coumarin 
dosing strategies could improve quality of care as well as enable safer treatment in more 
patients who would benefit from anticoagulation therapy.[22, 23] Therefore, it is important to 
determine whether there are common variants in genes which affect acenocoumarol dosage. 
Genome-wide association studies (GWAS) covering the majority of common variation in the 
human genome can be used in large samples to identify genetic variants that typically confer 
modest effect sizes for quantitative complex traits, defined in homogenous phenotypes, such 
as INR and coumarin dosage. The dose prediction models already developed for warfarin may 
not be applicable to acenocoumarol because of differences in pharmacokinetics between 
these coumarines.[24] A GWAS of acenocoumarol dosage either confirming already known 
or identifying new genetic influences may supply important information for the clinical trials 
on genotype predicted dosage being under way. Therefore, we conducted a GWAS in two 
independent cohorts to identify polymorphisms that could explain a large fraction of the 
variance in acenocoumarol maintenance dosage.
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Materials and methods
Setting and inclusion criteria
This study was carried out within the baseline cohort of the Rotterdam study (RS-I), consist-
ing of 7983 (response 78%). Subsequently, findings were replicated in the first extended 
cohort of the Rotterdam study (RS-II) with 3011 (response 67%) participants. The rationale 
and design of the Rotterdam study have been described elsewhere.[25, 26] In brief, the 
Rotterdam study is a prospective population-based cohort study, designed to study neuro-
logical, cardiovascular, locomotor and ophthalmological diseases in a population of people 
of 55 years and older. The RS-I cohort had baseline examinations during 1990–1993 with 
completion of standardized questionnaires, sampling of blood and isolation of DNA. The RS-II 
cohort consisted of a second independent cohort formed in 1999 with baseline examinations 
between 2000 and 2001.
A regional anticoagulation clinic monitors all inhabitants of Ommoord with an indication 
for anticoagulant therapy. This clinic covers the patients of the RS-I cohort as well as those 
from the RS-II cohort. The physician who treats the patient makes the choice of anticoagu-
lant. Up to now, all patients start with a standard dosing scheme of acenocoumarol (6–4–2 
mg) during day 1 up to day 3. Prothrombin times are monitored every 1–6 weeks by refer-
ence to the INR, dependent on the stability of the anticoagulant level. Doses are adjusted on 
the basis of the INR of the patient by computerized dose calculations. Since 1984, all data 
on dosing, laboratory and clinical data, including data on bleeding complications are fully 
computerized.
From both cohorts, subjects were included in our study population if they were genotyped 
for GWAS, and if they had started with acenocoumarol in the study period between 30 Octo-
ber 1985 and 8 December 2006, and if they had an INR assessment within 4 days after initial 
standard dosage of their treatment. Patients who were switched to or from phenprocoumon 
during the first 6 weeks of acenocoumarol treatment were excluded.
Genotyping
RS-I cohort. Genomic DNA was extracted from whole blood samples using the salting 
out method [27]. Micro array genotyping was performed in the whole RS-I cohort with 
proper quality DNA samples (n =6449) using the Infinium II HumanHap 550K Genotyping 
BeadChipw version 3 (Illumina, San Diego, CA, USA). The Illumina 550K Bead Chip array was 
genotyped in all participants of the original Rotterdam study cohort with proper quality DNA 
samples (n =6449). Intensity files were analyzed using the Bead Studio Genotyping Module 
software v.3.1.14. A no-call threshold of 0.15 was applied to a custom-generated cluster file 
derived from the Illumina-provided cluster file (based on the cluster definitions applied to 
the HapMap CEPH cohort). In the custom-cluster file, 2308 SNPs with GenCall scores less 
than 0.90 were visually checked by two observes and manually reclustered or zeroed ac-
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cordingly. Poorly performing samples with low call rate and 10th percentile GenCall score 
were excluded prior to calling genotypes. Any samples with a call rate below 97.5% (n = 209), 
excess autosomal heterozygosity >0.336 ~FDR <0.1% (n = 21), mismatch between called and 
phenotype gender (n = 36), or if there were outliers identified by the IBS clustering analysis 
(see below), clustering more than three standard deviations away from the population mean 
(n = 102) or if there were outliers identified by the IBS clustering analysis, clustering >3>97% 
(n = 129) were excluded from the analysis. In total, we disposed over 5974 analyzed samples 
having passed QC and inclusion criteria.
RS-II cohort. Genotyping was targeted in the whole RS-II cohort using the Infinium II Hu-
manHap 550K Duo Genotyping BeadChipR version 3 (Illumina) as part of a large population-
based project on genetics of complex traits and diseases, financed by the Dutch govern-
ment through the Netherlands Scientific Organization—Large Investments (NWO Groot; 
175.010.2005.011). Of the 3011 RS-II participants, 2613 (86.7%) gave consent for DNA analysis. 
Of these, 2548 (97.5%) were plated and included for the genome-wide genotyping. In the 
current study, we use the first set of RS-II samples made available on September 2008, which 
was genotyped successfully for 2020 samples of which 1895 remained for analyses after 
QC. We describe below the genotyping and QC processes for this first RS-II set. Genotyping 
procedures were followed according to Illumina manufacturer’s protocols. All participants of 
the RS-II cohort with proper quality DNA samples (n ¼ 2611) were genotyped with the array. 
Intensity files were analyzed using the Beadstudio Genotyping Module software v.3.2.32. A 
no-call threshold of 0.15 was applied to a custom-generated cluster file derived from the 
Illumina-provided cluster file (based on the cluster definitions applied to the HapMap CEPH 
cohort). Poorly performing samples with very low call rate (90%) and 10th percentile GeneCall 
score were excluded prior to calling genotypes. Any samples with a call rate below 97.5% 
or pending to be processed (n = 528), excess of autosomal heterozygosity (F< 20.05; n = 5) 
mismatch between called and phenotypic gender (n = 14), or if there were genetic outliers 
identified by the IBS clustering analysis (clustering more than three standard deviations away 
from the RS-II population mean; n = 81) or with IBS probabilities more than 40% (n = 25) were 
excluded from the analysis; in total, 1895 samples were analyzed. Of the 1895 individuals 
with a mean age of 65.20 (SD 8.34) years, 1032 (54.45%) were women.
Genotyping of CYP2C9*2 and VKORC1 C1173C>T. In order to check LD with variant alleles 
of these two genes which were not included in the Illumina 550 array, we included the cor-
responding SNPs which had already been genotyped within both study cohorts and were 
used in earlier studies [18, 24]. Genotyping for CYP2C9*2 allele variants was performed using 
the polymerase chain reaction followed by restriction enzyme digestion analysis (PCR-RFLP), 
as previously described [28]. For genotyping of the VKORC1 1173C>T SNP in intron 1, dbSNP: 
rs9934438, a TaqMan allelic discrimination assay was used as previously described [29].
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Phenotype definition
The mean weekly acenocoumarol dosage at the end of the first 6 weeks of treatment was 
regarded as stable maintenance dosage. Steady state of a drug is usually achieved within 5–7 
half-lives of drug elimination. The (S)-enantiomeric form of acenocoumarol has a 2–5-fold 
higher anticoagulant potency than the (R)-form. For acenocoumarol with a half-life of 2 h for 
the S-enantiomere, the initiation period of 6 weeks would be sufficient to reach steady state, 
even if its elimination was prolonged in patients with CYP2C9 variant alleles[30].
Statistical analysis
Basic model. The overall strategy involved linear regression analysis for the genotype–pheno-
type association of all SNPs within the Illumina 550 array in the index cohort and replication 
of the associations found in the second cohort. SNPs with a minor allele frequency, 0.01, a 
genotype call rate more than 95% or an exact HWE P-value less than 0.0001 were excluded 
from the analysis. We a priori declared results significant at P < 5 × 10−8, based on estimation 
of the multiple testing burden for GWAS of nearly all common variants in the human genome 
of European ancestry individuals for a target genome-wide α= 0.05.[31] For replication of the 
specific SNPs associated with acenocoumarol dosage within the index cohort, in the replica-
tion cohort, a P-value less than 0.05 was considered significant. This was done first with a 
basic model for dosage at the end of 6 weeks initiation period as outcome, adjusted for the 
clinical factors age, gender and BMI and the patient’s target INR. Target INR was included into 
our model in order to adjust for necessity of higher dosages due to intended therapeutic INR 
values. BMI was defined as (kg/m2) and missing values were imputed with a regression model 
consisting of maintenance dosage as outcome with age, gender and target INR as variables. 
In order to adjust acenocoumarol maintenance dosage by these covariates, the unstandard-
ized residuals from an additive linear regression model were used for genotype–phenotype 
associations in GWAS.
Extended model and meta-analysis. In order to detect SNPs within other genes indepen-
dently associated with acenocoumarol dosage, we repeated GWAS in an extended model 
further adjusting for influences of VKORC1 and CYP2C9 as done previously in the GWAS of 
warfarin [32]. In the extended model, those SNPs were taken as independent co-variates that 
were found by the basic model to be the strongest associated SNPs from the VKORC1 and 
from the CYP2C9 locus. For the extended model, we performed a meta-analysis combining 
the results of both GWAS from RS-I and RS-II using the beta estimates with inverse variance 
weighting and genomic control to control for inflation.
Subanalyses. As acenocoumarol maintenance dosage is the result of dosage titration due to 
INR measurements, the first INR after standard dosage is an outcome more directly represent-
ing the reaction of a patient to the drug. Therefore, we repeated GWAS for the basic model in 
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subanalyses with the first INR after the initial standard dosage scheme of acenocoumarol at 
the fourth day of treatment as outcome. In order to adjust for influences of co-medication on 
the acenocoumarol maintenance dosage, we repeated the GWAS including also current use 
of substrates and inhibitors of the CYP2C9 enzyme besides the variables of the basic model 
in a second subanalysis. As CYP2C9 co-medication, the following drugs were considered: 
amiodarone, carbamazepine, chloramphenicol, cimetidine, diclofenac, fluconazole, fluvas-
tatine, losartan, miconazole, phenylbutazone, phenytoin, sulphadiazine, sulphamethizole, 
sulphamethoxazole, sulphinpyrazone, tolbutamide, trimethoprim and zafirlukast.[28] In a 
third subanalysis, we repeated GWAS of acenocoumarol maintenance dosage adjusting for 
vitamin K intake at baseline besides the variables of the basic model.
Regression model on dosage for clinical impact. In a multivariate linear regression model, the 
additional contribution of newly found genetic factors was assessed by the adjusted r2 (r2adj). 
The r2adj statistic measures the proportion of the total variability explained by the model 
with adjustment for the number of parameters in the model.
Software
For the genome-wide association analysis, we used PLINK v.1.04 (59). The meta-analysis was 
performed using METAL. http://www.sph.umich.edu/csg/abecasis/Metal/) Formultivariate 
linear regression analysis, we used SPSS software (version 15.0).
Supplementary material
Supplementary Material is available at HMG online.
Results
Index and replication cohorts
For the index population from the total of 7983 subjects in the RS-I cohort, 5974 (75%) 
subjects were successfully genotyped and passed quality control (QC) for GWAS. Of these 
5974 subjects, 1451 (24%) started acenocoumarol therapy at a standard initial dose and 
had a first INR measurement at the fourth day available. Of the 3011 subjects in the RS-II 
cohort 1895 persons (63%) were successfully genotyped for GWAS and 287 subjects (15%) 
started with acenocoumarol during the study period and had an INR measurement on day 
4 after standard initial dose. Owing to study design, subjects in the replication cohort were 
on average 7 years younger and the percentage of male subjects was higher than in the RS-I 
cohort (50% versus 43%, Table 1). For BMI in the RS-I cohort, values for 39 persons (2.8%) 
had to be imputed and for the RS-II cohort, one value (0.3%) was missing. On average, BMI 
was slightly higher in the replication cohort. In our study populations, acenocoumarol was 
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prescribed with a very low target range (2.0–2.5) for short-term prophylactic treatment, with 
a low target INR range (2.5–3.5) also in patients for short-term prophylactic treatment, for 
deep venous thrombosis, pulmonary embolism, atrial fibrillation and cerebral ischemia, with 
medium target INR range (3.0–4.0) in patients with atrial fibrillation, myocardial infarction, 
vascular surgery, stroke, transient ischemic attacks and periphery artery disease and with a 
high target INR range (3.5–4.5) for patients with prosthetic heart valves (Table 1).
Polymorphisms associated with acenocoumarol dosage
Basic model. In the RS-I cohort, only SNPs on chromosome 16 and chromosome 10 were 
in genome-wide significant association with acenocoumarol dosage at the end of initiation 
period, adjusted for age, gender, BMI and target INR (Table 2 and Fig. 1). The 15 SNPs with 
P-values lower than 10−28 were all located on chromosome 16. Best associated, with a P-value 
of 2.0 × 10−123, was rs10871454, located in the Syntaxin 4 A–placental (STX4A) gene, flank-
ing the VKORC1 gene (Fig. 2). Each additional minor allele of this SNP showed a decrease of 
weekly acenocoumarol dosage with 5.2 mg/week. This SNP was in linkage disequilibrium 
(LD) (r2=1.0) with rs889548 scoring second in significance, with the third SNP, rs1978487 
(r2 =0.93) and to a lesser extent with the fourth SNP rs749767, r2 = 0.26. One SNP, rs7294, 
Table 1 Characteristics of the RS-I and of the RS-II cohort
RS-I cohort RS-II cohort
Number of patients 1451 287
Age in years, average (SD) 75.9 (7.9) 68.7 (9.5)
Gender (%)
 Male
 Female
620 (42.7)
831 (57.3)
144 (50.2)
143 (49.8)
Body Mass Index (BMI), average (SD) 26.9 (3.8) 27.9 (3.9)
Number of patients within a target INR-level (%):
 Very low: 2.0 – 2.5
 Low: 2.5 – 3.5
 Medium: 3.0 – 4.0
 High: 3.5 – 4.5
54 (3.7)
840 (57.9)
555 (38.2)
2 (0.1)
23 (8.0)
171 (59.6)
90 (31.4)
3 (1.0)
Table 2 GWAS of acenocoumarol maintenance dosage, basic model
Chromo-
some
SNP Gene Base pair
position
RS-I cohort RS-II cohort
P-valueSubjects Betaa R2 b P-value
16 rs10871454 STX4A 30955580 1451 -5.2 0.3198 2.0*10-123 1.4*10−24
10 rs4086116 CYP2C9 96697192 1450 -2.9 0.06871 3.3*10−24 1.6*10−6
The SNPs with lowest p-values each within chromosome 16 and within chromosome 10 are reported. For 
all 53 genome-wide signficant SNPs from the basic model we supply an online supplement for complete 
overview of all genome wide significant SNPs from the basic model. Basic model: adjusted for age, gender, 
BMI and target INR, significant results are printed in bold.
Abbreviations: STX4A (Syntaxin 4A, placenta). CYP2C9 (Cytochrome P450 2C9)
a dosage change of acenocoumarol in mg/week per additional variant allele
b Univariate r2 between acenocoumarol maintenance dosage and the specific SNP.
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was located within the VKORC1 gene and in some LD with rs10871454 (r2 = 0.36, Fig. 3) and 
reached genome-wide significance at a P=1.4 × 10−45. The SNP rs10871454 was in complete 
LD in our RS-I cohort with rs9934338 (VKORC1 1173C>.T, r2 = 0.99), one of the two SNPs that 
were able to predict the influence of VKORC1 on warfarin dosage [6, 33] and possibly one of 
the two causal putative SNPs within the VKORC1 gene (5) (Fig. 3).
Figure 1 Genome wide p-values for acenocoumarol dosage association in the RS-I cohort, basic model
Figure 1 Genome wide p-values for acenocoumarol dosage association in the RS-I cohort, basic 
model 
All p-values are shown for univariate effects using an additive linear regression model, adjusting for age, 
gender, BMI and target INR. Chromosomes are numbered on the x-axis. Genome-wide significance was set 
at the p-value 5 × 10−8 (see line). Evidently only polymorphisms within chromosome 16 and chromosome 
10 passed this threshold.
Figure 2 Position of the SNP on chromosome 16 with the lowest p-value on acenocoumarol dosage in the 
RS-I cohort, basic model
Figure 2 Position of the SNP on chromosome 16 with the lowest p-value on acenocoumarol 
dosage in the RS-I cohort, basic model 
Observed p-values (-log p) are shown for univariate effects of polymorphisms within 500 kb of rs10871454 
using an additive linear regression model in the RS-I cohort, adjusted for age, gender, BMI and target 
INR. Colour legend: black: the index SNP with the lowest P-value from our analysis; red: SNPs with linkage 
disequilibriumof r2=1.0 to the index SNP; blue: 0.8<= r2<=1.0; yellow: 0.5<=r2<=0.8; orange: 0.2<=r2<=0.5 
and white: r2<0.2.
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The second locus reaching genome-wide significance was located on chromosome 
10 (Table 2). The SNPs with the lowest P-values were rs4086116 (P= 3.3 × 10−24, Fig. 4) and 
rs4917639 (P= 8.0 × 10−24), both located within CYP2C9 and in complete LD with each other 
Figure 3 Linkage disequilibrium of the SNPs on chromosome 16 for VKORC1 within the RS-I cohort
Figure 3 Linkage disequilibrium of the SNPs on chromosome 16 for VKORC1 within the 
RS-I cohort 
 
The LD-plot with R2 values is shown for rs7294 (SNP within the VKORC1 gene), rs10871454 (SNP with the 
lowest p-value from GWA, basic model). rs9934438 (SNP VKORC1 1173C>T, possibly one of the putative 
functional SNPs within VKORC1).
Figure 4 Position of the SNP on chromosome 10 with the lowest p-value on acenocoumarol dosage in the 
RS-I cohort, basic model
Figure 4 Position of the SNP on chromosome 10 with the lowest p-value on acenocoumarol 
dosage in the RS-I cohort, basic model 
Observed p-values (-log p) are shown for univariate effects of polymorphisms within 500 kb of rs4086116 
using an additive linear regression model in the RS-I cohort, adjusted for age, gender, BMI and target 
INR. Colour legend: black: the index SNP with the lowest P-value from our analysis; red: SNPs with linkage 
disequilibriumof r2=1.0 to the index SNP; blue: 0.8<= r2<=1.0; yellow: 0.5<=r2<=0.8; orange: 0.2<=r2<=0.5 
and white: r2<0.2.
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(r2 =1.0). Our Illumina array included the CYP2C9*3 SNP (rs1057910), reaching a genome-wide 
significant association with acenocoumarol dosage at a P =.6.44 × 10−12. More SNPs within or 
flanking the CYP2C18, CYP2C19 and CYP2C8 genes reached genome-wide significance.
In our replication cohort RS-II, all SNPs on chromosome 16 were convincingly replicated 
(Table 2, Supplementary Material online). The two SNPs on chromosome 10 within CYP2C9 
scoring lowest for genome-wide significance in the RS-I cohort were replicated in the RS-II 
cohort with P-values less than 10−6, which is not genome-wide significant but yet far below 
the threshold of significance for replication (Table 2, Supplementary Material online). Further 
SNPs for CYP2C18 and CYP2C19 were replicated (P-values 10−6), but not for CYP2C8 (P =0.11).
Subanalysis. For GWAS on the first INR after initial standard dosage of acenocoumarol, P-
values of the basic model within the RS-I cohort were substantially higher, with rs10871454 
reaching a P < 10−15 instead of P < 10−123 for dosage at the end of initiation period as an 
outcome. Genome-wide significant values were only obtained for 11 SNPs from chromosome 
16 and thus no other genes besides VKORC1 were associated with INR after standard initial 
dosage of acenocoumarol. The other subanalyses on maintenance dosage adjusting for 
CYP2C9 co-medication or for vitamin K intake did not change our results.
Extended model. In the extended model, we included the SNPs with the lowest P-values 
from the basic model for VKORC1 (rs108714540) and CYP2C9 (rs4086116) as independent 
covariates (Table 3 and Fig. 5). After adjustment for the influence of these two genes on varia-
tion of acenocoumarol dosage, only three SNPs on chromosome 10 (rs1998591, rs2104543, 
rs12772169), all flanking the CYP2C18 gene, and one SNP in chromosome 19 within the 
Figure 5 Genome wide p-values for acenocoumarol dosage association in the RS-I cohort, extended 
model
Figure 5 Genome wide p-values for acenocoumarol dosage association in the RS-I cohort, 
extended model 
 
All p-values are shown for univariate effects using an additive linear regression model, adjusting for age, 
gender, BMI, target INR and rs10871454 and rs4086116 as independent covariates in the extended model. 
Chromosomes are numbered on the x-axis. Genome-wide significance was set at the p-value 5 × 10−8 (see 
line). Evidently only polymorphisms within chromosome 10 and chromosome 19 passed this threshold.
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CYP4F2 (rs2108622) gene reached genome-wide significance (Fig. 6). These four SNPs were 
replicated in our second cohort (Table 3). The three SNPs flanking CYP2C18 had also reached 
genome-wide significance in the basic model, whereas rs2108622 within CYP4F2 only had 
reached a P =7.0 × 10−5 in the basic model.
The acenocoumarol dosage variance for the CYP2C19 SNPs could partially, though not fully, 
be explained by the SNP rs4086116 within CYP2C9: the P-value for rs3862009, the CYP2C19 
SNP with the lowest P-value in the basic model, increased from P =1.3 × 10−11 in the basic 
model to P = 1.5 × 10−4 in the extended model after adjusting for rs4086116. Thus in the ex-
tended model, this SNP no longer achieved genome-wide significance. However, rs1322179 
and rs12767584, two other SNPs within CYP2C19, reached P-values of 10−6, still showing some 
association with the outcome though not genome-wide significant. These SNPs just failed to 
be replicated in our second cohort with P-values = 0.06.
Meta-analysis. A meta-analysis with pooling of data from both cohorts was performed for 
the extended model with age, gender, BMI, target INR, rs10871454 (VKORC1) and rs4086116 
(CYP2C9). P-values for the SNPs flanking CYP2C18 improved from P <10−9 for the extended 
model within the index cohort to P< 10−12 in the meta-analysis (Table 3). There was also an 
improvement for rs2108622 within CYP4F2 from P <10−8 to P <10−10. Two more SNPs within 
CYP4F2 became genome-wide significant in the meta-analysis. P-values for SNPs on chro-
Figure 6 Position of the SNP on chromosome 19 with the lowest p-value on acenocoumarol dosage in the 
RS-I cohort, extended model
Figure 6 Position of the SNP on chromosome 19 with the lowest p-value on acenocoumarol dosage 
in the RS-I cohort, extended model 
 
Observed p-values (-log p) are shown for univariate effects of polymorphisms within 500 kb of rs2108622 
using an additive linear regression model in the RS-I cohort, adjusted for age, gender, BMI, target INR and 
rs10871454 and rs4086116 as independent covariates in the extended model. Colour legend: black: the 
index SNP with the lowest P-value from our analysis; red: SNPs with linkage disequilibriumof r2=1.0 to the 
index SNP; blue: 0.8<= r2<=1.0; yellow: 0.5<=r2<=0.8; orange: 0.2<=r2<=0.5 and white: r2<0.2.
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mosome 3 remained at P< 10−7 and failed to reach genome-wide significance in the meta-
analysis. Further P-values for CYP2C19 decreased from 10−6 with the extended model in the 
index population to 10−7 in meta-analysis, but were still not genome-wide significant.
Independency of signals within the CYP2C cluster. In order to elucidate in how far the influ-
ence on acenocoumarol dosage of the SNPs within CYP2C18 were independent from CYP2C9, 
in an extended model on the CYP2C cluster we further adjusted for the effect of CYP2C9*3 by 
adding rs1057910 as another independent co-variate to our extended model. We chose this 
SNP as linkage between rs4086116, the lowest scoring SNP for CYP2C9 from our basic model, 
was reasonable adjusted with CYP2C9*2 (r2 =0.62) and poor with CYP2C9*3 (r2 = 0.26) (Fig. 7). 
Earlier it was shown that an association of rs4917639, being completely linked to rs4086116, 
could not fully be explained by CYP2C9*3 [12]. Thus rs1057910, representing CYP2C9*3, was 
expected to provide extra information on CYP2C9 activity which could not fully be explained 
by rs4086116. The outcome of the analysis with the additional adjustment for CYP2C9*3 
showed that P-values of the three SNPs on chromosome 10 flanking CYP2C18 increased from 
Table 3 GWAS of acenocoumarol dosage adjusted for VKORC1 and CYP2C9, the 15 SNPs with lowest 
p-values (extended models)
Chr SNP (rs) Gene Base Pair position RS-I cohort RS-II cohort
Extended modela
P-value
Meta-analysis
Extended
modela
Extended
modela
Extended CYP2C
modelb
P-value P-value P-value
10 1998591 CYP2C18 96397968 1.9*10−9 1.0*10−6 4.4*10−4 4.9 *10−12
10 2104543 CYP2C18 96419961 2.5*10−9 1.2*10−6 4.1*10−4 6.5*10−12
10 12772169 CYP2C18 96395319 3.0*10−9 1.4*10−6 4.1*10−4 7.7*10−12
19 2108622 CYP4F2 15851431 2.0*10−8 9.8*10−9 3.0*10−3 2.5*10−10
19 2074901 CYP4F2 15858422 1.9*10−7 9.3*10−8 1.2*10−2 8.3*10−9
3 10935268 CNTN4 138930175 7.7*10−7 7.9*10−7 0.42 8.18*10−7
3 9828150 CNTN4 2518302 9.7*10−7 4.5*10−7 0.56 1.94*10−6
3 4571230 CNTN4 2513769 1.3*10−6 9.9*10−7 0.56 9.1*10−6
10 1322179 CYP2C19 96565232 1.6*10−6 9.2*10−6 0.06 2.6*10−7
10 12767583 CYP2C19 96537453 1.6*10−6 9.5*10−6 0.06 2.8*10−7
10 1042194 CYP2C18 96485474 1.6*10−6 9.5*10−6 0.06 2.7*10−7
10 1926712 CYP2C18 96467844 1.7*10−6 9.7*10−6 0.04 2.0*10−7
10 2111995 No gene 107497352 3.2*10−6 6.6*10−6 0.77 8.9*10−6
19 12610189 CYP4F2 1585422 5.6*10−6 3.3*10−6 4.2*10−4 3.5*10−8
11 1892889 No gene 90011495 6.1*10−6 7.9*10−6 0.9914 2.7*10−5
Signficant results are printed in bold. Abbreviations: CYP2C18 (Cytochrome P450 2C18), CYP4F2 
(Cytochrome P450 4F2), CNTN4 (contactin 1), CYP2C19 (Cytochrome P450 2C19).
a The extended model contained beside the clinical factors age, gender, BMI and target INR within 
unstandardized residuals also rs10871454 (VKORC1) and rs4086116 (CYP2C9) as independent covariates
b The extended CYP2C model contained the clinical factors age, gender, BMI and target INR within 
unstandardized residuals and also rs10871454 (VKORC1), rs4086116 (CYP2C9) and rs1057910 (CYP2C9*3) 
as independent covariates
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10−9 up to 10−6, which means that CYP2C9*3 could partially but not completely explain varia-
tion on acenocoumarol dosage by SNPs flanking CYP2C18 (Table 3). These three SNPs were in 
complete LD with each other (r2= 0.99). Two other SNPs within CYP2C18 were independent 
from CYP2C9*3 and P-values in meta-analysis decreased from P =10−6 to P=10−7, still not 
reaching genome-wide significance. These two SNPs were completely linked to each other (r2 
=0.99) and also in complete LD with the two lowest scoring SNPs within CYP2C19, rs1322179 
and rs12767583 (Fig. 7).
Clinical implications
A multivariate model, including the clinical factors age, gender, BMI and target INR, but with-
out any genotypic data explained 12.6% of acenocoumarol dosage variation (Table 4). The 
addition of rs9934438 (VKORC1 C1173T) to this model dramatically increased the explained 
variance to 40.6% and the CYP2C9*2/*3 polymorphism could add another 5.8%. Replacing the 
SNPs commonly used in literature for VKORC1 activity by rs10871454, the SNP with the lowest 
P-value from our results, slightly improved the percentage of explained variance from 46.4 
to 46.6%. Replacing the commonly used combined CYP2C9*2/*3 genotype by the SNP with 
the lowest P-value from our results, rs4086116, nearly explained the same amount of dosage 
variation than the combined genotype (0.3% less). A model including age, gender, BMI, tar-
get INR, rs10871454 for VKORC1, rs4086116 for CYP2C9, rs2108622 for CYP4F2 and rs1998581 
for CYP2C18 could explain 48.8% of acenocoumarol dosage variation. Adding rs1057910 for 
the CYP2C9*3 polymorphism only contributed an additional 0.1% to the explained variance. 
Each additional variant allele of the CYP4F2 polymorphism and also each additional variant 
allele of the CYP2C18 polymorphism increased the weekly acenocoumarol dosage by 1.2 mg. 
Genotype and allele frequencies of the top SNPs for VKORC1, CYP2C9, CYP4F2 and CYP2C18 
were comparable between our study cohorts and to findings from literature (Table 5).
Figure 7 Linkage disequilibrium of the within the CYP2C cluster on chromosome 10 within the RS-I cohort
Figure 7 Linkage disequilibrium of the within the CYP2C cluster on chromosome 10 within the RS-I 
cohort 
 
rs12772169, rs1998591, rs2104543: flanking 
CYP2C18, top SNPs significant within the extended 
model. 
rs1926712, rs1042194 within CYP2C18, just non-
significant within the extended model. (p>10-6) 
rs12767583, rs1322179 within CYP2C19, just non-
significant witin the extended model (p>10-6) 
rs1799853 for CYP2C9*2 
rs4086116 within Cyp2C9, top SNP within the basic 
model  
rs1057910 fpr CYP2C9*3 
rs12772169, rs 9859 , rs2104543: flanking 
CYP2C18, top SNPs sign fica t wit in the extended 
model.
rs1926712, rs1042194 ithin CYP2C18, just non-
significant withi  t e exten e  model. (p>10−6)
rs12767583, rs1322179 within CYP2C19, just 
non-significant witin the extended model (p>10−6)
rs1799853 for CYP2C9*2
rs4086116 within Cyp2C9, top SNP within the 
basic model
rs1057910 fpr CYP2C9*3
The LD-plot with =r2 values is shown for different polymorphisms within CYP2C18, CYP2C19 and CYP2C9.
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Table 4 Explained variance of acenocoumarol maintenance dosage in different models
Basic model Added variables in different models r2adja
Age, gender, BMI, target INR 12.6%
Age, gender, BMI, target INR rs9934438 (VKORC1 1173C>T) 40,6%
Age, gender, BMI, target INR rs9934438 (VKORC1 1173C>T). rs1799853 and rs1057910 (combined CYP2C9*2/*3 
genotypes)
46.4%
Age, gender, BMI, target INR rs10871454 (Top SNP for VKORC1 in our results)combined rs1799853 and rs1057910 
(combined CYP2C9*2/*3 genotypes)
46.6%
Age, gender, BMI, target INR rs10871454 (Top SNP for VKORC1 in our results), rs4086116 (Top SNP for CYP2C9 in 
our results)
46.3%
Age, gender, BMI, target INR rs10871454 (Top SNP for VKORC1 in our results), rs4086116 (Top SNP for CYP2C9 in 
our results), rs1057910 (CYP2C9*3)
46.7%
Age, gender, BMI, target INR rs10871454 (Top SNP for VKORC1 in our results), rs4086116 (Top SNP for CYP2C9 in 
our results) rs1057910 (CYP2C9*3), rs2108622 (Top SNP for CYP4F2 in our results)
48.0%
Age, gender, BMI, target INR rs10871454 (Top SNP for VKORC1 in our results), rs4086116 (Top SNP for CYP2C9 in 
our results), rs1057910 (CYP2C9*3), rs2108622 (Top SNP for CYP4F2 in our results), 
rs1998581 (Top SNP for CYP2C18)
48.9%
Age, gender, BMI, target INR rs10871454 (Top SNP for VKORC1 in our results), rs4086116 (Top SNP for CYP2C9 in 
our results), rs2108622 (Top SNP for CYP4F2 in our results), rs1998581 (Top SNP for 
CYP2C18)
48,8%
a r 2: adjusted for the variance of acenocoumarol dosage explained by the model
Table 5 Genotype and allele frequencies of the top SNPs for VKORC1, CYP2C9, CYP4F2 and CYP2C18
RS-I cohort RS-II cohort From literature [13]
Chr 16: rs10871454 (%)(VKORC1)
 CC
 CT
 TT
Allelic frequency
527 (36.3)
718 (49.5)
206 (14.2)
C-allele 61.1% T-allele 38.9%
114 (39.7)
134 (46.7)
39 (13.6)
169 (38.8)
211 (48.4)
56 (12.9)
C-allele 63% T-allele 37%
Chr 10: rs4086116 (CYP2C9)
 CC
 CT
 TT
Allelic frequency
943 (65.0)
451 (31.1)
56 (3.9)
C-allele 80.6% T-allele 19.4%
194 (67.6)
84 (29.3)
8 (2.8)
Chr 10: rs1057910 (CYP2C9*3)*
 AA
 AC
 CC
Allelic frequency
1285 (88.6)
162 (11.2)
1 (0.1)
A-allele 94.3% C-allele 5.7%
250 (87.1)
33 (11.5)
3 (1.0)
Chr 19 rs2108622 (CYP4F2)
 CC
 CT
 TT
Allelic frequency
790 (54.4)
539 (37.1)
122 (8.4)
C-allele 73,0% T-allele 27,0%
147 (51.2)
223 (39.0)
28 (9.8)
216 (49.6)
183 (42.0)
37 (8.4)
C-allele 70.9% T-allele 29,1%
Chr 10 rs1998591 (CYP2C18)
 GG
 GA
 AA
Allelic frequency
897 (61.8)
487 (33.6)
66 (4.5)
G -allele 79% A-allele 21%
168 (58.5)
104 (36.2)
15 (5.2)
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Discussion
In this large population-based cohort study, VKORC1 and CYP2C9 were the main factors 
regulating acenocoumarol-induced anticoagulation, in line with similar findings for warfarin.
[32] In addition, polymorphisms in the CYP4F2 gene had influence on acenocoumarol dosage. 
The genome-wide significant association for rs2108622 within CYP4F2 and acenocoumarol 
dosage was replicated in our second cohort and was strengthened in the meta-analysis from 
our two study cohorts as P-values decreased and two more polymorphisms within this gene 
passed the genome-wide significant threshold of P < 5 × 10−8. Caldwell et al. [13] also found an 
association between the CYP4F2 genotype and warfarin dosage. Until now the physiological 
role of CYP4F2 in coumarin response or vitamin K pathway is only partially elucidated. CYP4F2 
hydroxylates the tocopherol phytyl side chain as the first step in the inactivation pathway of 
vitamin E.[34] As this side chain is quite similar to the side chains of the vitamins within the 
vitamin K group, CYP4F2 may also inactivate K vitamins by hydroxylation. Thus within the 
vitamin K cycle less substrate would be available for the activation of vitamin K-dependent co-
agulation factors. If variant alleles of rs2108622 decrease CYP4F2 activity as postulated before 
[13], this would prevent inactivation of vitamin K and thus explain the need for higher aceno-
coumarol dosages with ~1 mg/week more per additional variant allele. Adding rs2108622 
to a model of clinical factors, VKORC1 and CYP2C9 genotype information increased r2adj for 
acenocoumarol dosage variation by 1.3%. This is in line with the results of Caldwell et al [13] 
for warfarin where this SNP contributed with 2% to explanation of warfarin dosage variability.
In our GWAS of acenocoumarol dosage, rs10871454 had the lowest P-value. This SNP was 
located on chromosome 16, close to VKORC1. Cooper et al. [32] have previously found this 
SNP to be most strongly associated in a GWAS with warfarin dosage. Due to more subjects in 
our study, the P-value of this SNP in our study was 2.0 × 10−123 compared with a P-value of 6.2 
× 10−13 in the earlier study. The clinical implications of this SNP are unknown. As it is situated 
within another gene, the Syntaxin 4 gene, it is not coding for VKORC1 and thus cannot directly 
alter the structure of this protein. However, such polymorphisms might lower the intrahepatic 
mRNA expression for this enzyme, resulting in decreased enzyme activity which reduces the 
amount of drug target in the liver and leads to lower dosage requirement of coumarins.[33] 
The effect of rs10871454 may be through LD with a putative functional SNP within VKORC1. 
In our study population, rs10871454 was in complete LD (r2 =0.99) with rs9934438 (VKORC1 
1173C>T), one of the five single segregating SNPs that were able to explain all variation in 
warfarin dose caused by VKORC1.[7, 33] Earlier studies suggested rs9934438 or rs8050894 
as the possible putative functional SNP responsible for the association between VKORC1 
and coumarin dosage, as within the five representative VKORC1 SNPs, being in complete LD 
with each other, these two SNPs were the ones that remained conserved across species.[5] 
However, clinical implications may be only small as rs10871454 contributed only 0.2% more 
to the explained variance in acenocoumarol maintenance dosage than rs9934439.
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Besides chromosome 16, only SNPs on chromosome 10 reached genome-wide significance. 
This chromosome contains within a region of high LD a cluster of the following CYP2C genes: 
CYP2C8, CYP2C9, CYP2C18 and CYP2C19. Most strongly associated with acenocoumarol dos-
age were SNPs within the CYP2C9 gene, rs4086116 reaching the lowest P-value with P =3.29 
× 10−24. This SNP was in complete LD with SNP rs4917639 (r2 =1.0) which had been shown 
previously to be significantly associated to warfarin dosage.[12] This SNP was able to explain 
nearly as much of dosage variation as the combined CYP2C9*2/*3 genotype (only 0.3% less). 
Besides CYP2C9, only polymorphisms flanking CYP2C18 showed associations with aceno-
coumarol maintenance dosage that could not be fully explained by CYP2C9 polymorphisms. 
Possible associations of polymorphisms in the CYP2C19 gene could be explained through 
complete LD of these SNPs with polymorphisms in CYP2C18. For loci in the CYP2C8 gene, no 
association with acenocoumarol dosage could be demonstrated. In an earlier study, associa-
tions of CYP2C18 and CYP2C19 with warfarin dosage were fully explained by CYP2C9*2 and/
or *3 polymorphisms.[12] The independence of CYP2C18 from CYP2C9 polymorphisms in our 
study may be due to the fact that pharmacokinetics by CYP2C enzymes differs between war-
farin and acenocoumarol. Adding rs1998591 as an indicator for variance in CYP2C18 activity 
to our egression model increased the r2adj of acenocoumarol dosage variance by 1.2%. In 
comparison, adding the CYP2C9*3 SNP (rs1057910) to a model already including rs4086116 
for CYP2C9 polymorphisms increased the percentage of explained acenocoumarol dosage 
variation by only 0.1%.
The density and coverage of the polymorphism set used (HumanHap 550K) is substantial 
and represents ~90% of the common SNP variation in Caucasians as determined by the 
HapMap. Our measure of maintenance dosage was an incidental outcome as the dosage at 
the end of 6 weeks of the initiation period and might have been influenced by coincidental 
factors such as diet or concomitant use of substrates or inhibitors of metabolic enzymes 
such as CYP2C9. However as diet and prescription of co-medication are independent from 
genotypes, this should lead to non-random misclassification and rather weaken than inflate 
associations found. Nevertheless, we repeated our analysis in the index population for 
outcomes adjusted for vitamin K intake and also for current use of CYP2C9 co-medication. 
Both subanalyses did not change our results. Analysis with the first INR after standard initial 
acenocoumarol dosage confirmed our results for the VKORC1 polymorphisms as contributing 
most to interindividual variation in response to initial acenocoumarol treatment.
To our knowledge, this is the first GWAS for response to acenocoumarol dosage. We 
consider the chance of bias and confounding in this retrospective study as negligible. First, 
the Rotterdam study is a prospective cohort study and the regional anticoagulation clinic 
covered a complete area of more than one million inhabitants in the Rotterdam region. Con-
sequently, everyone who is treated with a coumarin anticoagulant as an outpatient will be 
registered as such and selection bias is highly unlikely, confirmed by the fact that in our study 
population genotypes were within Hardy Weinberg equilibrium (HWE). Also allele frequen-
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cies of the variant alleles were comparable to results for the same SNPs in other Caucasian 
populations.[13] Furthermore, acenocoumarol dosage and INR are well-defined phenotypes 
and our results were biologically plausible. We confirmed earlier associations with warfarin 
dosage for rs10871454 related to VKORC1 [32] and rs2108622 within CYP4F2 [13]. One of the 
strengths of our study lies in the high numbers of patients included. Thus power to detect 
possible associations for new genes independently from VKORC1 and CYP2C9 was consid-
erably larger than in earlier studies.[32] However, we did not detect further independent 
associations with acenocoumarol dosage besides VKORC1 and CYP2C9 for other genes than 
CYP4F2 and CYP2C18.
Conclusion
Our findings confirmed that acenocoumarol maintenance dosage mainly depends on poly-
morphisms in the VKORC1 and CYP2C9 genes. Independent from these two genes, only DNA 
variants in the CYP4F2 gene had a small additional influence on acenocoumarol dosage. From 
the CYP2C gene cluster on chromosome 10, only polymorphisms in the CYP2C18 gene added 
some extra information besides CYP2C9 polymorphisms on acenocoumarol dosage variation.
Abbreviations
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Abstract
Genome-wide association studies (GWAS) on warfarin and acenocoumarol showed that 
interindividual dosage variation mainly is associated with single nucleotide polymorphisms 
(SNPs) in VKORC1 and to a lesser extent with CYP2C9 and CYP4F2. For phenprocoumon dos-
age also the genes encoding CYP3A4 and ApoE might play a role. Our objective was to asses 
the association between common genetic variants within VKORC1, CYP2C9, CYP4F2, CYP3A4 
and ApoE and phenprocoumon maintenance dosage, as well as to identify novel signals 
using GWAS. We selected all subjects from the Rotterdam Study who were treated with 
phenprocoumon. For each SNP, we tested the association between the above-mentioned 
genotypes and age-, sex-, body mass index- and target international normalized ratio (INR) ad-
justed-phenprocoumon maintenance dosage. Within our study population (N=244), VKORC1, 
CYP2C9, CYP4F2 genotypes together explained 46% of phenprocoumon maintenance dos-
age variation. Each additional VKORC1 variant allele reduced phenprocoumon maintenance 
dosage by 4.8 mg/week (p<0.0001) and each additional CYP2C9 variant allele by 2.2 mg/week 
(p=0.002). Each additional variant allele of CYP4F2 increased phenprocoumon dosage by 1.5 
mg/week (p=0.022). Variant alleles of CYP3A41*B and of ApoE showed no association with 
phenprocoumon dosage. Genome wide significant SNPs were all related to VKORC1 activity. 
Best associated were two SNPs in complete linkage disequilibrium with each other and with 
SNPs within VKORC1: rs10871454 (Syntaxin 4A (STX4A)) and rs11150604 (ZNF646), each with a 
P-value of 2.1 × 10−22. Each reduced weekly phenprocoumon maintenance dosage by 4.9 mg 
per variant allele. In conclusion, similar to earlier findings with warfarin and acenocoumarol, 
phenprocoumon maintenance dosage depended on polymorphisms in the VKORC1 gene. 
CYP2C9 and CYP4F2 were of modest relevance.
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Introduction
Coumarin anticoagulants are first choice in treatment and prevention of thromboembolic 
diseases.[1] Clinical management of anticoagulation with coumarins is difficult, as a target 
range has to be achieved by drugs with a narrow therapeutic index and high intra- and 
interindividual variability in pharmacokinetic and pharmacodynamic response. The impor-
tance of maintaining coumarin users within the therapeutic range is driven by the aim of 
preventing thromboembolic events as well as by the necessity to minimize the risk of serious 
bleeding, the main manifestation of coumarin toxicity. Despite management of coumarin 
use by regular measurements of international normalized ratio (INR) through anticoagula-
tion clinics in the Netherlands, these drugs still are a leading cause of preventable hospital 
admissions.[2, 3] Genetic variation in the vitamin K epoxide reductase complex subunit 1 
(VKORC1) and cytochrome P450 2C9 (CYP2C9) genes in combination with age, sex and body 
mass index (BMI) has been shown to account for 30-50% of the variability in dosage of 
warfarin and acenocoumarol.[4-11] According to genome-wide association studies (GWAS) 
of warfarin and acenocoumarol, dosage variation was mainly associated with certain single 
nucleotide polymorphisms (SNPs)in linkage disequilibrium with SNPs within VKORC1 and to 
a lesser extent in CYP2C9 and CYP4F2.[12-14] Genetic variation for VKORC1 resulted in 28% 
of warfarin- or acenocoumarol dosage variation between subjects, variant alleles in CYP2C9 
variation explained 9% for warfarin and 6% for acenocoumarol maintenance dosge and a 
CYP4F2 polymorphism counted for 1% of coumarin dosage variation. For phenprocoumon, 
used frequently in many European countries, fewer candicate gene studies have been 
conducted and a GWAS has not been performed so far. Some studies were suggestive of 
associations between phenprocoumon maintenance dosage or bleedings and CYP2C9 poly-
morhisms [15-20] and one study showed an increased bleeding risk with increasing number 
of VKORC1 variant alleles [21]. Two studies investigated VKORC1 and CYP2C9 polymorphisms 
together and found that polymorphisms in both genes influenced anticoagulation therapy 
with phenprocoumon.[22, 23] The metabolism of phenprocoumon however, is different 
from the other coumarins and therefore influences of CYP-isoenzymes on phenprocoumon 
maintenance dosage might differ from those already shown for warfarin and acenocoumarol.
[18, 24, 25] The effect of CYP2C9 should be smaller, as 40% of phenprocoumon is eliminated 
unmetabolized in contrast to warfarin and acenocoumarol which are fully metabolized by 
CYP enzymes.[26] Until now, data for the influence of CYP4F2 on the activity of phenprocou-
mon are lacking. Effects of CYP4F2 polymorphisms on phenprocoumon dosage might be 
similar to those on warfarin and acenocoumarol, as this enzyme seems to reduce the amount 
of available vitamine K.[27] Genotypes of the polymorphic protein Apolipoprotein E (ApoE) 
were also shown to affect acenocoumarol dosage. These gentoypes are defined by three 
alleles ε2, ε3 and ε4 at a single gene locus on chromosome 19.[28] Since they affect plasma 
vitamin K levels they are also likely to influence phenprocoumon dosage. Phenprocoumon 
84
hydroxylation has been shown in vitro to depend, besides CYP2C9, on CYP3A4.[18, 25] The G 
allele of the polymorphismCYP3A4*1B (-392A>G), rs2740574, located in the promotor region 
of the CYP3A4 gene, was associated with enhanced CYP3A4 expression due to reduced bind-
ing of a transcriptional repressor.[29]
The objective of our study was to assess whether and to what extent common genetic 
variants within VKORC1, CYP2C9, CYP4F2, ApoE and CYP3A4 modify the dosage requirement 
of phenprocoumon. As a second objective we performed a hypothesis-free genome wide 
association study to find novel associations with phenprocoumon maintenance dosage as 
the outcome of interest.
Methods
Setting and inclusion criteria
We selected all subjects from the first two cohorts of the Rotterdam Study (RS-I and RS-II). The 
rationale and design of the Rotterdam Study have been described elsewhere.[30-32] In brief, 
the Rotterdam Study is a prospective population-based cohort study, consisting of 98% Cau-
casians and designed to study neurological, cardiovascular, locomotor and ophthalmologic 
diseases in a population of people of 55 years and older. The RS-I cohort consisted of 7,983 
subjects (response 78%) and the RS-II cohort of 3,011 participants (response 67%). The RS-I 
cohort had baseline examinations during 1990 – 1993 with completion of standardized ques-
tionnaires, sampling of blood and isolation of DNA. The RS-II was formed as an independent 
cohort in 1999 with baseline examinations between 2000 and 2001. A regional anticoagula-
tion clinic monitors all inhabitants of Ommoord with an indication for anticoagulant therapy. 
This clinic covers the patients from the RS-I cohort as well as those from the RS-II cohort. 
From this clinic, since 1984, all data on dosing, laboratory and clinical data, including data 
on bleeding complications are fully computerized. We could retrieve data for the subjects of 
the first two cohorts of the Rotterdam Study as of 1985. This was permitted by the Medical 
ethical Committee of the Erasmus Medical Center as all participants gave full written consnt. 
The physician who treats the patient makes the choice of anticoagulant. Prothrombin times 
are monitored every 1-6 weeks by reference to the INR, dependent on the stability of the 
anticoagulant level. Doses are adjusted on the basis of the INR of the patient by computer-
ized dose calculations.
Our study population consisted of all patients of the RS-I and RS-II cohorts in whom ge-
notyping or imputation was succesful and who started with phenprocoumon in the study 
period between 30th October 1985 and 9th September 2009, using it consecutively for at least 
42 days. From the 5,974 subjects of the RS-I cohort who were genotyped and had passed 
quality control, 202 (3%) started phenprocoumon therapy in our study period between 30th 
October 1985 and 9th September 2009 and continued therapy for at least 42 days. From the 
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2,157 participants of the RS-II cohort with succesfull genotyping, 42 subjects (2%) used phen-
procoumon during the study period for at least 42 days. Consequently, the study population 
comprised of 244 subjects. For the GWAS, we used the RS-I cohort with 202 patients as index 
cohort and the 42 patients from the RS-II cohort for validation of novel signals.
Genotyping
From all RS participants those with available DNA were genotyped using Illumina Infinium 
II HumanHap BeadChips, Illumina Inc, San Diego, Los Angelos, USA, at the Department of 
Internal Medicine, Erasmus Medical Center following manufacturer’s protocols. RS-I partici-
pants (n=6,449) were genotyped with 550k (V.3) single and duo chips, while RS-II participants 
(n=2,516) were genotyped with 550k (V.3) duo and 610k Quad chips. Genotype calling was 
performed in RS-I using BeadStudio software (version 0.3.10.14) and GenomesStudio in RS-II. 
Participants with call rates <97.5%, excess autosomal heterozygosity, sex mismatch or outly-
ing identity-by-state clustering estimates were excluded. After quality control, 5,974 RS-I 
participants and 2,157 RS-II participants remained with complete data on genotyping.[33] 
For imputation 512 349 autosomal SNPs in RS-I and 466 389 autosomal SNPs in RS-II were 
used after exclusions for call rates less than 98%, Hardy-Weinberg equilibrium P value of less 
than 10 – 6, and minor allele frequency (MAF) of less than 1%, in MACH (softwarepackage 
within METAL) (version 1.00.15 for RS-I and 1.00.16 for RS-II) with reference to the 2 543 886 
SNPs of the HapMap CEU (release 22, build 36, http://hapmap.ncbi.nlm.nih.gov/cgi-perl/
gbrowse/hapmap27_B36/)[34, 35] The SNPs coding for the ApoE haplotypes, rs429358 and 
rs7412, were not available form the imputed database. Therefore we used ApoE genotypes 
available for the RS-I cohort as described before.[28]
Phenotype definition
Physicians aim for a therapeutic target INR by titrating phenprocoumon dosage. The quan-
titative outcome for our study was the phenprocoumon maintenance dosage (mg/week) 
given to a patient after 42 days of continuous use. Steady state of a drug is usually achieved 
within 5-7 half-lives of drug elimination. For phenprocoumon with a half-life of 160 hours (6,7 
days), steady state would be reached after a treatment period of at least 5 weeks.[36]
Statistical analysis
Candidate gene study
For the association of variant alleles in the genes VKORC1, CYP2C9 and CYP4F2, we used the 
following SNPs: rs10871454, located 60 kb 5’ of VKORC1, rs4086116 for CYP2C9 and rs2108622 
for CYP4F2. These SNPs had scored the lowest p-values within these genes in our earlier GWAS 
with acenocoumarol and were available for both cohorts.[14] Furthermore rs10871454 was in 
complete linkage disequilibrium (LD, r2 = 0.99) with rs9934438 (VKORC1 113C>T), one of the 
five single segregating SNPs that were able to explain all variation in warfarin dose caused by 
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VKORC1.[6, 37] This tag SNP for CYP2C9, rs4086116, was in complete LD with rs4917639, a SNP 
shown to be significantly associated to warfarin dosage and to be in perfect LD (r2=1) with 
a composite minor allele formed by aggregating CYP2C9*2 and *3.[11] The genetic variance 
of CYP3A4*1B (-392A>G) was represented by rs2740574[29] and for ApoE we used the three 
alleles ε2, ε3 and ε4 at a single gene locus on chromosome 19.[28] Phenprocoumon main-
tenance dosage was compared in VKORC1, CYP2C9, CYP4F2, CYP3A4 and ApoE genotypes in 
allele effect models with linear regression analysis adjusted for age, sex, target INR, BMI and 
cohort. Target INR was included into our model in order to adjust for the necessity of higher 
dosages due to intended therapeutic INR values for certain indications. BMI was defined as 
(kg/m2) and missing values were imputed with a regression model consisting of maintenance 
dosage as outcome with age, sex and target INR as variables. In order to adjust for differences 
between the two cohorts and the way of genotyping, we also adjusted for cohort origin. 
Interaction between variables was tested with interaction terms.
GWAS
For the GWAS the overall strategy involved linear regression analysis for the genotype–
phenotype association of 2.5 million markers. SNPs with a Minor Allele Frequency (MAF) < 
0.05 were excluded from the analysis. We chose a MAF of 0.05 as a threshold in order to 
increase the specificity of positive findings. We considered results significant at p < 5*10−8, 
based on estimation of the multiple testing burden for genome-wide association studies of 
nearly all common variants in the human genome of European ancestry individuals for a 
target genome-wide P<0.05.[38] For replication of the specific SNPs associated with phen-
procoumon dosage within the index cohort, in the replication cohort a p-value < 0.05 was 
considered significant. This was done with a basic model for phenprocoumon maintenance 
dosage as the outcome, adjusted for age, sex and BMI and the patient’s target INR. We per-
formed a meta-analysis with the results from the basic model for the RS-I- and RS-II-cohort 
to strengthen our findings from the index cohort. In order to detect SNPs within other genes 
independently associated with phenprocoumon dosage and different from those detected 
in the basic model, we repeated GWAS in an extended model further adjusting for influences 
of the genes having a genome wide significant association with the outcome in the basic 
model as done previously in the GWAS of warfarin [13] and on acenocoumarol [14]. In the 
extended model these SNPs were to be taken as independent co-variables that were found 
by the basic model to be the strongest associated SNPs within the gene.
Software
Multivariate linear regression analysis was performed with SPSS software, version 15.0. 
(IBM corp., Chicago, USA) For the genome-wide association analysis we used ProbABEL 
(http://mga.bionet.nsc.ru/Byurii/ABEL/ [39]). The meta-analysis was performed using METAL 
(http://www.sph.umich.edu/csg/abecasis/Metal/index.html).
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Results
Cohort characteristics
The 244 subjects of our study population were on avarage 75 years old and 62% were male 
(table1). For BMI, values for 5 persons (2%) had to be imputed. The mean BMI of the study 
population was 26.8. In our study population, phenprocoumon was prescribed with a very 
low target range (2.0–2.5) for short-term prophylactic treatment, with a low target INR range 
(2.5–3.5) also in patients for short-term prophylactic treatment, for deep venous thrombosis, 
pulmonary embolism, atrial fibrillation and cerebral ischemia and with medium target INR 
range (3.0–4.0) in patients with atrial fibrillation, myocardial infarction, vascular surgery, 
stroke, transient ischemic attacks and periphery artery disease. The majority (68%) used 
phenprocoumon with a medium INR target range. The mean weekly dosage of phenprocou-
mon was 13.8 mg/week with a range from 0.77–57.8 mg/week. The 25, 50 and 75 percentiles 
were 9.0, 12.7 and 18.0 mg/week respectively.
Table 1 Description of the study population with phenprocoumon users
Number of patients (%)
Patients within RS-cohorts
 RS-I
 RS-II
244
 202
 42
Age in years, average (SD) 75.2 (9.2)
Sex (%)
 Male
 Female
151 (62)
93 (38)
Body Mass Index (BMI), average (SD) 26.8 (3.7)
Number of patients within a target INR-level (%):
 Very low: 2.0 – 2.5
 Low: 2.5 – 3.5
 Medium: 3.0 – 4.0
4 (2)
74 (30)
166 (68)
Mean weekly dosage [mg/week] at the end of the initiation period of 42 days (range) 13.8 (0.77 – 57.8)
Genotype-phenotype associations and explained variance
Each additional VKORC1 variant allele reduced phenprocoumon maintenance dosage by 4.8 
mg/week (p<0.0001) and each additional CYP2C9 variant allele by 2.2 mg/week (p=0.002). 
Each additional variant allele of CYP4F2 increased phenprocoumon dosage by 1.5 mg/week 
(p=0.022) (table 2). There was no significant multiplicative interaction of effect measures be-
tween the variant alleles of these genes (p=0.70 for an interaction between polymorphisms 
in VKORC1 and CYP2C9, p=0.60 for VKORC1 and CYP4F2 and p=0.38 for interaction between 
CYP2C9 and CYP3A4). Variant alleles of CYP3A41*B and of ApoE showed no association with 
phenprocoumon dosage. There was a borderline significant trend for each additional allele 
ε3 and ε4 allele of ApoE with decreasing phenprocoumon dosage (p=0.04), however with 
modest effect (beta = -0.005 mg/week). We found additive effects of the variant alleles of 
CYP2C9 and CYP4F2 on VKORC1 (see figure 1 for VKORC1 and CYP4F2).
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Within our study cohort the multivariate basic model including age, sex, BMI and target 
INR explained 16.1% of phenprocoumon maintenance dosage (table 3). Adding rs10871454 
(VKORC1) to this model markedly increased the explained variance to 42.2%. SNP rs4086116 
(CYP2C9) could add 2.9% and rs2108622 (CYP4F2) contributed an additional 0.9%. A final 
model of the basic variables together with genetic variation of VKORC1, CYP2C9 and CYP4F2 
explained 46.0% of phenprocoumon maintenance dosage variation.
GWAS
In the RS-I cohort, 32 SNPs with a MAF>0.05 were in genome wide significant association 
with phenprocoumon maintenance dosage, adjusted for age, sex, BMI and target INR. They 
were all located on chromosome 16 between position 30432177 and 31241737. The VKORC1 
gene is located at 31102175 - 31106276. Strongest association was observed for rs10871454, 
with 4.9 mg/week decrease of phenprocoumon dosage per minor allele copy (MAF= 0.39, 
position 30955580, P=1.4*10−18, table 4, figure 2). Similarly associated was rs11150604. Per 
Figure 1 VKORC1 and CYP4F2 genotypes associated with phenprocoumon maintenance dosage 
[mg/week]
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Table 3 Explained phenotypic variance of phenprocoumon maintenance dosage
Basic model Added variables r2 adj a
Age, sex, BMI, target INR 16.1%
Age, sex, BMI, target INR rs10871454 (STX4Ab) 42.2%
Age, sex, BMI, target INR rs10871454 (STX4A) and rs4086116 (CYP2C9) 45.1%
Age, sex, BMI, target INR rs10871454 (STX4A), rs4086116 (CYP2C9) and rs2108622 (CYP4F2) 46.0%
a Adjusted variance of phenprocoumon dosage explained by the model. The analysis is also adjusted for 
the cohort.
b STX4A is closely linked to rs9934438, possibly one of the putative funictional SNPs within VKORC1.
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additional minor allele copy the phenprocoumon maintenance dosage decreased with 4.9 
mg/week (MAF = 0.39, position 30944521, P=1.4*10−18). These two SNPs were in complete 
linkage disequilibrium with each other (r2=1.00) and signals were replicated in the RS-II 
cohort (p-value <0.05). In meta-analysis P-values of these decreased further (p=2.1*10−22). 
On chromosome 9 we found four borderline significant signals: rs1980889 (MAF=0.11, posi-
tion 91089065, P = 5.3*10−8, table 4), on the Cyclin-dependent kinases regulatory subunit 2 
(CKS2) gene, decreased phenprocoumon maintenance dosage with 5.6 mg/week; the other 
three SNPs n chromosome 9 with a p-value of 8*10−8, were all on the SHC (Src homology 2 
domain containing) transforming protein 3 (SHC3). However, these four SNPs on chromosom 
9 were not replicated in the RS-II cohort. In meta-analysis their p-values increased up to 10−4. 
In the extended GWAS-model, we included the SNP rs1087145 as independent covariable 
beside age, sex, BMI and target INR. From this analysis, no SNPs passed the threshold for 
genome-wide significance for p<5*10−8. However there were SNPs with p-values <10−7, all on 
Table 4 GWAS of phenprocoumon maintenance dosage, basic model
Chr SNP Gene Base Pair position RS-I cohort RS-II cohort Meta-analysis, model
Betaa P-value P-value P-value
16 rs11150604 ZNF646 30944521 -4.9 1.4*10−18 2,5*10−3 2,1*10−22
16 rs10871454 STX4Ab 30955580 -4.9 1.4*10−18 2,5*10−3 2,1*10−22
9 rs1980889 CKS2 91089065 -5.6 5.3*10−8 0.39 4.9*10−5
9 rs746357 SHC3 91027380 -5.7 7.9*10−8 0.71 2.3*10−4
Signficant results are printed in bold. The basic model: adjusted for age, sex, BMI and target INR.
The two SNPs with the lowest P-values each within chromosome 16 and chromosome 9 are reported. For 
all 32 genome wide significant SNPs from the basic model, we supply an online supplement for complete 
overview.
a dosage change of phenprocoumon in mg/week per additional variant allele
b STX4A is located 60 kb 5 of VKORC1 and closely linked to rs9934438, possibly one of the putative 
functional SNPs within VKORC1.
Gene abbreviations: ZNF64 (Zinc finger protein 646), STX4A (Syntaxin 4 A), CKS2 (CDC28 protein kinase 
regulatory subunit 2), SHC3 (SHC (Src homology 2 domain containing) transforming protein 3).
Figure 2 Genome wide p-values for phenprocoumon dosage association in the RS-I-population , adjusted 
for age, sex, BMI and target INR (MAF>0.05)
Figure 2 Genome wide p-values for phenprocoumon dosage association in the RS-I-population , 
adj sted for age, sex, BMI and target INR (MAF>0.05) 
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chromosome 9 in the genes CKS2 (catalytical subunit of the cyclin dependent kinase), SHC3 
(Src homology 2 domain containing transfroming protein 3)and IL33(Interleukin 33).
Discussion
Our study confirms that apart from therapeutic considerations such as target INR, variation in 
phenprocoumon maintenance dosage mainly depends on a VKORC1 polymorphism, similar 
to warfarin and acenocoumarol. VKORC1, the target of coumarins, is the essential enzyme 
in regenerating vitamin K which is oxidated when contributing to activation of coagulation 
factors. Subjects with variant alleles of VKORC1 express less VKORC1 enzyme, have reduced 
ability to regenerate vitamin K and are less able to activate coagulation factors. Consequently, 
a lower dosage of coumarins is needed to reduce coagulation activity within the therapeutic 
target range. The GWAS brought up rs10871454 (Syntaxin 4 A (STX4A)) and rs1150604 (Zinc 
finger protein 646 (ZNF646)) as variants with the strongest association with phenprocoumon 
dosage. Two GWAS were earlier performed on warfarin and acenocoumarol.[13, 14] In both 
GWAS, the SNP rs10871454 was the one strongest associated with maintenance dosage as it 
was the case in our GWAS on phenprocoumon. Within our imputed dataset, rs1150604 was as 
strongly associated. This SNP is in complete linkage disequlibrium with rs10871454 and their 
effect may be through LD with a putative functional SNP within VKORC1.[6, 37] In our study 
population a VKORC1 polymorphism explained 26% of phenprocoumon dosage variation 
between patients and each variant allele decreased the weekly phenprocoumon dosage by 
nearly 5 mg. Thus, the influence of rs10871454 on phenprocoumon is similar to that on the 
other coumarins, explaining approximately 28% of the warfarin and acenocoumarol dosage 
variation [12, 14]. There were borderline significant signals in the SHC3, CKS9 and IL33 genes. 
These genes code for proteins not known for specific biological functions within coagula-
tion or interfering with phenprocoumon effectiveness. The CKS2 gene encodes a protein 
that binds to the catalytic subunit of the cyclin dependent kinases and is essential for their 
biological function. [40] SHC3 codes for the Src homology 2 domain containing transforming 
protein 3 which is involved in the signal transduction pathways in cortical neurons.[40] The 
IL33 defines the interleukin 33 protein that induces T helper cytokines.[40]As numbers in 
the replication cohort were too low, we could not significantly replicate these findings nor 
could we strengthen the association in the meta-analysis. Within larger study populations 
these signals should be further elucidated. Repeating GWAS after adjustment for VKORC1, 
revealed no further genome-wide significant signals. This may be due to low numbers in the 
index cohort as the association with CYP4F2 which we earlier showed with acenocoumarol 
required nearly 1,500 subjects to be able to pass the genome wide significance threshold. 
From the studies with phenprocoumon conducted so far, only one had a higher numbers 
of users (N=281) [23] than our study and other studies included less than 100 patients.[16] 
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In the GWAS we also did not detect an association of phenprocoumon maintenance dosage 
with CYP2C9 polymorphisms. This may be explained by lack of power as well as by a weaker 
dependency of phenprocoumon kinetics on this enzyme than warfarin and acenocoumarol.
[24] As a candidate gene, CYP2C9 polymorphisms could explain an additional 3% of interin-
dividual variation of phenprocoumon maintenance dosage in a model with age, sex, BMI, tar-
get INR and a VKORC1 polymorphism. As expected, the influence of CYP2C9 polymorphisms 
on phenprocoumon dosage was lower than on warfarin dosage (12% of explained dosage 
variance [12]) and on acenocoumarol (6% of explained dosage variance [14]). Each CYP2C9 
variant allele reduced weekly phenprocoumon dosage by 2.2 mg. CYP2C9 catalyses the bio-
transformation of S-warfarin, R- and S-acenocoumarol and 4’, 6 and 7 hydroxylation of S- and 
R-phenprocoumon.[17] Patients with CYP2C9 polymorphisms metabolize coumarins slower 
which requires a lower maintenance dosage to stay within the therapeutic window. Associa-
tions of CYP2C9 polymorphisms with warfarin and acenocoumarol dosage have been shown 
convincingly in various studies.[15, 41, 42] However, unlike warfarin and acenocoumarol, 
phenprocoumon excretion is less influenced by genetic variation of CYP2C9, because phen-
procoumon is eliminated both as parent compound (approximately 40%) and hydroxylated 
metabolites (approximately 60%).[24] Earlier studies on the association of polymorphisms 
in CYP2C9 with phenprocoumon maintenance dosage showed no effect [15] or moderate 
effects only[16, 17].
We further found an association of a CYP4F2 polymorphism and phenprocoumon mainte-
nance dosage with a weekly dosage increase of 1.5 mg per variant allele with a p-value for 
significance of 0.023. As we tested 5 candidate genes, under correction for multiple testing 
this proceeds the adjusted p-value of 0.01 for the additive model. However, this may be due 
to low numbers and the effect of homozygous CYP4F2 variant alleles still remained signifi-
cant (p=0.007). Its ability to account for interindividual dosage variation was modest with an 
additional 1% within the complete model which included the other genetic variants. This is 
similar to the additional influence of this gene on warfarin and acenocoumarol dosage.[12, 
14] Until now the physiological role of CYP4F2 in coumarin response or vitamin K pathway 
is only partially elucidated. CYP4F2 hydroxylates the tocopherol phytyl side chain as the first 
step in the inactivation pathway of vitamin E.[27] As this side chain is quite similar to the 
side chains of the vitamins within the vitamin K group, CYP4F2 catalyzes metabolisation 
of vitamin K1.[43] Thus within the vitamin K cycle less substrate would be available for the 
activation of vitamin K-dependent coagulation factors. Variant alleles of rs2108622 change 
the protein coding sequence and thus decrease CYP4F2 activity [44]. As polymorhpisms were 
not shown to change the mRNA expression leves of CYP4F2, the loss of enzyme activity may 
be caused by either affecting the translation or degradation of CYP4F2.[44] Therefore variant 
alleles of CYP4F2 are likely to prevent the inactivation of vitamin K, eplaining the need for the 
demonstrated higher weekly phenprocoumon dosage with each additional CYP4F2 variant 
allele of rs2108622.
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We did not find an association between phenprocoumon maintenance dosage and 
rs2740574, a SNP coding for the CYP3A41*B. Associations between this gene and phen-
procoumon have been shown so far only in vitro.[24] A review concluded that CYP3A activity 
is affected by multiple non-genetic factors and that to date no single genetic defect is known 
to determine the total metabolic clearance of CYP3A4 substrates.[45] For the ApoE genotypes 
we found a very small clinically neglectable trend of a marginal phenprocoumon dosage 
decrease of 0.005 mg/week with each additional ε3 and ε4 allele. Possibly due to low num-
bers, we could not detect associations with a specific allele. In 1,490 acenocoumarol treated 
patients from the Rotterdam Study we have earlier shown that those with homozygous ε4 
allele required a lower maintenance dosage (-1 mg acenocoumarol /week, p=0.02) and those 
being homozygous for the ε2 allele needed dosage increase (+3,5 mg acenocoumarol /week, 
p=0.04).[28]
With the polymorphisms of the three genes found to influence phenprocoumon dosage, 
we built a model, explaining 46% of phenprocoumon maintenance dosage variation. To 
our knowledge, this is the first study on the combined effects of polymorphisms in VKORC1, 
CYP2C9 and CYP4F2 genes on phenprocoumon maintenance dosage. We consider the chance 
of bias and confounding in this study as negligible. The Rotterdam study is a prospective 
cohort study and the regional anticoagulation clinic covers a complete area of more than 
one million inhabitants in the Rotterdam region. Consequently, everyone who is treated with 
a coumarin anticoagulant as an outpatient will be registered as such and selection bias is 
highly unlikely. Because data were gathered prospectively, also information bias is unlikely. 
Phenprocoumon dosage is a well defined phenotype and our results are biologically plau-
sible.
The associations of VKORC1 and CYP2C9 with maintenance dosages of all three coumarins 
represent one of the most promising applications of pharmacogenetics to date. In Cauca-
sians, the benefit from genetic forecasting on warfarin dosage has already been shown [46] 
and a multicentre study in seven European countries for all three coumarins is underway [47]. 
If that study can show that genotype-guided dosing can improve the percentage of follow-
up time witihin therapeutic range, these findings can be used to increase safety of patients 
treated with coumarins. Genotyping prior to therapy might help to decide whether a subject 
with variant alleles of VKORC1 and CYP2C9 should preferably be treated with a thrombin 
inhibitor such as dabigatran instead of treatment with a coumarin.
In conclusion, we demonstrated that apart from therapeutic considerations such as 
indication and target INR, phenprocoumon maintenance dosage mainly depends on poly-
morphisms in the VKORC1 gene. Although of modest effect size, CYP2C9 and CYP4F2, are also 
relevant for phenprocoumon dosage.
94
References
 [1] Hirsh J, Bauer K, Donati M, Gould M, Samama M, Weitz J, et al. Parenteral anticoagulants: American 
College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 
133(6): 141S-59S.
 [2] van der Hooft C, Dieleman JP, Siemes C, Aarnoudse ALHJ, Verhamme KC, Stricker BHC, et al. Adverse 
drug reaction-related hospitalisations: a population-based cohort study. Pharmacoepidemiol Drug 
Safety 2008; 17(4): 365-71.
 [3] Leendertse A, Egberts A, Stoker L, Bemt van der P. Frequency of and risk factors for preventable 
medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168(1890-6).
 [4] Teichert M, van Schaik RHN, Hofman A, Uitterlinden AG, de Smet PA, Stricker BHC, et al. Genotypes 
associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol 
anticoagulation during the initial treatment period Clinical Pharmacology and Therapeutics 2009; 
85(4): 379-86.
 [5] D’Andrea G, D’Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism 
in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant ef-
fect of warfarin. Blood 2005 Jan 15; 105(2): 645-9.
 [6] Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, et al. VKORC1 haplotypes and 
their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb 
Haemost 2005 Oct; 94(4): 773-9.
 [7] Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and 
VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: 
proposal for a new dosing regimen. Blood 2005 Oct 1; 106(7): 2329-33.
 [8] Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, et al. Influence of co-
agulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene 
polymorphisms on warfarin dose requirements. Clin Pharm Therap 2006; 79(4): 291-302.
 [9] Carlquist JF, Horne B, Muhlestein J, Lappé D, Whiting B, Kolek M, et al. Genotypes of the cytochrome 
p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly deter-
mine stable warfarin dose: a prospective study. J Thromb Thrombolysis 2006; 22: 191-7.
 [10] Oldenburg J BC, Fregin A, Geisen C, Müller-Reible C, Watzka M. Current pharmacogenetic devel-
opments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. 
ThrombHaemost 2007; 98 (3): 570-8.
 [11] Wadelius M, Chen L, Eriksson N, Bumpstead S, Ghori J, Wadelius C, et al. Association of warfarin 
dose with genes involved in its action and metabolism. Hum Genet 2007; 121: 23-34.
 [12] Takeuchi R, McGinnis R, Bourgeois S, Barnes CE, Eriksson N, Soranzo N, et al. A genome-wide asso-
ciation study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin 
dose. PLoS Genet 2009; 5(3): e1000433. Published online 2009 March 20. doi: 10.1371/journal.
 [13] Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, et al. A genome-wide scan 
for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112: 
1022-7.
 [14] Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RHN, Hofman A, et al. A 
genome-wide association study of acenocoumarol maintenance dosage. Human Molecular Genet-
ics 2009 October 1, 2009; 18(19): 3758-68.
 [15] Visser LE, van Vliet M, van Schaik RHN, Kasbergen AAH, de Smet PA, Vulto AG, et al. The risk of 
overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on aceno-
coumarol or phenprocoumon. Pharmacogenetics 2004; 14: 27-33.
95
Chapter 3.3: Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9 and CYP4F2 genes
 [16] Schalekamp T, Oosterhof M, E. Mv, Meer van der F, Conemans J, Hermans M, et al. Effects of cy-
tochrome P459 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol 
Therap 2004; 76(5): 409-17.
 [17] Kirchheiner J, Ufer M, Walter E, Kammerer B, Kahlich R, Meisel Cea. Effects of CYP2C9 polymorphisms 
on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics 
2004; 14: 19-26.
 [18] Ufer MK, B. Kahlich, R. Kirchheiner, J. Yasar, U. Brockmöller, J. Rane, A. Genetic polymorphisms of 
cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. 
Xenobiotica 2004; 34: 847 - 59.
 [19] Werner D, Werner U, Wuerfel A, Grosch A, Lestin H, Eschenhagen T, et al. Pharmacogenetic char-
acteristics of patients with complicated phenprocoumon dosing. Eur J Clin Pharmacol 2009; 65(8): 
783-8.
 [20] Hummers-Pradier E, Hess S, Aham I, Papke T, Pieske B, Kochen M. Determination of bleeding risk 
using genetic markers in patients taking phenprocoumon Eur J Clin Pharmacol 2003; 59: 213-9.
 [21] Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Buller HR. A C1173T dimorphism in the 
VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005 Oct; 2(10): e312.
 [22] Schalekamp T, Brassé BP, Roijers JFM, van Meegen E, van der Meer FJM, van Wijk EM, et al. VKORC1 
and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both 
genotypes affects dose requirement. Clin Pharmacol Ther 2006; 81(2): 185-93.
 [23] Qazim B, Stöllberger C, Krugluger W, Dossenbach-Glaninger A, Finsterer J. Dependency of phen-
procoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes. J Thromb Haemost 2009; 
28(2): 211-4.
 [24] Ufer M. Comparative pharmacokinetics of vitamin K antagonists. Clin Pharmacokinet 2005; 44(12): 
1227-46.
 [25] Beinema M, Brouwers JB, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, 
acenocoumarol and phenprocoumon. Thromb Haemost 2008; 100: 1052-7.
 [26] Stehle S, Kirchheiner J, Lazar A, Fuhr U. Pharmaccogenetics of oral anticoagulants. A basis for dose 
individualization. Clin Pharmacokinet 2008; 47(9): 565-94.
 [27] Sontag T, Parker R. Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism: novel 
mechanism of regulation of vitamin E status. J Biol Chem 2002; 277: 25290 - 6.
 [28] Visser L, Trienekens P, De Smet P, Vulto A, Hofman A, van Duijn C, et al. Patients with an ApoE epsi-
lon4 allele require lower doses of coumarin anticoagulants. Pharmacogenet Genomics 2005; 15(2): 
69-74.
 [29] Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity 
of the CYP3A4*1B promoter variant. Environmental and Molecular Mutagenesis 2003; 42(4): 299-
305.
 [30] Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability 
in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991 Jul; 7(4): 403-22.
 [31] Hofman A, Breteler M, van Duijn C, Krestin G, Pols H, Stricker B, et al. The Rotterdam Study: objec-
tives and design update. Eur J Epidemiol 2007 2007; 22: 819-29.
 [32] Hofman A, Breteler M, Van Duijn C, Janssen H, Krestin G, Kuipers E, et al. The Rotterdam Study: 2010 
objectives and design update. Eur J Epidemiol 2009; 24: 553-72.
 [33] Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, et al. Meta-analyses of 
genome-wide association studies identify multiple loci associated with pulmonary function. Nat 
Genet; 42(1): 45-52.
96
 [34] Li Y, Abecasis G. Rapid haplotype reconstruction and missing genotype inference. Am J Hum Genet 
2006; S79: 2290.
 [35] NN. The International HapMap Project. Nature 2003; 426: 789-96.
 [36] Flockhart D, O’Kane D, Williams M, Watson M, Gage B, Gandolfi R, et al. Pharmacogenetic testing of 
CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008; 10(2): 139-50.
 [37] Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes 
on transcriptional regulation and warfarin dose. N Engl J Med 2005 Jun 2; 352(22): 2285-93.
 [38] Pe‘er I YR, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genomewide associa-
tion studies of nearly all common variants. Gen Epidemiol 2008; 32(4): 381-5.
 [39] Aulchenko Y, Struchalin M. ProbABEL manual. http: //mgabionetnscru/~yurii/ABEL/manualpdf 
2009; visited on 5th of March 2010.
 [40] The Human Gene Compendium. GeneCards. http: //wwwgenecardsorg/cgi-bin/
carddisppl?gene=Shc3 visited 3rd of August 2010.
 [41] Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 
CYP2C9 with warfarin dose requirement and risk of bleeding complications. The Lancet 1999; 
353(9154): 717-9.
 [42] Schalekamp T, Brassé BP, Roijers JFM, Chahid Y, van Geest-Daalderop JHH, de Vries-Goldschmeding 
H, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: Interaction 
between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006; 80(1): 13-22.
 [43] McDonald M, Rieder M, Nakano M, Hsia C, Rettie A. CYP4F2 is a Vitamin K1 oxidase: an explanation 
for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 2009; 75(6): 1337-46.
 [44] Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, et al. CYP4F2 genetic variant 
alters required warfarin dose. Blood 2008; 111(8): 4106-12.
 [45] Lee S-J, Goldstein JA. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide 
polymorphisms and their detection with genotyping tests. Pharmacogenomics 2005; 6(4): 357-71.
 [46] Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJR, Bumpstead S, et al. The largest prospective 
warfarin-treated cohort supports genetic forecasting. Blood 2009 January 22, 2009; 113(4): 784-92.
 [47] van Schie RMF, Wadelius M, Kamali F, Daly AK, Manolopoulos VG, de Boer A, et al. Genotype-guided 
dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-
PACT) trial design. Pharmacogenomics 2009; 10(10): 1687-95.
Chapter 4
Drug interactions with acenocoumarol

Chapter 4.1
Proton pump inhibitors and the risk of 
overanticoagulation during acenocoumarol 
maintenance treatment
100
Abstract
In the Netherlands, several reports described a potentiation of acenocoumarol-induced 
anticoagulation by co-medication of (es)omeprazole. Our objective was to investigate the ef-
fects of co-medication with PPIs on overanticoagulation during acenocoumarol maintenance 
treatment. All subjects from the Rotterdam Study who received acenocoumarol maintenance 
treatment between April 1st, 1991 and September 9th, 2009 were followed for events of an 
international normalized ratio (INR) ≥6, until death, end of treatment, or end of the study 
period. With the Andersen-Gill extension of the Cox proportional hazards model, risks for 
repeated events of overanticoagulation in relation to concomitant PPI use were calculated. 
The risk for overanticoagulation was most pronounced for esomeprazole (HR 1.99, 95% 
CI 1.55 – 2.55) and lansoprazole (HR 1.49, 95% CI 1.05 – 2.10). There was also a lower and 
non-significant risk increase for the other PPIs. In conclusion, caution should be paid to co-
medication with esomeprazole and lansoprazole (and possibly also with other PPIs) during 
acenocoumarol treatment.
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Introduction
Coumarin anticoagulants are first choice in treatment and prevention of arterial or venous 
thrombosis.[1] Warfarin, acenocoumarol and phenprocoumon act as vitamin-K antagonists 
by inhibiting the synthesis of coagulation factor II, VII, IX and X. Due to a particularly nar-
row therapeutic range, patients treated with these drugs have to be closely monitored by 
regular assessments of the international normalized ratio (INR) to warrant anticoagulation 
without serious bleedings. Individual dosing schemes differ widely between patients, mainly 
due to genetic variation in the vitamin K epoxide reductase complex subunit 1 (VKORC1) 
and cytochrome P450 2C9 (CYP2C9) genes. In addition, age, sex and body mass index (BMI) 
are important determining factors.[2-9] Therefore, coumarin dosage is carefully titrated dur-
ing an initiation period by reference to the INR to achieve a stable individual maintenance 
dosage. However, also within the maintenance period, effects of coumarins can vary due 
to interactions with co-medication, development of co-morbidity or changes in lifestyle. In 
the Netherlands, acenocoumarol and phenprocoumon are most frequently used whereas 
warfarin is only given on rare occasions. Although management of coumarin use in the Neth-
erlands is constantly monitored in anticoagulation clinics by regular INR-measurements to 
obtain optimal INR-levels, bleeding associated with coumarins is among the leading causes 
of drug-induced hospital admissions.[10, 11] Over the years, different drugs were reported 
to increase the anticoagulation effect of coumarins.[12, 13] Until April 2009, the Netherlands’ 
national pharmacovigilance center (LAREB) received nine reports about an increase of the 
anticoagulant effect of acenocoumarol within eleven days after start of treatment with 
omeprazole and seven reports in combination with esomeprazole.[14] Cases of coumarin 
potentiation by other PPIs have not been reported. In four of these reports, the INR rose 
above six. INR measurements rising above four are increasingly associated with overantico-
agulation, and above six the chance of serious bleedings strongly increases.[15] Competitive 
inhibition of CYP2C19 has been suggested as a possible mechanism for interactions of PPIs 
with other drugs.[13] Although earlier studies did not show changes in acenocoumarol phar-
macokinetics or pharmacodynamics[16] or a need of acenocoumarol dosage adjustment 
[17], the Dutch Federation of Anticoagulation Clinics added esomeprazole and omeprazole 
to the list of drugs potentially interacting with coumarins as of January 2010.[18] Before that 
date, Dutch computerized medication surveillance systems of GPs and pharmacists did not 
flag interactions between acenocoumarol and PPIs.
In a large prospective population-based cohort study, we investigated whether co-medica-
tion with the PPIs omeprazole, pantoprazole, lansoprazole, rabeprazole or esomeprazole was 
associated with an increased risk of overanticoagulation during acenocoumarol maintenance 
treatment and whether an effect was modified by CYP2C19 variant alleles.
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Methods
Setting
We selected all subjects from the three cohorts of the Rotterdam Study (RS-I, RS-II and RS-III). 
The rationale and design of the Rotterdam Study have been described elsewhere.[19-21] 
In brief, the Rotterdam Study is a prospective population-based cohort study, designed to 
study neurological, cardiovascular, locomotor and ophthalmologic diseases in a population 
of people of 45 years and older. During different periods, eligible inhabitants of Ommoord, a 
suburb of Rotterdam, were invited to participate. The RS-I cohort consisted of 7,983 subjects 
(response rate 78%), the RS-II cohort of 3,011 participants (response rate 67%) and the RS-III 
cohort of 3,932 subjects (response rate 65%). The RS-I cohort had baseline examinations dur-
ing 1990–1993 with completion of standardized questionnaires, blood sampling and DNA 
isolation. The RS-II was formed as an independent cohort in 1999 with baseline examinations 
between 2000 and 2001 and the RS-III cohort was examined between 2006 and 2008.
A regional anticoagulation clinic, Star Medical Diagnostic Center, monitors all inhabitants of 
Ommoord with an indication for anticoagulant therapy. This clinic covers the patients from all 
three RS cohorts. From this clinic, since 1984, all data on dosing, laboratory and clinical data, 
including data on bleeding complications are fully computerized. The patients own treating 
physician decides about the type of anticoagulant. Prothrombin times are monitored every 
1-6 weeks, depending on the target level and stability of the INR. Coumarin doses are ad-
justed on the basis of computerized dose calculations. More than 99% of participants fill their 
drug prescriptions at seven regional pharmacies, which are fully computerised. Complete 
data on drug use from these pharmacies were available as of January1st, 1991. The pharmacy 
data include the Anatomical Therapeutical Chemical (ATC)-code[22], the filling date, the total 
amount of drug units per prescription, the prescribed daily number of units, and product 
name of the drugs. As PPIs we included omeprazole (selected from pharmacy dispensing 
data by the ATC code of the WHO [22], A02BC01), pantoprazole (A02BC02), lansoprazole 
(A02BC03), rabeprazole (A02BC04) and esomeprazole (A02BC05).
Cohort and outcome definition
Our study population consisted of all patients of the three RS cohorts who started with 
acenocoumarol in the study period from April 1st, 1991 through September 9th, 2009 and 
used it consecutively for at least 42 days. The start date of April 1st was chosen to ensure that 
at least 3 months of medication history from the pharmacy was available for each cohort 
member. We regarded the period starting 42 days after initiation with acenocoumarol as 
maintenance period. In general, steady state of a drug is usually achieved within 5-7 half-lives 
of drug elimination. For (R-)acenocoumarol, the enantiomeric form on which treatment ef-
fects mainly depend, with a half-life of 8 hours, a period of 6 weeks taken as initiation period 
was considered extensive enough to reach a steady state.[23] In patients from the Rotterdam 
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study using acenocoumarol during the maintenance period, we took an event of an INR of 6 
and greater after baseline study enrolment as an outcome. INR levels ≥6 are associated with 
an extensively increased risk of bleedings.[15] We excluded INR events of six and greater that 
happened within 21 days of an earlier event.
Cofactors
The following baseline patient characteristics were considered as potential confounders or 
effect modifiers: sex, age, BMI, and target INR level. BMI was defined as (kg/m2) and missing 
values were imputed with a linear regression model consisting of INR≥6, age, sex and target 
INR as variables. We further adjusted for oral non-steroidal anti-inflammatory drugs (NSAIDs) as 
co-medication (ATC code M01A), since PPIs might have been started because of treatment with 
an NSAID and NSAIDs have been shown earlier to increase acenocoumarol effectiveness.[24]
In a subanalysis we studied the association of acenocoumarol maintenance treatment with 
use of ranitidine (A02BA02). This drug is used for the same indication and not known to be 
dependent on biotransformation via CYP2C19. [25] In further subanalyses, we studied effect 
modification of the CYP2C19*2 variant allele (rs4244285) on an INR ≥6 during use of aceno-
coumarol. To date, about 19 variant alleles of CYP2C19 have been identified.[26] The majority 
of individuals can be classified into three phenotype groups, homozygous and heterozygous 
extensive metabolizers and poor metabolizers. They are determined by the wild-type geno-
type and two mutated alleles, CYP2C19*2 and CYP2C19*3. The principal defect, CYP2C19*2 
(rs4244285) with a G-allele for normal function and an A-allele as variant with decreased 
efficiency, leads to a truncated protein and was genotyped in our population. CYP2C19*3 is 
rare in Caucasians and was not genotyped in the Rotterdam Study.[15]
Genotyping
All RS participants with available DNA were genotyped using Illumina Infinium II Human-
Hap BeadChips at the Department of Internal Medicine, Erasmus Medical Center following 
manufacturer’s protocols. RS-I participants (n=6,449) were genotyped with 550k (V.3) single 
and duo chips, while RS-II participants (n=2,516) were genotyped with 550k (V.3) duo and 
610k Quad chips. RS-III (n=2.420) participants were genotyped with the Human 610 Quad Ar-
rays of Illumina. Genotype calling was performed in RS-I using BeadStudio software (version 
0.3.10.14), GenomesStudio in RS-II and Bead Studio (v3.2.23) in RSIII. Participants with call 
rates <97.5%, excess autosomal heterozygosity, sex mismatch or outlying identity-by-state 
clustering estimates were excluded. After quality control, 5,974 RS-I participants, 2,157 RS-II 
and 2,078 RS-III participants remained with complete data on genotyping.[27] For imputa-
tion, 512,349 autosomal SNPs in RS-I and 466,389 autosomal SNPs in RS-II and RS-III were 
used after exclusions for call rate < 98%, HWE P<10−6, and MAF <1%, in MACH (version 1.00.15 
for RS-I, 1.00.16 for RS-II and RS-III) with reference to the 2,543,886 SNPs of the HapMap CEU 
(release 22, build 36).[27]
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Statistical analysis
Within a subject, an INR ≥6 could occur more than once and co-medication with PPIs could 
change during acenocoumarol treatment period. In order to include all information available 
for the whole study period, we used the Andersen-Gill extension of the Cox proportional haz-
ards model. This model allows to study multiple events of an INR ≥6 within one subject and 
in association with PPI use as a time-varying covariable.[28] All subjects on acenocoumarol 
maintenance therapy were followed as of April 1st, 1991, from their first INR assessment until 
the last INR assessment because of the end of their treatment, last INR ≥6 event or the end of 
the study period, whichever came first. The date on which an INR ≥6 occurred was taken as the 
index date. In order to exclude protopathic bias, patients were only considered as exposed to 
PPIs at the index date if they had started PPI at least 3 days before that date. Each case was 
compared for PPI exposure to all subjects who were on acenocoumarol maintenance treat-
ment at the index date.[29] Thus cases could serve as controls on other index dates when 
still being on acenocoumarol treatment. We computed hazard ratios (HRs) and their 95% 
confidence intervals (CIs) for all events of an INR≥6. Risk estimates were adjusted for age, sex, 
target INR, BMI and NSAID co-medication. To study effect modification by CYP2C19 genotype, 
patients were stratified according to their genotype as CYP2C19*2 homozygous G-alleles and 
variant type (CYP2C19*2 heterozygous G/A-alleles or CYP2C19*2 homozygous A-alleles).
SPSS 15.0 was used for data management and SAS 9.20 for the Andersen-Gill analysis.
Results
Of the 14,926 subjects in the Rotterdam cohorts, 2,755 had used acenocoumarol during the 
study period for longer than 42 days continuously as maintenance therapy. In 887 subjects 
an INR ≥6 was measured at least once and in total 2146 INR ≥6 occurred, between 1 and 22 
events per subject at a median of 2 per person. Baseline characteristics of patients with an INR 
≥6 and the total cohort are shown in table 1. 43% subjects with acenocoumarol maintenance 
therapy were male, mean age at study entry was 69 years and mean BMI 27.2 kg/m2. BMI 
values had to be imputed in 280 subjects (10.9%). Increasing age and higher INR target levels 
significantly increased the risk to develop an INR≥6. Higher BMI measures were associated with 
a decreased risk of overanticoagulation. From the 2,059 subjects successfully genotyped for 
CYP2C19*2, 1,464 (71.1%) were homozygous for the CYP2C19*2 G-allele and 545 (28.9%) had a 
variant genotype with an A-allele. The frequency of the CYP2C19*2 variant allele A was 15.7% 
and alleles were in Hardy-Weinberg equilibrium (HWE, p-value=0.93). Subjects homozygous 
with the variant A-allele of CYP2C19*2 had a decreased risk on overanticoagulation during 
acenocoumarol treatment (HR 0.54; 95% CI 0.36-0.83). As this group was quite small (2.4%), we 
pooled subjects homozygous and heterozygous for the variant A-allele. Any variant A-allele 
was then no longer associated with the risk of overanticoagulation (HR 0.99; 95% CI 0.89-1.11).
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In our cohort in total 457 (16.6%) subjects used omeprazole, 160 (5.8%) pantoprazole, 102 
(3.7%) lansoprazole, 286 (10.4%) rabeprazole and 149 (5.4%) esomeprazole (table 2). In 223 
events of an INR ≥6 a PPI (10.4% of all events) was used on the index date for at least three 
days. Co-medication during acenocoumarol maintenance treatment with esomeprazole was 
associated with a doubled risk of an INR ≥6 (HR 1.99; 95% CI 1.55–2.55) and co-medication 
with lansoprazole increased the risk by 49 percent (HR 1.49; 95% CI 1.05–2.10, table 2). The 
other PPIs also increased the risk of overanticoagulation less pronounced between 1.12 and 
1.23 times, but associations were just below the significance threshold after adjustment for 
co-medication with NSAIDs. Co-medication with ranitidine, used by 229 subjects (10.5%), 
showed no association with overanticoagulation (HR 1.06, 95% CI 0.83–1.35).
For esomeprazole and lansoprazole we investigated whether the CYP2C19 genotype 
modified the interaction with acenocoumarol (table 3). We did not find a multiplicative in-
Table 1 Characteristics of acenocoumarol users with INR of 6.0 or greater and total cohort
Patients with INR>=6.0 (N=887) Total cohort (N=2,755) HRa 95% CI
Gender
Male (%)
Female (%)
405 (45.7)
482 (54.3)
1,192 (43.3)
1,563 (56.7)
1.00
1.25
Reference
(1.15 – 1.36)
Start age (years)
45 – 54
55 – 64
65 – 74
75 – 84
>85
10(1.1%)
72 (8.1%)
214 (24.1%)
389 (43.9%)
202 (22.8%)
114 (4.2%)
383 (14.0%)
907 (33.2%)
998 (36.5%)
334 (12.2%)
1.00
2.89
2.74
4.14
6.10
Reference
1.75 – 4.78
1.69 – 4.45
2.56 – 6.68
2.63 – 14.1
BMI (kg/m2)
15.0 – 20.0
20.1 – 25.0
25.1 – 30.0
>30.0
17 (1.9)
228 (25.7)
492 (55.5)
150 (16.9)
45 (1.6)
718 (26.1)
1446 (52.6)
539 (19.6)
1.00
0.70
0.68
0.56
Reference
0.52 – 0.93
0.51 – 0.91
0.42 – 0.76
Target level (INR)
2.0 – 2.5
2.0 - 3.5
3.0 - 4.0
3.5 - 4.5
1 (0.1)
389 (43.9%)
482 (54.3%)
15 (1.7%)
118 (4.3)
1728 (62.7%)
889 (32.3%)
20 (0.7%)
1.00
10.1
27.9
65.4
Reference
3.23 – 31.2
9.00 – 86.7
17.3 - 247
Subjects with NSAID use 89 (10.0) 470 (17.0) 1.31 1.15 – 1.50
CYP2C19*2 genotypesb
GG
GA
AA
N=648 (73.1% of all cases)
472 (72.8%)
167 (25.8%)
9 (1.4%)
N=2059 (74.7% of the total group)
1464 (71.1%)
545 (26.5)%
50 (2.4%)
1.00
0.96
0.54
Reference
0.87 – 1.07
0.36 – 0.83
Statistically significant values are printed in bold
a Univariate analysis of RR were performed with an Andersen-Gill model. RRs cannot be calculated with 
the numbers in this table because controls may later become cases; significant values are printed in bold.
b For the CY2C19*2 genotype within total cohort, allelic frequency of the G-allele was 84.3%, of the 
A-allele 15.7%, and HWE was 0.93
Abbreviations: INR, international normalized ratio; HR, hazard ratio; CI, confidence interval; HWE, Hardy-
Weinberg equilibrium.
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teraction between the drugs separately or grouped for use of either of the drugs and at least 
one CYP2C19*2 variant allele. To investigate presence of an additive effect modification we 
formed 4 groups for the combinations of drug use yes and no with absence and presence of 
CYP2C19*2 variant alleles. No additive effect modification was detected either.
Table 2 Association between overanticoagulation (INR≥6) under acenocoumarol maintenance treatment 
and proton pump inhibitors
PPI Total cohorta 
(N=2,755) and use of 
a specific drug
Andersen-Gill analysisa
Cases with use of a specific drug 
with at least one INR≥6.0
HRb (95% CI) HRc (95% CI)
Omeprazole 457 82 1.18 (1.01 – 1.38) 1.12 (0.96 – 1.32)
Pantoprazole 160 31 1.27 (0.97 – 1.67) 1.21 (0.92 – 1.59)
Lansoprazole 102 24 1.50 (1.06 – 2.12) 1.49 (1.05 – 2.10)
Rabeprazole 286 44 1.30 (1.01 – 1.67) 1.23 (0.95 – 1.58)
Esomeprazole 149 42 2.08 (1.63 – 2.67) 1.99 (1.55 – 2.55)
Subanalysis
Ranitidine 290 44 1.08 (0.84 – 1.35) 1.06 (0.83 – 1.35)
Statistically significant values are printed in bold
a In this time-dependent analysis, exposure in case patient and in the rest of the cohort is assessed at the 
time of the outcome in each case patient (index date). As control patients can be used multiple times, 
the number of assessments in the reference group is much larger than the number of individuals. Hence, 
crude HRs cannot be calculated from the data in this table.
b adjusted for age, sex, BMI and target INR
c adjusted for age, sex, BMI, target INR and use of non-steroidal anti-inflammatory drugs, ATC-group 
M01A.
Table 3 Association between overanticoagulation (INR≥6.0), esomeprazole and lansoprazole, stratified by 
CYP2C19*2 genotype
HRa (95% CI) P-value of 
multiplicative 
interaction
Interaction between esomeprazole and CYP2C19*2 genotypes (homozygous G-allele / at 
least one variant A-allele)
0.15
No use of esomeprazole, CYP2C19*2 homozygous G-allele 1.00 reference
No use of esomeprazole, CYP2C19*2 at least one variant A allele 0.94 (0.84 – 1.04)
Use of esomeprazole, CYP2C19*2 homozygous G-allele 1.97 (1.47 – 2.64)
Use of esomeprazole, CYP2C19*2 at least one variant A allele 1.05 (0.47 – 2.34)
Interaction between esomeprazole or lansoprazole and CYP2C19*2 genotypes (wild type 
genotype / variant alleles)
0.73
No use of esomeprazole or lansoprazole, CYP2C19*2 homozygous G-allele 1.00 reference
No use of esomeprazole or lansoprazole, CYP2C19*2 at least one variant A allele 0.92 (0.83 – 1.03)
Use of esomeprazole or lansoprazole, CYP2C19*2 homozygous G-allele 1.69 (1.31 – 2.19)
Use of esomeprazole or lansoprazole, CYP2C19*2 at least one variant A allele 1.52 (0.93 – 2.50)
Statistically significant values are printed in bold
a adjusted for age, sex, BMI, target INR and use of nonsteroidal anti-inflammatory drugs, ATC-group M01A.
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Discussion
In our study population, all PPIs tended to increase the risk of overanticoagulation during 
acenocoumarol maintenance treatment. This was most pronounced for esomeprazole, dou-
bling the risk of overanticoagulation and for lansoprazole with a risk increase of 49%. Risk 
increases for omeprazole, pantoprazole and rabeprazole were between 12 and 23% and just 
failed to reach significance after adjustment for NSAID co-medication.
PPIs have been mentioned occasionally as potential risk factors for overanticoagulation 
during treatment with vitamin K antagonist in case reports, however most case control 
studies and trials concluded no effect of clinical relevance.[12, 17] The highest number of 
case reports and pharmacokinetic studies are available for omeprazole in combination with 
coumarins. Two case reports described an INR increase in users of phenprocoumon after 
initiation of omeprazole and return to normal after its cessation.[30] One case controls study 
found no evidence for an interaction between omeprazole and acenocoumarol. They used 
acenocoumarol dose adjustment as an outcome which did not differ between a group of 
acenocoumarol users with omeprazole as co-medication and a group acenocoumarol users 
without interfering co-medication.[16] However, in contrast to dosage adjustments, INR 
measures are directly related to acenocoumarol effects. A pharmacokinetic study showed 
that omeprazole increased plasma concentration of R-warfarin by nearly 10% whereas there 
was no effect on S-warfarin, the more active isomer.[31] The authors concluded that an ef-
fect of omeprazole on the anticoagulation activity of warfarin was not likely to be of clinical 
importance. This finding was confirmed by a randomized double-blind cross-over-study 
where coagulation time of warfarin during omeprazole use was not significantly changed 
compared to placebo.[32] Also within acenocoumarol users, one cohort study and one trial 
found no evidence for an interaction between acenocoumarol and omeprazole.[16, 17] For 
pantoprazole, a trial showed no effect on phenprocoumon treatment. [33] However, the trials 
were only short term trials with small numbers of subjects and the cohort study took dosage 
change as an outcome without regard to INR measurements. In one study for co-medication 
with lansoprazole or rabeprazole in patients after open heart surgery,[34] lansoprazole 
enhanced the anticoagulation effects of warfarin whereas rabeprazole could be used con-
comitantly without increasing the risk of overanticoagulation. We are not aware of a clinical 
study on the effect of esomeprazole on coumarins to support our findings.
As a possible mechanism a competitive inhibition of CYP2C19 by PPIs on coumarin clear-
ance has been mentioned as both drug groups are metabolized by this enzyme and the INR 
increases in the case reports were reported within 11 days after start of the PPI.[13, 35, 36] 
Within coumarins, the (R-)enantiomeric form of warfarin and both forms of acenocoumarol 
are metabolized by CYP2C19.[13, 37] In general, the (S-)isomers of the coumarins are more ef-
fective. However, for acenocoumarol, the (S-)form has an extremely short half live of 2 hours 
and acenocoumarol effects mainly depend on the (R-)enantiomeric form of which about 20% 
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is metabolized via CYP2C19. Therefore, for acenocoumarol more than for warfarin, a phar-
macokinetic interaction with PPIs via CYP2C19 might lead to an effect of clinical relevance. 
Clearance of PPIs is conducted primarily by CYP2C19. In vitro studies showed that all five 
PPIs were able to competitively inhibit CYP2C19, but to a different extent. Lansoprazole had 
the highest inhibitory potency of CYP2C19 in vitro.[38] Rabeprazole had a relatively lower 
in vitro inhibition of CYP2C19 than the other PPIs, possibly as it is metabolized mainly via a 
non-enzymatic reaction to a thioether compound with only minor CYP2C19 involvement.
[34, 36, 38] Omeprazole and esomeprazole in vitro also reduced CYP2C19 activity [38] and 
were more potent than pantoprazole.[39] Theoretically a competition for scarce CYP2C19 
enzyme might prolong the effectiveness of the coumarins which would result in an increased 
INR. In subjects with variant allele genotypes and decreased enzyme availability this effect 
may be even more pronounced. However, from our analysis, no multiplicative or additive 
effect modification of CYP2C19*2 variant alleles on the association between esomeprazole 
or lansoprazole and acenocoumarol was detected. Possibly the effect of the variant allele 
on acenocoumarol elimination was too small and more cases are needed to warrant enough 
power for a genotype-stratified analysis.
Our results show a more pronounced association for esomeprazole than for omeprazole. 
Omeprazole is a racemic composition of its two optical isomers, (S-)omeprazole (esomepra-
zole) and (R-)omeprazole.[40] The clearance of the two enantiomeric omeprazole-forms by 
CYP2C19 is stereo-selective and depend for (R-)omeprazole more on the CYP2C19 enzyme 
than for (S-)enantiomeric form.[40-42] In vivo, CYP2C19 was responsible for 90% of the 
metabolism of (R-)omeprazole and 70% of (S-)omeprazole.[42] The interaction potential for 
esomeprazole, however, was expected to be similar to omeprazole because of the higher 
standard dose used for esomeprazole (40 mg) compared to omeprazole (20 mg) in clinical 
practice and lower clearance of esomeprazole. [25, 38, 42] In our study population, omepra-
zole and esomeprazole were used in similar defined daily doses (DDD), omeprazole at a mean 
DDD of 1.35 (range 0.21–4.50) and esomeprazole at a mean DDD of 1.23 (range 0.33–4.00). 
However, these DDDs do not represent equipotent dosages as 1 DDD omeprazole equals 20 
mg and 1 DDD esomeprazole 30 mg. Consequently in our study population, esomeprazole 
was used in a much higher pharmacological dosage than omeprazole.
Our study is the first observational cohort study of an increase of acenocoumarol effective-
ness by co-medication of all PPIs separately with a substantial number of subjects during the 
whole period of acenocoumarol maintenance treatment within a subject. We consider the 
chance of bias and confounding due to study design as negligible. First, the Rotterdam Study 
is a prospective cohort study and the regional anticoagulation clinic covered a complete 
area of more than one million inhabitants in the Rotterdam area. Consequently, everyone 
who is treated with a coumarin anticoagulant as an outpatient will be registered as such and 
selection bias is unlikely. Second, all medication use of all subjects was almost completely 
covered by the pharmacy data we retrieved and during the study period PPIs were only avail-
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able on prescription via pharmacies. Any lack of compliance would move our results into the 
direction of the null hypothesis, and would tend to make our results conservative. During our 
study period, an association between PPI and acenocoumarol overanticoagulation was not 
yet common knowledge. Third we followed the cohort members during their whole period 
of acenocoumarol maintenance therapy and compared cases to all other cohort members 
available at the index dates for PPI exposure. The analysis made use of all data available and 
adjusted for time varying effects. However, in observational studies there is always a risk of 
confounding by indication. We therefore performed the same analysis for rantidine, a H2-
receptor antagonist used for the same indication but not known for inhibitory potential of 
CYP2C19. We did not find an association for ranitidine with an increased risk on achieving INR 
≥6 during acenocoumarol treatment. As PPIs might have been started to treat the symptoms 
of an increased INR, in our analysis use of PPIs – and also ranitidine – had to be started for at 
least 3 days prior to the index date. We did not take bleedings as an outcome because PPI 
s are likely to be started with complaints preceding gastrointestinal bleeding. Associations 
found might be due to protopathic bias.
In conclusion, in this population-based cohort study among outpatients of an anticoagula-
tion clinic using acenocoumarol for maintenance treatment, esomeprazole doubled the risk 
on an INR ≥6 and lansoprazole tended to increase this risk by approximately 50%. For omepra-
zole, pantoprazole and rabeprazole, a risk increase was less pronounced and non-significant. 
Our results suggest that extra monitoring during acenocoumarol treatment may be warranted 
in patients on esomeprazole or lansoprazole and this perhaps applies to other PPIs as well.
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Chapter 4.2
Selective serotonin reuptake inhibitors 
and the risk of overanticoagulation during 
acenocoumarol maintenance treatment
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Abstract
Potentiation of warfarin-induced anticoagulation by co-medication with selective serotonin 
reuptake inhibitors (SSRIs) has been described previously. Our objective was to investigate 
the effects of co-medication with SSRIs on overanticoagulation during acenocoumarol 
maintenance treatment. All subjects from the Rotterdam Study who received acenocoumarol 
maintenance treatment between April 1st, 1991 and September 9th, 2009 were followed for 
the event of an international normalized ratio (INR) ≥6, until death, end of treatment or end 
of the study period. With the Andersen-Gill extension of the Cox proportional hazards model, 
risks for repeated events of overanticoagulation in relation to concomitant SSRI use were 
calculated. The risk for overanticoagulation during acenocoumarol maintenance treatment 
was increased in combination with fluvoxamine (HR 2.63, 95% CI 1.49–4.66) and venlafaxine 
(HR 2.19, 95% CI 1.21–3.99) but not for the other SSRIs. In conclusion, fluvoxamine and ven-
lafaxine were associated with a more than double risk of INR measures ≥6 in acenocoumarol 
treated subjects.
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Introduction
Coumarin anticoagulants are first choice in treatment and prevention of arterial or venous 
thrombosis.[1] Warfarin, acenocoumarol and phenprocoumon act as vitamin-K antagonists 
by inhibiting the synthesis of coagulation factor II, VII, IX and X. Due to a particularly narrow 
therapeutic range, patients treated with these drugs have to be closely monitored by regular 
assessments of the international normalized ratio (INR) to warrant anticoagulation without 
serious bleedings. Individual dosage differs widely between patients, mainly due to genetic 
variation in the vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome 
P450 2C9 (CYP2C9) genes in combination with age, sex and body mass index (BMI).[2-9] 
Therefore during an initiation period, coumarin dosage is carefully titrated by reference to 
the INR to achieve a stable individual maintenance dosage. However, also within the mainte-
nance period effects of coumarins can vary due to interactions with co-medication or devel-
opment of co-morbidity. In the Netherlands, acenocoumarol and phenprocoumon are most 
frequently used whereas warfarin is only given on rare occasions. Although management 
of coumarin use in the Netherlands is constantly monitored in anticoagulation clinics by 
regular INR-measurements to obtain optimal INR-levels, bleeding associated with coumarins 
is among the leading causes of drug-induced hospital admissions.[10, 11]
Selective serotonin reuptake inhibitors (SSRIs) have also been reported to increase the 
risk of bleeding [12-17]. Increase of prothrombin time was described in several case reports 
for fluvoxamine and fluoxetine in combination with warfarin. [18-21] Results from a case 
control study for the combination of acenocoumarol or phenprocoumon with SSRIs showed 
a risk increase for non gastrointestinal bleeding, but not for gastrointestinal bleeding.[22] 
Another case control study reported a small risk increase for upper gastrointestinal haemor-
rhage with SSRIs which was most pronounced for venlafaxine.[23] However, there was no 
evidence for effect modification on bleeding risk for SSRI use in combination with warfarin.
[23] A further case control study on initiation of SSRIs in warfarin users found no significant 
risk increase of hospitalization for upper gastrointestinal bleeding.[24] The Dutch Federation 
of Anticoagulation Clinics included the group of SSRIs in the list of drugs for extra monitor-
ing during coumarin treatment although the separate contribution of individual SSRIs and 
the exact underlying mechanism of the interaction are not yet known.[25] The mechanism 
might be pharmacodynamic as serotonin release is important for the platelet aggregation 
and inhibition of its reuptake by SSRIs might prevent haemostasis additional to the effects 
on anticoagulation by coumarins.[14] The mechanism of the interaction might also be phar-
macokinetic as fluvoxamine and sertraline were reported to inhibit CYP2C9, the main me-
tabolizing enzyme of coumarins.[26] This would increase coumarin effectiveness and might 
result in increase of INR and bleedings. In a large prospective population-based cohort study, 
we investigated whether co-medication with the SSRIs fluoxetine, citalopram, paroxetine, 
sertraline, fluvoxamine, escitalopram or venlafaxine was associated with an increased risk of 
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was modified by CYP2C9 variant alleles.
Methods
Setting
We selected all subjects from the three cohorts of the Rotterdam Study (RS-I, RS-II and RS-III). 
The rationale and design of the Rotterdam Study have been described elsewhere.[27-29] 
In brief, the Rotterdam Study is a prospective population-based cohort study, designed to 
study neurological, cardiovascular, locomotor and ophthalmologic diseases in a population 
of people of 45 years and older. The RS-I cohort consisted of 7,983 subjects (response rate 
78%), the RS-II cohort of 3,011 participants (response rate 67%) and the RS-III cohort of 3,932 
subjects (response rate 65%). The RS-I cohort had baseline examinations during 1990–1993 
with completion of standardized questionnaires, sampling of blood and isolation of DNA. 
The RS-II was formed as an independent cohort in 1999 with baseline examinations between 
2000 and 2001 and the RS-III cohort was examined between 2006 and 2008.
A regional anticoagulation clinic, Star Medical Diagnostic Center, monitors all inhabitants 
of Ommoord, a suburb of Rotterdam, with an indication for anticoagulant therapy. This clinic 
covers the patients from all the RS cohorts. From this clinic, since 1984, all data on dosing, 
laboratory and clinical data, including data on bleeding complications are fully computerized. 
The physician who treats the patient decides about the type of anticoagulant. Prothrombin 
times are monitored every 1-6 weeks, dependent on the target level and stability of the INR. 
Coumarin doses are adjusted on the basis of computerized dose calculations. More than 99% 
of participants fill their drug prescriptions at seven regional pharmacies, which are fully com-
puterised. Complete data on drug use from these pharmacies were available as of 1 January 
1991. In order to assess initiation of SSRIs, we used data from 1st April, 1991 through 9th 
September, 2009. The pharmacy data include the Anatomical Therapeutical Chemical (ATC)-
code[30], the filling date, the total amount of drug units per prescription, the prescribed daily 
number of units, and product name of the drugs. As SSRIs we included fluoxetine (ATC code 
N06AB03), citalopram (N06AB04), paroxetine (N06AB05), sertraline (N06AB06), fluvoxamine 
(N06AB08), escitalopram (N06AB10) and venlafaxine (N06AX16).
Cohort and outcome definition
Our study population consisted of all patients of the three RS cohorts who started with 
acenocoumarol in the study period between 1st April 1991 and 9th September 2009, using it 
consecutively for at least 42 days. We regarded a treatment period starting 42 days after ini-
tiation with acenocoumarol as maintenance period. Steady state of a drug is usually achieved 
within 5-7 half-lives of drug elimination. The (S-)enantiomeric form of acenocoumarol has a 
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2-5 fold higher anticoagulant potency than the (R-)form, however due to the extremely fast 
clearance of the (S-)enantiomeric, treatment effects are mainly due to (R-) acenocoumarol. 
For (R-)acenocoumarol with a half-life of 8 hours, a period of 6 weeks taken as initiation 
period was considered extensive enough to reach a steady state.[31] In patients from the 
Rotterdam study using acenocoumarol during the maintenance period, we took an event 
of an INR of 6 and greater after baseline study enrolment as an outcome. INR levels ≥ 6 are 
associated with an extensively increased risk of bleedings.[32] An assessment of the INR ≥ 
6 occurring in a particular individual within 21 days of an earlier event was considered as 
part of one event episode. When occurring more than 21 days after an earlier event, it was 
considered as a new event.
Cofactors
The following baseline patient characteristics were considered as potential confounders or 
effect modifiers: sex, age, BMI, and target INR level. BMI was defined as (kg/m2) and miss-
ing values were imputed with a linear regression model consisting of INR≥6, age, sex and 
target INR as variables. We further adjusted for co-medication with oral non-steroidal anti-
inflammatory drugs (NSAIDs, M01A) and proton pump inhibitors (A02BC) as these drugs have 
been shown to interact with acenocoumarol with effects on INR measures.[33, 34]
We did not adjust for co-medication with platelet inhibitors (B01AC), acetyl salicylic 
acid (N02BA), and corticosteroids (H02AB, H02BX), as these drugs do not influence the INR 
assessment. We verified the independency of our results from this co-medication in an ad-
ditional analysis (results not given). In a sub-analysis we studied the interaction between 
acenocoumarol maintenance treatment with the use of nortriptyline (N06AA01) or mirtazap-
ine (N06AX11).These are frequently prescribed antidepressants that are not metabolized 
via CYP2C9 and thus unlikely to cause a pharmacokinetic interaction. Nortriptyline and 
mirtazapine furthermore have no significant affinity for the serotonin transporter[35] and 
consequently are not likely to show a pharmacodynamic interaction either. In an additional 
sub-analysis we studied effect modification of a CYP2C9 variant (T-) allele (rs4086116) on an 
INR ≥6 during use of acenocoumarol. Within the CYP2C cluster, this SNP was found to be most 
strongly associated with acenocoumarol dosage variation and explained nearly as much of 
dosage variation as the combined CYP2C9*2/*3 genotypes[36]. This SNP was genotyped in 
al three RS-cohorts. We did not expect effect-modification by VKORC1 variant alleles as this 
gene is not involved in mechanism or kinetics of the SSRIs. We confirmed the independency 
of this assumption with results in an additional analysis (results not given).
Genotyping
From all RS participants, those with available DNA were genotyped using Illumina Infinium 
II HumanHap BeadChips at the Department of Internal Medicine, Erasmus Medical Center 
following manufacturer’s protocols. RS-I participants (n=6,449) were genotyped with 550k 
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(V.3) single and duo chips, while RS-II participants (n=2,516) were genotyped with 550k (V.3) 
duo and 610k Quad chips. RS-III (n=2.420) participants were genotyped with the Human 610 
Quad Arrays of Illumina. Genotype calling was performed in RS-I using BeadStudio software 
(version 0.3.10.14), GenomesStudio in RS-II and Bead Studio (v3.2.23) in RSIII. Participants 
with call rates <97.5%, excess autosomal heterozygosity, sex mismatch or outlying identity-
by-state clustering estimates were excluded. After quality control, 5,974 RS-I participant, 
2,157 RS-II and 2,078 RS-III participants remained with complete data on genotyping.[37] For 
imputation 512,349 autosomal SNPs in RS-I and 466,389 autosomal SNPs in RS-II and RS-III 
were used after exclusions for call rate < 98%, HWE P<10−6, and MAF <1%, in MACH (ver-
sion 1.00.15 for RS-I, 1.00.16 for RS-II and RS-III) with reference to the 2,543,886 SNPs of the 
HapMap CEU (release 22, build 36).[37]
Statistical analysis
Within a subject, an INR ≥6 could occur more than once and co-medication with SSRIs could 
change during an acenocoumarol treatment period. In order to include all information avail-
able for the whole study period, we used the Andersen-Gill extension of the Cox proportional 
hazards model. This model allows to study multiple events of an INR ≥6 within one subject 
and uses exposure to SSRIs as a time-varying covariable.[38] All subjects on acenocoumarol 
maintenance therapy were followed as of April 1st, 1991, from their first INR assessment until 
the last INR assessment because of the end of their treatment or last INR ≥6 event, the end 
of study period, or death, whichever came first. The date on which an INR ≥6 occurred was 
taken as the index date. Each case was compared for SSRI exposure to all subjects who were 
on acenocoumarol maintenance treatment at the index date.[39] Thus cases could serve as 
controls on other index dates when still being on acenocoumarol treatment until their last 
measure of an INR ≥6. We computed hazard ratios (HRs) and their 95% confidence intervals 
(CIs) for all events of an INR ≥6. Risk estimates were adjusted for age, sex, target INR, BMI and 
co-medication with NSAID or proton pump inhibitors. To study effect modification by CYP2C9 
genotype, subjects from the study population who were successfully genotyped were strati-
fied as wild type (CYP2C9 homozygous C-alleles) and variant type (CYP2C9 heterozygous C/T-
alleles or CYP2C9 homozygous T-alleles). SPSS 15.0 was used for data management and SAS 
9.20 for the Andersen Gill analysis.
Results
Of the 14,926 subjects in the Rotterdam cohorts, 2,755 had used acenocoumarol during the 
study period for longer than 42 days continuously as maintenance therapy. In 887 subjects 
an INR ≥6 was measured at least once. Baseline characteristics of patients with an INR ≥6 and 
the total cohort are shown in table 1. From the subjects on acenocoumarol maintenance 
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therapy 43% were male, mean age at study entry was 69 years and mean BMI 27.2 kg/m2. BMI 
values had to be imputed in 280 subjects (10.9%). Increasing age and higher INR target levels 
significantly increased the risk to develop an INR ≥ 6. Higher BMI measures were associated 
with a decreased risk of overanticoagulation. From the 2,059 subjects successfully genotyped 
for CYP2C9, 1,352 (65.7%) had a wild type genotype and 712 (34.3%) had a variant genotype. 
The frequency of the CYP2C9 variant T-allele was 19.1% and alleles were in Hardy-Weinberg 
equilibrium (HWE, p-value=0.65). In subjects being homozygous for the CYP2C9 variant allele 
the risk for an INR ≥6 was increased 1.38 times (95% CI 1.12–1.70).
In our cohort in total 225 subjects (5%) used SSRIs of whom 18 subjects used fluoxetine, 
32 citalopram, 97 paroxetine, 23 sertraline, 26 fluvoxamine, 2 escitalopram and 14 venlafax-
ine (table 2). In 38 events of an INR ≥6 a SSRI (4.3% of all events) was used on the index 
date. Co-medication during acenocoumarol maintenance treatment with fluvoxamine and 
Table 1 Characteristics of acenocoumarol users with INR of 6.0 or greater and total cohort
Patients with INR>=6.0
(N=887)
Total cohort (N=2,755) HRa 95% CI
Gender
Male (%)
Female (%)
405 (45.7)
482 (54.3)
1,192 (43.3)
1,563 (56.7)
1.00
1.25
Reference
(1.15 – 1.36)
Start age (years)
45 – 54
55 – 64
65 – 74
75 – 84
>85
10(1.1%)
72 (8.1%)
214 (24.1%)
389 (43.9%)
202 (22.8%)
114 (4.2%)
383 (14.0%)
907 (33.2%)
998 (36.5%)
334 (12.2%)
1.00
2.89
2.74
4.14
6.10
Reference
1.75 – 4.78
1.69 – 4.45
2.56 – 6.68
2.63 – 14.1
BMI (kg/m2)
15.0 – 20.0
20.1 – 25.0
25.1 – 30.0
 >30.0
17 (1.9)
228 (25.7)
492 (55.5)
150 (16.9)
45 (1.6)
718 (26.1)
1,446 (52.6)
539 (19.6)
1.00
0.70
0.68
0.56
Reference
0.52 – 0.93
0.51 – 0.91
0.42 – 0.76
Target level (INR)
2.0 – 2.5
2.0 - 3.5
3.0 - 4.0
3.5 - 4.5
1 (0.1)
389 (43.9%)
482 (54.3%)
15 (1.7%)
118 (4.3)
1728 (62.7%)
889 (32.3%)
20 (0.7%)
1.00
10.1
27.9
65.4
Reference
3.23 – 31.2
9.00 – 86.7
17.3 - 247
Subjects with NSAID use
Subjects with PPI use
89 (10.0)
198 (22.3)
470 (17.0)
862 (31.3)
1.31
1.46
1.15 – 1.50
1.31 – 1.64
CYP2C9 genotypesb
CC
CT
TT
N=648 (73.1% of all cases)
428 (66.0%)
192 (29.6%)
28 (4.3%)
N=2,059 (74.7% of the total group)
1,352 (65.7%)
629 (30.5)%
78 (3.8%)
1.00
0.95
1.38
Reference
0.86 – 1.05
1.12 – 1.70
Abbreviations: INR, international normalized ratio; HR, hazard ratio; CI, confidence interval; HWE, Hardy-
Weinberg equilibrium.
a Univariate analysis of HR were performed with the Andersen-Gill model. HRs cannot be calculated with 
the numbers in this table because controls may later become cases; significant values are printed in bold.
b For the CY2C9 genotype within total cohort, allelic frequency of the C-allele was 80.9%, of the T-allele 
19.1%, and HWE was 0.96
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venlafaxine more than doubled the risk on an INR≥6, for fluvoxamine by 2.63 times (95% CI 
1.49–4.66) and for venlafaxine by 2.19 times (95% CI 1.21–3.99). The other SSRIs showed no 
association with overanticoagulation.
For fluvoxamine and venlafaxine we investigated whether the CYP2C9 genotype modified 
the interaction with acenocoumarol (table 3). We did not find a multiplicative effect measure 
modification for an interaction between fluvoxamine or venlafaxine and at least one CYP2C9 
variant allele. To investigate presence of an additive effect measure modification we formed 
4 groups for the combinations of drug use ‘yes’/’no’ with absence and presence of CYP2C9 
variant alleles. No additive effect measure modification was detected either.
Discussion
In our study population, use of fluvoxamine and venlafaxine was associated with a more 
than double risk of overanticoagulation during acenocoumarol maintenance treatment. Co-
medication with the other SSRIs, fluoxetine, citalopram, sertraline or escitalopram, was not 
associated with an INR≥6. Our findings for fluvoxamine are supported by two case reports 
for INR increase during warfarin treatment.[18, 21] We did not find a study of the effect of 
venlafaxine on INR measures. In agreement with our results, clinical drug trials with fluox-
Table 2 Association between overanticoagulation (INR≥6) under acenocoumarol maintenance treatment 
and SSRIs
SSRI Number of patients with 
drug use within total cohort 
a (N=2,755)
Andersen-Gill analysisa
Cases with use of a specific drug 
with at least one INR≥6.0
HRb (95% CI) HRc (95% CI)
Fluoxetine 18 1 0.50 (0,07 – 3.55) 0.48 (0.07 – 3.40)
Citalopram 32 3 0.62 (0.20 – 1.94) 0.63 (0.20 – 1.95)
Paroxetine 97 18 1.15 (0.81 – 1.65) 0.99 (0.68 – 1.44)
Sertraline 23 2 1.07 (0.34 – 3.34) 1.02 (0.33 – 3.18)
Fluvoxamine 36 8 2.46 (1.39 – 4.34) 2.63 (1.49 – 4.66)
Escitalopram 2 0 P=0.95 P=0.95
Venlafaxine 14 6 2.37 (1.37 – 4.10) 2.19 (1.21 – 3.99)
Sub-analysis
Nortriptyline 12 2 0.60 (0.25 – 1.44) 0.55 (0.21 – 1.47)
Mirtazapine 45 8 1.01 (0.54 – 1.88) 1.09 (0.58 – 2.04)
Statistically significant values are printed in bold
a In this time-dependent analysis, exposure in case patient and in the rest of the cohort is assessed at the 
time of the outcome in each case patient (index date). As control patients can be used multiple times, 
the number of assessments in the reference group is much larger than the number of individuals. Hence, 
crude RRs cannot be calculated from the data in this table.
b adjusted for age, sex, BMI and target INR; if none of the cases was exposed, P values are given instead 
of HRs.
c adjusted for age, sex, BMI, target INR and use of non-steroidal anti-inflammatory drugs (ATC-group M01A) 
or proton pump inhibitors (A02BC) if none of the cases was exposed, P values are given instead of HRs.
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etine, citalopram, and sertraline reported no or only very small increases in prothrombin time 
which were not regarded to be of clinical relevance.[40-42]
A possible pharmacokinetic mechanism might be by competitive inhibition by SSRIs of the 
oxidative metabolism of coumarins via CYP2C9. Differences between the SSRIs could be ex-
plained through differences within the inhibitory potential on CYP2C9 which would prolon-
gate the effectiveness of the coumarins and result in increased INR-measures. However, there 
is no consistent classification of the SSRIs concerning their inhibitory potential on CYP2C9. 
Fluvoxamine and fluoxetine have been reported to inhibit CYP2C9 most strongly within the 
SSRIs in one study[43], another mentioned fluoxetine, fluvoxamine and paroxetine with the 
highest potential for CYP2C9 interactions and had insufficient data to make a prediction for 
venlafaxine[44], whereas a Dutch textbook on drug information only described CYP2C9 in-
hibition for fluvoxamine and sertraline but not for the other SSRIs or venlafaxine.[26] For the 
coumarins, CYP2C9 is the principal catalyst for the (S-) enantiomeric forms of warfarin and 
acenocoumarol.[45] In general, the (S-)isomers of the coumarins are more effective. However, 
for acenocoumarol, the (S-)form has an extremely short half live of 2 hours and acenocouma-
rol effects mainly depend on the (R-)enantiomeric form of which about 60% is metabolized 
Table 3 Association between overanticoagulation (INR ≥6.0), exposure to fluvoxamine or venlafaxine, 
stratified by CYP2C9 genotype
RRa (95% CI) P-value of 
multiplicative 
interaction
Interaction between fluvoxamine and CYP2C9 genotype (wild type genotype / variant 
alleles)
0,48
No use of fluvoxamine, CYP2C9 wild type genotype 1.00 reference
No use of fluvoxamine, CYP2C9 variant alleles 1.08 (0.98 – 1.18)
Use of fluvoxamine, CYP2C9 wild type genotype 1.99 (0.64 – 6.20)
Use of fluvoxamine, CYP2C9 variant alleles 1.22 (0.30 – 4.89)
Interaction between venlafaxine and CYP2C9 genotype (wild type genotype / variant 
alleles)
0,56
No use of venlafaxine, CYP2C9 wild type genotype 1.00 reference
No use of venlafaxine, CYP2C9 variant alleles 1.08 (0.98 – 1.19)
Use of e venlafaxine, CYP2C9 wild type genotype 2.13 (1.10 – 4.12)
Use of venlafaxine, CYP2C9 variant alleles 4.52 (0.63 – 32.4)
Interaction between fluvoxamine or venlafaxine and CYP2C9 genotype (wild type 
genotype / variant alleles)
0,49
No use of fluvoxamine or venlafaxine, CYP2C9 wild type genotype 1.00 reference
No use of fluvoxamine or venlafaxine, CYP2C9 variant alleles 1.08(0.98 – 1.19)
Use of fluvoxamine or venlafaxine, CYP2C9 wild type genotype 2.10 (1.18 – 3.71)
Use of fluvoxamine or venlafaxine, CYP2C9 variant alleles 4.52 (0.63 – 32.3)
Statistically significant values are printed in bold
a adjusted for age, sex, BMI, target INR and use of nonsteroidal anti-inflammatory drugs, ATC-group M01A 
and proton pump inhibitors (A02BC)
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via CYP2C9. Thus interactions via CYP2C9 inhibition may be more relevant for warfarin than 
for acenocoumarol. From our analysis, no effect modification of a CYP2C9 variant allele was 
detected on the effect of fluvoxamine or venlafaxine on INR increase within acenocoumarol 
users. Possibly, more cases are needed to attain enough power for a genotype-stratified 
analysis that can confirm the effect of the CYP2C9 genotypes on a pharmacokinetic interac-
tion between acenocoumarol and SSRIs.
Besides a pharmacokinetic interaction that leads to increased INR levels, SSRIs deplete 
platelet serotonin levels and impair platelet aggregation with a subsequent increase of the 
risk of haemorrhage.[12-17] This risk might be higher for fluoxetine, paroxetine and sertraline 
as they inhibit the reuptake of serotonin stronger than citalopram and fluvoxamine. Unfortu-
nately, in our study population of 2,755 acenocoumarol users and within these 222 SSRI users, 
we did not have enough bleeding events for stratified analysis for the separate SSRIs to prove 
this assumption. Other studies on warfarin reported no risk increase for the combination with 
SSRIs on upper gastrointestinal bleedings [23, 24, 46]. For acenocoumarol one case-control 
study found a risk increase on non gastrointestinal bleedings in combination with SSRIs[22]. 
However, this study did not stratify for the separate SSRIs. For a final estimation concerning 
the safety of SSRIs in combination with coumarins, the risks for bleedings with a specific SSRI 
should be studied.
Our study is the first observational cohort study on a risk increase of overanticoagulation 
with acenocoumarol by co-medication of all SSRIs during acenocoumarol maintenance treat-
ment. We consider the chance of bias and confounding de to study design as negligible. 
First, the Rotterdam Study is a prospective cohort study and the regional anticoagulation 
clinic covered a complete area of more than one million inhabitants in the Rotterdam area. 
Consequently, everyone who is treated with a coumarin anticoagulant as an outpatient will 
be registered as such and selection bias is unlikely. Second, all medication use of all subjects 
was almost completely covered by the pharmacy data we retrieved and SSRIs were only avail-
able on prescription via pharmacies. Any lack of compliance would move our results into 
the direction of the null hypothesis, and would tend to make our results conservative. Third, 
we followed the cohort members during their whole period of acenocoumarol maintenance 
therapy and compared cases to all other cohort members available at the index dates for SSRI 
exposure. This analysis made use of all data available and adjusted for time varying effects.
However, in observational studies there is always a risk of confounding by indication. We 
therefore performed the same analysis for nortriptyline and mirtazapine, two antidepres-
sants used for the same indication but not known for inhibitory potential of CYP2C9. As 
expected, we did not find an association for these drugs with an increased risk on achieving 
INR ≥6 during acenocoumarol treatment.
In conclusion, in this population-based cohort study among outpatients of an anticoagula-
tion clinic using acenocoumarol for maintenance treatment, fluvoxamine and venlafaxine 
were associated with a more than double risk on an INR≥6. Fluoxetine, citalopram, paroxetine, 
123
Chapter 4.2: Selective serotonin reuptake inhibitors and the risk of overanticoagulation
sertraline and escitalopram had no association with overanticoagulation during acenocou-
marol maintenance treatment. If the latter drugs increase the risk of bleeding, it is likely that 
another mechanism is causative.
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Introduction
Epidemiology is usually defined as “the study of the distribution, determinants and control 
of health related states and events in populations”.[1] Pharmaco-epidemiology focuses on 
drugs as determinants or risk factors for health outcomes.[2] If a drug increases the risk of a 
disease, this is usually called an adverse drug event, and the decrease of the disease risk is 
regarded as therapeutic drug effect. In clinical practice, drug response can differ considerably 
between patients: some patients do not respond at all to certain drug treatments whereas 
others respond too strongly or have serious adverse effects. Consequently, the precise dose 
required to achieve a response can vary considerably between patients. Commonly accord-
ing to a ‘one dose fits all’ paradigm, patients start with standard dosages and if necessary 
treatment is accustomed to individual response. An example of a drug with which ‘one dose 
fits all’ gives problems is the antimalarial agent mefloquine of which a weekly dose of 250 mg 
caused neuropsychiatric adverse effects in vulnerable individuals.[3] Therefore this approach 
can put patients at considerable risks of serious adverse effects, further illustrated by the 
finding that approximately 6% of unplanned hospital admissions were due to medication of 
which potentially half could have been avoided if individual risk factors of the patients had 
been recognized and dealt with in advance.[4, 5] The contribution of genetic variation to 
these individual risk factors is the topic of interest in pharmacogenetics.[6] In this thesis, the 
influences of genetic variability in the recently detected VKORC1 gene on aortic calcification 
and blood coagulation as well as coumarin effectiveness were studied. As part of that, also 
hypothesis-free genome-wide associations with coumarin effectiveness were investigated. 
We focused on treatment with coumarins because this is a drug group with established 
clinical use but with a small therapeutic range and a potentially life-threatening bleeding 
risk. Coumarin anticoagulants are among the most important causes of iatrogenic hospital 
admissions [4, 5]. The limits and merits of the individual studies underlying this thesis have 
been discussed in the previous chapters. In this chapter we will discuss our main findings 
and put them into the broader context of potential clinical implications and further research.
Main findings
Mendelian randomization to VKORC1 genotypes
In 2004 the gene encoding the molecular target of coumarin anticoagulants, vitamin K epox-
ide reductase complex subunit 1 (VKORC1) was identified.[7, 8] Mutations in this gene lead 
to deficiency of the vitamin K dependent proteins: the coagulation factors and protein C, S, 
Z and Matrix Gla protein (MGP). The dependency of these proteins on the VKORC1 enzyme 
differs within tissues. In the liver, besides VKORC1 another enzyme is involved in the activa-
tion of coagulation factors, in extra hepatic tissues however, the activation of MGP is fully 
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dependent on VKOR activity. [9, 10]. The key function of MGP is to inhibit tissue calcification.
[11] As genetic variation in the VKORC1 gene leads to a lifelong diminished functionality of 
the VKORC1 enzyme, we assumed that the effects of the variant genotype should become vis-
ible in vascular calcification. As genotypes are assigned randomly when passed from parents 
to offspring during meiosis, the distribution of genotypes in a population follows a pattern 
which is called “Mendelian randomization”. Consequently, the population genotype distribu-
tion is supposed to be unrelated to the confounders that typically plague observational stud-
ies. We were able to show that the presence of the variant T-allele of the VKORC1 1173C>T 
SNP (rs9934438) was associated with a significantly increased risk of aortic calcification by 
21%. Expectedly, this risk increase was relatively small as it is unlikely that a common genetic 
variation in the population found at one locus would cause a high risk of clinical relevant 
outcomes with a disadvantage in survival. Potential clinical implications of our finding are 
not clear yet as vascular calcification might lead to plaque erosion[12] as well as to plaque 
stabilization[13]. One study showed that this variant allele of VKORC1 was less prevalent in 
patients with venous thromboembolism[14], but further studies are needed to elucidate its 
association with pulmonary embolism, myocardial infarction and stroke.
Influences of VKORC1 and CYP2C9 polymorphisms on coumarin effectiveness
After the identification of the VKORC1 gene [7, 8] and the detection of single nucleotide 
polymorphisms which were able to explain variation in the activity of the coded enzyme, 
many studies were performed on the genetic influence of polymorphisms in this gene on 
treatment with warfarin [15-39] and fewer with acenocoumarol [40-43] and phenprocou-
mon.[44-46]. The influence of reduced VKORC1 activity on interpersonal dosage variation 
was comparable for each coumarin with 26-28%.[45, 47-49] This agreement was expected as 
the three coumarins operate pharmacodynamically via inhibition of the VKORC1 protein. The 
effects of CYP2C9 polymorphisms on coumarin dosage were less and varied due to different 
pharmacokinetics from 12% for warfarin[48], 6% for acenocoumarol[49], to a negligible influ-
ence on phenprocoumon dosage [50].
In chapter 3, we described the results from our candidate gene studies with polymorphisms 
in the VKORC1 and the CYP2C9 gene on acenocoumarol and phenprocoumon dosage. In 
agreement with the other studies, VKORC1 polymorphisms explained 28% of acenocoumarol 
and 26% of phenprocoumon dosage variation; CYP2C9 polymorphisms explained 5.8% of 
variation of acenocoumarol and 2.9% of phenprocoumon dosage. In chapter 3.1, we further 
showed that variance in the VKORC1 and the CYP2C9 gene significantly increased the risk 
of overanticoagulation during the initiation period (OR per VKORC1 variant allele: 1.57; 
95% CI 1.19–2.07) and OR per CYP2C9*2 or *3 variant alleles: 1.28; 95% CI 1.04–1.56). Each 
VKORC1 variant allele was associated with a decrease in acenocoumarol dosage by 5.09 mg/
week and for each CYP2C9 *2 or *3 allele dosage decreased by 1.80 mg/week. In chapter 
3.3, we described the results of genetic variation in these two genes on phenprocoumon 
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maintenance dosage: per VKORC1 variant allele phenprocoumon dosage decreased by 4.8 
mg/week and per CYP2C9 variant allele by 2.2 mg/week. It has to be noted that in the analy-
sis for acenocoumarol we used the combined genotype of CYP2C9*2 and *3 with in total 6 
composed genotypes (*1/*1, *1/*2, *1/*3, *2/*2, *2/*3, *3/*3) whereas for phenprocoumon 
we represented CYP2C9 activity by one SNP with 3 genotypes (wild type genotype, hetero-
zygous for a variant allele and homozygous for the variant allele). Consequently, the stronger 
influence of polymorphisms in CYP2C9 on acenocoumarol was visible in 9 mg/week (divided 
in dosage changes of 1.8 mg/week for five variant genotypes), compared to 4.4 mg/week for 
phenprocoumon (divided in dosage changes of 2.2 mg/week for two variant genotypes). We 
could show that the dosage variation due to reduced activity in the VKORC1 and the CYP2C9 
gene added up without multiplicative modification of the effect measure. This independency 
of the effects from genetic variation within the VKORC1 and CYP2C9 genes was expected as 
etiologically the mechanisms of operation differ between the two genes and linkage disequi-
librium is unlikely due to their location on different chromosomes.
No further relevant genes related with coumarin effectiveness from GWAS
Until now two GWAS were performed on warfarin effectiveness.[47, 48] The first warfarin 
GWAS by Cooper et al involved 181 patients and found a significant association for the VKROC1 
gene only.[47] CYP2C9 did not show genome-wide significance but further genotyping in a 
replication cohort confirmed the strong effect for VKORC1 and the weaker CYP2C9 effect.[47] 
In a second GWAS on warfarin effectiveness by Takeuchi et al with 1,053 subjects involved, 
both VKORC1 and CYP2C9 reached genome-wide significance and after adjustment for their 
influences, the weaker association of CYP4F2 was detected.[48] Our GWAS with 1,525 subjects, 
described in chapter 3.2, confirmed these results for acenocoumarol with identification of SNPs 
in the VKORC1, CYP2C9 and CYP4F2 genes and added a novel feature by detecting a genome-
wide significant association of the CYP2C18 gene. As no substrates for CYP2C18 have so far 
been identified, the association may relate to the adjacent CYP2C19 gene, which codes for 
an enzyme that metabolizes (R-)acenocoumarol for 20%.[51] In a review, these three GWAS 
on coumarin dose requirement were considered valuable to confirm findings from previous 
candidate-gene studies.[52] However, they have not detected novel genetic factors that sub-
stantially affect coumarin maintenance dosage apart from a small additional contribution of 
CYP2C19 for acenocoumarol dose.[52] In chapter 3.3 we described a GWAS on phenprocoumon 
maintenance dosage in 202 subjects. This number was sufficient to confirm the major influence 
of SNPs in the VKORC1 gene, but we did not have enough power to detect weaker associations.
All present evidence clearly suggests that effectiveness of all three coumarins mainly 
depends on genetic variation of VKORC1 and CYP2C9. With large patient cohorts polymor-
phisms in CYP4F2 could be detected that accounted for 1% of coumarin dosage variation. 
For acenocoumarol also polymorphisms in CYP2C18 had a similar influence. It is unlikely that 
there are other genes with influence on coumarin effectiveness stronger than that.
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Drug-drug interactions with acenocoumarol
In chapter 4, we described the risk of overanticoagulation during acenocoumarol mainte-
nance treatment by co-medication with proton pump inhibitors, PPIs, (chapter 4.1) and by 
selective serotonin reuptake inhibitors, SSRIs (chapter 4.2). We took an INR value of six and 
greater as outcome for overanticoagulation as the risk of bleeding steeply increases from this 
point.[53] Within the PPIs, co-medication with esomeprazole doubled the risk of an INR≥6 (HR 
1.99; 95% CI 1.55–2.55) and lansoprazole was associated with a 50% risk increase (HR 1.49; 
95% CI 1.05–2.10). The risk estimates for co-medication with omeprazole, pantoprazole and 
rabeprazole were lower and did not reach statistical significance. For the SSRIs, combination 
of acenocoumarol with fluvoxamine and venlafaxine was associated with a more than double 
risk on an INR≥6, for fluvoxamine with HR 2.63; 95% CI 1.49–4.66 and for venlafaxine with 
HR 2.19; 95% CI 1.21-3.99. The other SSRIs did not increase the risk of overanticoagulation 
with acenocoumarol. For drugs from both drug groups, case reports had signaled a possible 
drug-drug interaction with coumarins.[54-64] The Dutch Federation of Anticoagulation Clin-
ics had added the whole group of SSRIs, and as of January 2010 (es)omeprazole, to the list 
of potentially interacting drugs with coumarins.[65] From our results, the guidelines of the 
Dutch Federation of Anticoagulation Clinics for extra INR monitoring with PPIs should be 
expanded with lansoprazole. For the SSRIs extra INR monitoring seems necessary for fluvox-
amine and venlafaxine.
Interethnic genetic variation
Our findings described above all concern Caucasian populations with a prevalence of 
VKORC1 variant alleles of approximately 40%. Prevalence of VKORC1 variant alleles however 
is much higher in Asians with 95% and much lower in African Americans with 14% of the 
population.[66] The most frequent genotype (‘major allele’) in a population is called ‘wild 
type genotype’ for those genotypes with two alleles. For VKORC1, the most frequent geno-
type in Asians is the variant genotype in Caucasians. Due to the higher prevalence of the less 
active VKORC1 protein, Asians are more sensitive to coumarins than Caucasians. In African 
Americans, however, reduced activity of VKORC1 is less prevalent and thus on average higher 
coumarin dosages are needed in this population than in Caucasians.[15, 66, 67] Related to 
the prevalence of the VKORC1 genotypes, coumarin dosages for other ethnic groups are in 
the range between Asians and African American subjects.[28, 30, 35, 67] Consequently, the 
ability to predict the risk of overanticoagulation varies across races as some studies showed 
that VKORC1 polymorphisms were less useful in predicting overanticoagulation in African 
Americans.[68, 69]
The prevalence of CYP2C9*2 and *3 variant alleles also differs according to race. Poly-
morphisms in this gene were more common in Caucasians (13% for *2 and 7% for *3[70]) 
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compared to African Americans (2.9% for *2 and 2.0% for *3[71]) and Asians (0.1% for *2 and 
1.1-3.6% for *3[71]). Therefore, dosage algorithms based on VKORC1 and CYP2C9 genotypes 
have to be calculated and validated separately in the different populations.[72]
Methodological considerations
Adequate sample size for GWAs
In our GWAS on phenprocoumon (chapter 3.3) we were able to detect associations with ge-
netic variation in the VKORC1 gene but not with the CYP2C9 and CYP4F2 genes. However, with 
the candidate gene approach influence of genetic variation in the CYP2C9 and CYP4F2 genes 
was detected. With the 202 subjects included in our study, numbers were too low to trace 
weaker sources of variation in these genes, let alone to find new ones. The power to trace 
genome wide significantly dosage changes of 1–2 mg/week in genes with a variant allele 
frequency of 20% in a population of 200 subjects was only 2%. In our acenocoumarol study 
with 1500 subjects we had 80% power to detect SNPs with an allele frequency of 10% at a 
genome wide significance threshold of 5 × 10−8 associated with dosage changes of 4-5 mg/
week. In comparison, to find under these conditions a SNP with an allele frequency of 10% 
to detect dosage changes of 1-2 mg/week would require 3.500 subjects. To detect milder 
effects of dosage changes of 0.5 mg/week with a frequency of the variant allele of 5% at 
genome wide significance with a power of 80% would require a study population of 15,000 
subjects. Therefore the GWAS on coumarins performed so far were able to detect relatively 
large effects for frequent genetic variation. As the dosing algorithms built with this informa-
tion still only detect half of the interpersonal variance of coumarin dosage, there may still be 
a substantial contribution of other currently unknown genetic variant alleles.
Repeated measurement analysis for recurrent events
Associations between an exposure and a certain event are usually studied with logistic re-
gression analysis. With the Cox proportional hazards model, the time to event is also taken 
into account. However, these models require independence of events and can only deal with 
one outcome per person. Bleedings and events of INR ≥6.0, however, can occur repeatedly in 
the same person during the period of coumarin treatment. To make efficient use of all avail-
able information, advanced analysis techniques can be applied. With generalised estimating 
techniques (GEE) it is possible to take the dependency of observations within one person into 
account by adjusting for recurrent events within the same subject. This is done by adding a 
correlation matrix to the regression model that estimates the correlation between outcomes 
at different time points within one patient.[73] Logistic GEE analysis enabled us to analyze the 
whole pattern of all recurrent INR ≥6 events during acenocoumarol maintenance therapy in 
chapter 3.1. Another method is the Andersen Gill (AG) analysis, which is an extension of the 
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Cox proportional hazards model and allowed to study time dependent associations of repeat-
ed events. With conventional Cox-regression models cases are censored after the first event 
and thus further events are not taken into account. In chapter 4, we studied possible influence 
of co-medication on elevated INR values during acenocoumarol treatment. The exposure to 
co-medication could vary over time. With conventional Cox regression analysis we would 
have missed relevant information as due to censoring at the first event, the information from 
later events is missed. When a certain combination of exposures is relatively rare, censoring at 
the first event may substantially reduce power. Application of the AG analysis increased our 
power to detect the effects of co-medication. The results from this analysis were comparable 
to results from conventional Cox regression analysis in order of magnitude, but confidence 
intervals became smaller. Apparently, repeated measurements techniques can be useful for 
the analysis of repeated events to time dependent exposure variables and interacting drugs.
From pharmacogenetics to individualized drug therapy
Coumarins seem to be ideal candidates for the application of genetic-guided medicine as 
their effectiveness mainly depends on genetic variation in two genes, and because they are 
widely prescribed and have to be handled carefully within a narrow therapeutic range to 
prevent serious adverse effects.[74] In 2007, the Food and Drug Administration extended the 
product labelling information of warfarin with the notification that genetic data might be 
relevant for prescribing decisions.[75] However, this has not led to a change in guidelines by 
specialist societies such as the American College of Chest Physicians [76] because of lack of 
randomized data to provide evidence of the benefits and risks of dosing algorithms includ-
ing genotype information.[77-79] Up to now, dosing algorithms have been developed that 
combine age, sex, body weight and co-medication with genetic information and were made 
online available.[74] However, their use in clinical practice is still limited as their application is 
complicated.[70] First, assessments on the utility of pharmacogenetic determined coumarin 
dosage algorithms showed that the accuracy of predicted values was highest in the catego-
ries with the most extreme dosages.[80] Warfarin-related genotyping was not cost-effective 
in all users and might be only useful in those with a high risk for haemorrhage at the start 
of therapy.[81] Currently, two trials are ongoing to prove the clinical benefit of personalized 
dosage prediction in terms of safety and clinical utility. One is a multicentre study in seven 
European countries, the European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) 
trial [82], the other study is the NIH-funded Clarification of Optimal Anticoagulant through 
Genetics (COAG) trial in the US [83]. It has to be noted that the situation in the Netherlands 
differs from the other countries as here anticoagulation therapy with coumarins is monitored 
by specialised clinics. Therefore possible incremental benefits of personalized dosage predic-
tion found by these studies have to be specifically evaluated for the Dutch situation.
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If these studies prove that dosing according to a genotype-guided algorithm will increase 
the safety and efficacy of oral anticoagulation therapy at acceptable cost-effectiveness, this 
could lead to pharmacogenetic dosing at initiation of coumarin therapy in hospitals as well 
as in primary care.[82]
A future role for pharmacists
In the Netherlands, anticoagulation clinics have a major task in managing anticoagulation 
treatment. In order to keep the INR outcomes within the target range, extra monitoring is 
necessary if medication is added that affects response to coumarins. Community and hospital 
pharmacists have the responsibility to search for alternatives available that do not interfere 
with coumarins. If alternatives are not an option, pharmacists have to inform the patient’s 
anticoagulation clinic to warrant adequate adjustment of coumarin dosage during additional 
use of the interacting medication. Care of pharmacists for coumarin users was measured in a 
set of quality indicators for community pharmacies, developed by the Drug Safety Unit of the 
Inspectorate for Health Care (IGZ) and the Royal Dutch Association for the Advancement of 
Pharmacy (KNMP).[84] Evaluation from the measurement over the year 2009 showed that all 
1,830 community pharmacies which completed the questionnaire had working procedures 
implemented to inform anticoagulation clinics, patients or prescribers about the necessity 
of extra INR monitoring. Ninety-four percent of community pharmacies in general directly 
informed the anticoagulation clinics when interacting co-medication was dispensed. This 
showed that pharmaceutical care concerning coumarin treatment is broadly implemented in 
daily practice. Another quality indicator from this set calculated patients with probable inter-
actions between coumarins and miconazol as percentage of all coumarin users. As this drug 
combination is hazardous and alternatives for miconazol are available that do not interact 
with coumarin effectiveness, this combination has to be absolutely avoided. The prevalence 
of this combination was estimated by the aid of dispensing data from community pharma-
cies which were collected by the Dutch Foundation of Pharmaceutical Statistics (SFK). As a 
result in 81% of the community pharmacies, no patients on this combination were detected, 
14% of the pharmacies had a maximum of 1% of coumarin users potentially exposed to this 
combination and 5% of pharmacies had higher percentages. Thus the majority of community 
pharmacies efficiently handled coumarin-drug interactions, but this still has to be improved 
in a small group of pharmacies.
The role of the pharmacist in the safe use of coumarins could extend substantially in future 
with the availability of genetic information. Herewith, pharmacists could give individualized 
advice on drug choice, interactions and contra-indications based on personalized risk/ benefit 
considerations. In anticipation of this development, the Drug Information Centre of the Royal 
Dutch Association for the Advancement of Pharmacy as of 2006 started in supplying infor-
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mation on genetic variation that can influence drug effectiveness.[85] Currently information 
on the polymorphisms in the following genes is available CYP2D6, factor V Leiden, CYP2C9, 
CYP2C19, VKORC1, thiopurine methyltransferase (TPMTI) and UDP-glucuronosyltransferase 
(UGT1A1). For the drugs influenced by genetic variation, in future this information has to be 
linked in pharmacies’ and prescribers’ computer systems to perform “individualized medi-
cation surveillance” prior to dispensing. In this way, besides a personalized dosage advise 
genotypes could be taken into account to classify the relevance of a drug/drug interaction. 
Consequently, signaling of such an interaction might then become more specific and de-
pend on the question whether the patient is a poor, normal or extensive metabolizer. At 
this moment, co-medication of coumarins with co-trimoxazol is acceptable with additional 
monitoring but should preferably be avoided.[86] With information of CYP2C9 activity avail-
able, co-medication with co-trimoxazol might be acceptable in patients with normal CYP2C9 
enzyme activity in combination with extra INR-monitoring and would thus not be ‘flagged’ by 
the system. For persons with CYP2C9 variant alleles, however, there should be an alert for this 
interaction because in these patients the combination potentially introduces an unaccept-
able risk of overanticoagulation and bleeding that has to be avoided.
Future research
At the moment, we are still a long way from the day when a patient presents a DNA “chip”, 
a key-chain tag bearing the patients electronic health record, to get a dose of personalized 
medicine.[6] However, expectations in the US on economic effectiveness from standard 
use of genetic testing in general practice to determine initial warfarin dose are high with 
potentially 85,000 serious bleeds and 17,000 strokes to be avoided annually.[87] Future re-
search has to show if these predictions are realistic. Possibly the ongoing studies on genetic 
forecasting of coumarin dosage in Europe and the US might accelerate developments to 
personalized medicine if they are able to show that genotype-guided dosing can improve 
safe use of coumarins at expenses that are outweighed by the benefits of saving costs for the 
treatment of serious adverse effects. Developments in information technology and broad 
social acceptance of determining and sharing genetic information, might bring the “DNA key 
chain” closer to reality. This genetic information might then be used to predict a patient’s drug 
response and by this to optimize treatment choice for the individual patient: For clopidogrel 
in March 2010, the US Food and Drug Administration approved a new label with a “boxed 
warning” describing the diminished effectiveness of the standard drug dosing in individu-
als with impaired metabolic function (so-called poor metabolizers) based on their CYP2C19 
genotype.[88] As genetic tests are available, patients with genetic polymorphisms could be 
identified and alternative treatment strategies, either higher clopidogrel dosing regimens or 
the use of other antiplatelet agents, should be considered in those patients. However, at the 
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moment, we are still waiting for the results of the ongoing trials and therefore clopidogrel 
therapy and CYP2C19 genetic testing remain a limited piece of the overall therapeutic puzzle 
of individualized drug therapy.[89] For coumarins, results from cost-benefit studies with 
direct comparison between effectiveness of coumarins and the direct thrombin inhibitors 
in daily practice might show whether subjects with variant alleles in the VKORC1 as well as 
in the CYP2C9 genes should get a direct thrombin inhibitor such as dabigatran instead of 
a coumarin anticoagulant. In these persons, stable anticoagulation with coumarins is hard 
to achieve and the increased risk of life-threatening bleedings in these patients might pos-
sibly outweigh the still unknown risks of direct thrombin inhibitors in long term treatment. 
When the results of ongoing research can be translated into clear guidelines, pharmacists 
could apply these new insights together with other patient related factors (e.g. age, sex, 
co-medication, co-morbidity, allergic reactions and environmental agents such as smoking 
and alcohol) and drug related factors (e.g. pharmacokinetics, pharmacodynamics, adverse ef-
fects, interactions, contra-indications) into individualized drug choice and drug monitoring.
Conclusion
Despite all difficulties to handle coumarins in clinical practice, these drugs will keep playing 
an important role in anticoagulation therapy until newer drugs have proven their superiority.
Due to their marked influence on coumarin response, the VKORC1 and CYP2C9 genotypes 
are suitable for an individualized medicine approach in anticoagulation therapy with couma-
rins. In the future pharmacists, could play an important role in “ individualized medication 
surveillance” if ongoing research proves the benefits of pharmacogenetic testing and if 
pharmacists succeed in combining genetic information with other patient and drug related 
factors to improve medication effectiveness and medication safety.
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Chapter 6.1: Summary
Coumarins are drugs with established value in clinical use but with a small therapeutic 
range and a potentially life-threatening bleeding risk. As warfarin is the coumarin used most 
frequently worldwide, the majority of studies is published on this anticoagulant. Due to 
different pharmacokinetic properties of each drug, these results may not be applicable to 
acenocoumarol and phenprocoumon, the coumarins which are predominantly used in the 
Netherlands. The studies described in this thesis are a contribution to the ongoing research 
in finding the right balance between benefits and risks of coumarin treatment. They were all 
performed within the Rotterdam Study, a large prospective population-based cohort study 
to assess the prevalence, incidence, and determinants of diseases in the elderly.
In Chapter 1 a general introduction to anticoagulation therapy, the pharmacodynamic and 
pharmacokinetic characteristics of coumarins, candidate gene and genome-wide association 
studies (GWAS) is given. In chapter 2 we investigated whether genetic variation in the vita-
min K epoxide reductase complex subunit 1 (VKORC1) with a lifelong reduced activity of the 
encoded enzyme was associated with increased calcification of the aortic far wall. We found a 
statistically significant risk increase of 21% (95% CI 2 to 43%) on aortic calcification in persons 
with at least one variant allele compared to those with the wild type genotype. In chapter 
3.1 we studied the effects of variant alleles in the VKORC1 and the cytochrome P450 isoform 
2C9 (CYP2C9) genes on anticoagulation therapy with acenocoumarol during the initial treat-
ment period. With the standard dosage scheme of 6, 4 and 2 mg acenocoumarol during the 
first three days of treatment initiation, at the first INR measurement each VKORC1 variant 
allele was significantly associated with a 85% risk increase of severe overanticoagulation. 
During the first six weeks of treatment, persons with variant alleles in both genes remained 
at an increased risk for severe overanticoagulation although dosage was titrated during this 
period by INR outcomes to a personal maintenance dosage. The dosage for acenocoumarol 
maintenance therapy was decreased for each VKORC1 variant allele by 5.1 mg/week and for 
each CYP2C9 variant allele by 1.8 mg/week. Chapter 3.2 described the results of a GWAS on 
acenocoumarol maintenance dosage. Inter personal dosage variation mainly depended on 
polymorphisms in the VKORC1 (28%) and CYP2C9 (6%) genes. Genetic variation in CYP4F2 and 
CYP2C18 contributed with 1% each. A model with age, sex, body mass index, target INR and 
one polymorphism within each of the VKORC1, CYP2C9, CYP4F2 and CYP2C18 genes explained 
48.8% of variation in acenocoumarol maintenance dosage. In chapter 3.3 we studied genetic 
influences on phenprocoumon maintenance dosage. We used a candidate gene approach 
to study the association with single nucleotide polymorphisms (SNPs) in VKORC1, CYP2C9 
and CYP4F2¸using SNPs we had already identified in the GWAS on acenocoumarol. We fur-
thermore assessed associations with apolipoprotein E (ApoE) as genotypes in this gene were 
shown earlier to affect acenocoumarol dosage. In a GWAS, we studied these and more genetic 
associations with phenprocoumon maintenance dosage. We confirmed earlier findings that 
phenprocoumon maintenance dosage mainly depended on polymorphisms in the VKORC1 
gene. Genetic variation within CYP2C9 and CYP4F2 genes were of modest relevance. A model 
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with age, sex, body mass index, target INR and one polymorphism within each of the VKORC1, 
CYP2C9 and CYP4F2 genes explained 46.0% of variation in phenprocoumon maintenance dos-
age. In chapter 4.1 we investigated the effects of co-medication with proton pump inhibitors 
(PPIs) on INR≥6 values during acenocoumarol maintenance treatment. Until April 2009, nine 
case-reports were collected by the Netherlands’ national pharmacovigilance center (LAREB) 
for omeprazole and seven for esomeprazole. Co-medication with esomeprazole was associ-
ated with a significant double risk of overanticoagulation and lansoprazole increased this 
risk by 50%. There were also risk increases for the other PPIs, but these increases were lower 
and statistically non-significant. In chapter 4.2 we studied the effects of co-medication with 
selective serotonin reuptake inhibitors (SSRIs) on INR≥6 values during maintenance therapy 
with acenocoumarol. Combinations with fluvoxamine and venlafaxine more than doubled 
the risk for overanticoagulation (for fluvoxamine HR=2.63; 95% CI 1.49–4.66 and for venla-
faxine HR= 2.19; 95% CI 1.21–3.99). Co-medication with the other SSRIs was not associated 
with INR values of six and higher. The general discussion in chapter 5 summarized the main 
findings and discussed some methodological issues. Implications of our findings on the treat-
ment with coumarins and the role of the pharmacist together with recommendations for 
future research were given.
Chapter 6.2
Samenvatting
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Chapter 6.2: Samenvatting
Coumarine anticoagulantia hebben hun waarde bewezen in de klinische praktijk. Zij hebben 
echter een smalle therapeutische breedte waardoor een behandeling met deze genees-
middelen kan leiden tot levensbedreigende bloedingen. Warfarine wordt uit de groep van 
coumarines wereldwijd het meest voorgeschreven, en daarom zijn over dit middel de meeste 
studies beschikbaar. Aangezien de coumarines onderling verschillen in hun farmacokineti-
sche eigenschappen laten zich de bevindingen voor warfarine niet zonder meer vertalen naar 
acenocoumarol en fenprocoumon, de coumarines die in Nederland voornamelijk worden ge-
bruikt. De artikelen in dit proefschrift leveren een bijdrage aan het lopende onderzoek naar 
de optimale verhouding tussen nut en risico bij de behandeling met deze geneesmiddelen. 
Het hier beschreven onderzoek is verricht binnen de Rotterdam Studie, een groot prospectief 
bevolkingsonderzoek naar de frequentie en de oorzaken van chronische ziekten bij ouderen.
Hoofdstuk 1 geeft een algemene introductie over de bloedstolling en de therapie met 
geneesmiddelen voor antistolling, de farmacodynamiek en farmacokinetiek van de couma-
rines en de bijzonderheden van onderzoeken naar associaties met kandidaat genen en met 
genen uit het hele genoom. In hoofdstuk 2 onderzochten wij of een genetische variatie in 
het vitamine K epoxide reductase complex subeenheid 1 (VKORC1), met als gevolg hiervan 
een levenslang verlaagde enzymactiviteit, in relatie stond met verkalking van de aorta. Wij 
vonden een met 21% statistisch significant verhoogd risico op aorta verkalking in dragers 
van tenminste één variant allel in het VKORC1 gen ten opzichte van personen met het meest 
voorkomende genotype. In hoofdstuk 3.1 onderzochten wij de effecten van variant allelen 
in de VKORC1 en de cytochrome P450 isoform 2C9 (CYP2C9) genen op de werkzaamheid van 
acenocoumarol tijdens de startfase van de therapie. De mate van de intensiteit van anti-
stolling werd uitgedrukt in ‘international normalised ratio’ (INR), waarbij een uitkomst van 6 
en hoger een sterk verhoogde kans op bloedingen geeft, de zogenoemde ‘doorgeschoten’ 
INR. De gebruikelijke standaarddosering met 6 mg (dag 1), 4 mg (dag 2) en 2 mg (dag 3) 
acenocoumarol gedurende de eerste drie dagen van de therapie verhoogde in dragers van 
elk extra VKORC1 variant allel het risico op een doorgeschoten INR met 85%. Gedurende de 
eerste zes weken van de behandeling met acenocoumarol bleef het risico op doorgeschoten 
antistolling verhoogd in personen met variant allelen in beide genen ondanks het feit dat de 
dosering gedurende deze instellingsperiode met behulp van de INR uitkomsten en gewenste 
therapeutische ‘target level’ bijgesteld werd tot een individuele onderhoudsdosering. De uit-
eindelijke individuele onderhoudsdosering acenocoumarol was met 5.1 mg/week per variant 
allel in het VKORC1 gen verlaagd, en per CYP2C9 variant allel met 1.8 mg/week. Hoofdstuk 3.2 
schetst de invloed van genetische factoren op de onderhoudsdosering van acenocoumarol 
met behulp van een genoom-brede associatie (GWA) studie. GWA onderzoeken maken het 
mogelijk om naast de bekende factoren nieuwe genetische loci te identificeren die invloed 
hebben op de variatie van de acenocoumarol dosering tussen personen. Wij vonden dat de 
verschillen in acenocoumarol onderhoudsdosering vooral bepaald werden door polymorfis-
men in de genen VKORC1 (met 28%) en CYP2C9 (met 6%). Genetische variatie in CYP4F2 en 
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CYP2C18 droeg hier voor ieder gen met 1% aan bij. Een wiskundig model opgebouwd uit de 
variabelen leeftijd, geslacht, body mass index, INR-streefwaarde en een polymorfisme binnen 
de VKORC1, CYP2C9, CYP4F2 en CYP2C18 genen kon 48.8% van de verschillen tussen personen 
voor de hoogte van acenocoumarol onderhoudsdosering verklaren. In hoofdstuk 3.3 bestu-
deerden wij de genetische invloeden op de onderhoudsbehandeling met fenprocoumon. 
Met een ‘kandidaat gen’ studieopzet brachten wij de invloed op de onderhoudsdosering 
met fenprocoumon in kaart van uit onderzoek met warfarine en acenocoumarol bekende 
‘single nucleotide polymorphisms’ (SNPs) binnen VKORC1, CYP2C9, CYP4F2 en apolipoprotein 
E (ApoE). In een GWAS zochten wij verder naar mogelijke associaties met nieuwe genen. Wij 
konden bevestigen dat ook de onderhoudsdosering fenprocoumon vooral bepaald werd 
door variatie in het VKORC1 gen. Daarnaast waren polymorfismen in CYP2C9 en CYP4F2 van 
kleiner belang. Een wiskundig model opgebouwd uit de variabelen leeftijd, geslacht, body 
mass index, INR-streefwaarde en een polymorfismen binnen de VKORC1, CYP2C9 en CYP4F2 
genen kon 46.0% van de verschillen tussen personen voor de hoogte van phenprocoumon 
onderhoudsdosering verklaren. In hoofdstuk 4.1 onderzochten wij de effecten van een 
behandeling met proton pomp remmers (PPIs) tijdens een onderhoudsbehandeling met 
acenocoumarol op het doorschieten van de INR. Aanleiding waren negen meldingen over het 
doorschieten van de INR tijdens acenocoumarol gebruik in combinatie met omeprazol en ze-
ven meldingen voor de combinatie met esomeprazol die tot april 2009 door het Nederlandse 
bijwerkingen centrum LAREB verzameld waren. Wij vonden voor esomeprazol een verdub-
beld risico op een INR≥6, en voor lansoprazol een risicoverhoging van 50%. Voor de andere 
PPIs vonden wij lagere risico’s die overigens statistisch niet significant waren. In hoofdstuk 
4.2 bestudeerden wij de effecten van co-medicatie met selectieve serotonine heropname 
remmers (SSRIs) op INR waarden van 6 en hoger tijdens een onderhoudsbehandeling met 
acenocoumarol. Fluvoxamine en venlafaxine zorgden voor een meer dan verdubbeld risico 
op doorschieten tijdens een behandeling met acenocoumarol (voor fluvoxamine was het 
relatieve risico 2.63, 95% betrouwbaarheidsinterval (95% BI) 1.49–4.66, en voor venlafaxine 
2.19, 95% BI 1.21–3.99). De overige SSRIs lieten geen verhoogd risico zien op een INR waarde 
van 6 en hoger tijdens behandeling met acenocoumarol. In de algemene discussie in hoofd-
stuk 5 hebben wij de belangrijkste bevindingen van de studies in dit proefschrift en een 
aantal methodologische overwegingen hierbij besproken. Tevens schetsten wij de beteke-
nis van onze bevindingen voor de behandeling met coumarines, de rol van de apotheker 
bij het veilige gebruik van deze geneesmiddelen, en gaven wij aanbevelingen voor verder 
onderzoek op dit gebied.
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